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General introduction
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1GENERAL INTRODUCTION
Inflammatory Bowel Disease
Inflammatory Bowel Disease (IBD) is a chronic, progressive and disabling inflammatory disease 
of the gastrointestinal tract. IBD includes Ulcerative Colitis (UC) and Crohn’s Disease (CD). 
There is a small percentage of patients in whom no clear distinction between UC or CD can 
be made, hence the term IBD-unclassified (IBD-U). The majority of IBD patients experience a 
relapsing and remitting course. The etiology is still unknown, but is thought to result from an 
interaction between both genetic and environmental factors as well as intestinal microflora, 
causing an inappropriate and ongoing intestinal mucosal immune response. Worldwide IBD 
incidence and prevalence is rising and in Europe there are almost 3 million patients, 1-7 including 
90,000 patients in The Netherlands. IBD cannot be cured. Currently available drugs are able 
to some extent to suppress symptoms and inflammation, but are not able to significantly alter 
the natural disease course.8-10
Ulcerative Colitis 
UC affects the colonic mucosa in a continuous way, starting in the rectum and variably extends 
to more proximal colon segments. There is no gold standard to diagnose UC. Diagnosis is made 
by combining clinical symptoms, laboratory tests, imaging, endoscopy and histology results. 
Typical clinical symptoms are diarrhea and bloody stools. Sometimes patients report urgency, 
fecal incontinence, fatigue, mucus discharge, nocturnal defecations, and abdominal discomfort 
(cramps), depending on the extent of the disease.1, 7 A small proportion of patients present 
with severe disease.11 Endoscopy typically shows continuous colonic inflammation with rectal 
involvement and clear demarcation of inflammation and normal looking mucosa. For a reliable 
histological diagnosis of UC, a minimum of 2 biopsies from at least 5 sites in the colon and 
the ileum should be obtained.7 UC is usually classified based on extent and severity of disease 
according to the Montreal classification (Table 1ab).12 
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Table 1a Extent of disease (UC) according to Montreal
Terminology Distribution Description
E1 Proctitis Involvement limited to the rectum
E2 Left-sided colitis Involvement limited to the proportion of the colon 
distal to the splenic flexure
E3 Extensive colitis (pancolitis) Involvement extends proximal to the splenic flexure, 
including pan-colitis 
Table 1b Severity of UC according to Montreal
Terminology Severity Definition
S0 Clinical remission Asymptomatic
S1 Mild UC Passage of ≤ 4 stools/day (+/-blood)
Absence of any symptomatic illness
Normal inflammatory markers (ESR)
S2 Moderate UC Passage > 4 stools/day
Minimal signs of systemic toxicity 
S3 Severe UC Passage ≥ 6 stools/day
Pulse rate ≥ 90 beats/minute
Temperature ≥ 37.5°C
Hemoglobin < 10.5 g/100 ml
ESR ≥ 30 mm/h
Crohn’s Disease
In CD all segments of the gastrointestinal tract can be affected, the most common being the 
terminal ileum and colon. It can present as a progressive disease with segmental and transmural 
inflammation, leading to bowel damage and disability. There is no available gold standard to 
diagnose CD. Diagnosis is established on clinical symptoms, laboratory investigations, imaging, 
endoscopy and histology results. Symptoms of CD are heterogeneous, due to the segmental 
manifestation, but typical is a young patient (20-30 years old) presenting with abdominal 
pain and chronic diarrhea. Systemic symptoms as malaise, fever, weight loss, and fatigue are 
common.2, 3 Endoscopy typically shows rectal sparing of inflammation, longitudinal ulcers, 
cobblestone appearance of the intestinal mucosa and skip lesions, inflamed areas interposed 
with normal mucosa.3 Depending on the phenotype of the disease, fistula and strictures can be 
found (Table 2). To establish the histological diagnosis of CD, ileocolonoscopy with 2 biopsies 
from 5 colonic segments and the terminal ileum are needed. Further radiological investigation 
of the small bowel is recommended. CD is usually classified by phenotype, which is based on age 
at diagnosis, location of disease and disease behavior according to the Montreal classification12 
(Table 2).
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Table 2 Montreal classification CD
Terminology Definition
Age at diagnosis
A1 ≤ 16 years
A2 Between 17 and 40 years
A3 > 40 years
Disease location
L1 Terminal ileum
L2 Colon
L3 Ileocolon
L4 Upper GI location
Disease behavior
B1 non-stricturing non-penetrating
B2 stricturing
B3 penetrating at any time during the disease course
‘p’ (added to B stadium) occurrence of perianal fistulae or abscesses
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THIS THESIS
This thesis comes from real-life IBD practice. As a practicing clinician I am in daily contact with 
my patients. They are the reasons why I started this endeavor. I have listened to IBD patients 
who shared their most troublesome recurring complaints with me. During our weekly meeting 
with our multidisciplinary IBD consultation team controversial discussion points are brought up, 
and the IBD literature is rapidly moving. These three elements are the foundation of my thesis. 
Therefore the general aim of this thesis is broad and framed as an effort to further improve daily 
real-life IBD care and clinical outcomes. Most chapters start with a patient case from my own 
IBD practice. I obtained informed consent from these patients to tell their story because their 
concerns and problems in everyday life are illustrative for the subsequent section.
This thesis is divided into 3 parts. 
1]	 The	first	part	of	this	thesis	concerns	research	focusing	on	IBD	treatment	targets.	
2]	 The	second	part	of	this	thesis	investigates	the	effect	of	used	definitions	(strict	or	broad)	
on	outcomes	in	IBD	trials.	We	were	interested	to	know	whether	the	use	of	different	
cut-offs	for	a	particular	definition	influences	the	results	of	a	study.
3] The third part of this thesis focuses on the translation of evidence gained through 
clinical	studies	to	real-life	IBD	practice.
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1MODELS
We used several models to address our research questions
In Chapter 2 we describe a nation-wide	structured	survey on IBD management in daily 
practice. 
Chapter 3 describes a single-centre case–control study concerning the prevalence and 
determinants of fatigue in IBD patients, with Lynch syndrome gene carriers as a control group. 
In Chapter 4 we performed a systematic	review	and	meta-analysis to review efficacy of 
5-Aminosalicylic acid (5-ASA) on mucosal healing (MH) and to describe and compare all used 
definitions for MH in UC. 
In Chapter 5 we performed a systematic	review that concerns the impact of using different 
definitions and cut-offs in IBD literature for Cytomegalovirus (CMV) colitis, CMV reactivation 
and CMV infection. 
In chapter 6 we describe a retrospective single-centre cohort study concerning inter- and 
intra-observer agreement of histological scoring systems in colonic biopsies from UC patients 
with MH and limited histological inflammation. 
In Chapter 7 we describe two	intervention	studies with MMX-mesalazine and the use of High- 
Performance Liquid Chromatography (HPLC) to evaluate adherence by measuring urinary 
(N-acetyl-) 5-ASA (Nac-5-ASA) excretion. First a prospective pilot study in healthy volunteers 
was performed and second a randomized prospective multi-centre study was performed in 
UC patients. 
In Chapter 8 we performed a prospective single-centre cohort study to evaluate whether 
proactive Therapeutic Drug Monitoring (TDM) in IBD patients treated with infliximab (IFX) was 
cost-effective and resulted in a better clinical response after six months of follow-up compared 
to conventional treatment. 
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PART I Treatment targets in IBD
General 
In recent years IBD treatment targets have changed considerably. Goals have veered from 
(mainly) symptom-based management to combined treatment goals that encompass both 
clinical outcome measures and endoscopy results. The main reason for this shift was the 
cumulative evidence that a portion of IBD patients in clinical remission still had ongoing mucosal 
inflammation resulting in structural damage.13, 14 Mucosal healing (MH) was introduced as an 
important therapeutic target in clinical practice and trials as it is associated with a reduction in 
steroid use, complications, hospitalizations, and surgeries in IBD patients.15-19 
Composite treatment targets
Both for UC and CD, composite treatment targets including patient reported outcome measures 
(PROMS) and mucosal healing (MH) were proposed by the International Organization for the 
Study of Inflammatory Bowel Diseases (IOIBD) consensus group and the European Crohn’s 
Colitis Organisation (ECCO) UC/CD treatment guidelines. For UC this was described as 
endoscopic remission (MH) combined with resolution of rectal bleeding and diarrhea/altered 
bowel habit. MH was defined as resolution of friability and ulceration at colonoscopy. For CD 
the definition was resolution of abdominal pain and diarrhea/altered bowel habit and endoscopic 
remission (MH), defined as resolution of ulceration at ileocolonoscopy, or resolution of findings 
of inflammation on cross-sectional imaging in patients who cannot undergo ileocolonoscopy.3, 
7, 20 Until now there is no unified global definition of MH that is used in clinical trials or in IBD 
daily practice.
Clinical treatment targets- fatigue
While therapeutic strategies in clinical trials more and more focus on MH and deep remission, 
high quality of life and well-being for IBD patients in daily life remains crucial.21, 22 One of the 
main recurring topics in an IBD out-patient clinic is fatigue, which is multi-factorial and can 
have a severe negative impact on a person’s quality of life.23-26 There is a relationship with active 
disease, but even in remission more than 40% of IBD patients suffer from fatigue.27, 28 Because 
fatigue is multi-factorial, improving symptoms by health care professionals is challenging.29-33 In 
addition to IBD disease activity and several reversible causes of fatigue such as iron deficiency, 
anemia, or low vitamin D, also psychological, emotional and behavioral factors may play a role.34-
37 Multiple fatigue scales are available for chronic diseases,38-40 with the ‘Inflammatory Bowel 
Disease Fatigue patient self-assessment’ (IBD-F) being disease specific.41 The Piper Fatigue 
Scale (PFS) was initially developed for cancer patients, but is known as a well-developed and 
widely used instrument in chronic diseases because of its multidimensional character and strong 
theoretical foundation.42
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1Aims
We aimed to answer the following questions:
- which treatment targets and definitions are used in Dutch real world IBD practices? (Ch2)
- what factors in daily IBD care may influence clinical decision-making? (Ch2)
- what is the prevalence of fatigue in IBD outpatients? (Ch3)
- can we define determinants of fatigue in IBD outpatients? (Ch3)
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PART II The outcome of IBD trials - 
The impact of using different 
definitions and cut-offs in IBD 
Mucosal healing (MH)
Despite the clinical relevance of MH, there is still no standardized definition for MH to use in 
clinical trials as well as in clinical practice. Over the years several endoscopic scoring systems 
have been developed to simplify and standardize the process of evaluating endoscopic disease 
activity. Only few were fully validated and most scores are complex, limiting its use in daily 
practice. Examples are the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) for UC, 43, 
44 the Crohn’s Disease Endoscopic Index of Severity (CDEIS) and the Simple Endoscopic Score 
(SES-CD) for CD.45-47 In daily IBD care more practical but not fully validated definitions are often 
used such as ‘the complete resolution of the visible alteration or lesions’, 48 or endoscopic Mayo 
score ≤ 1.49 The described heterogeneity of definitions for MH both in practice but specifically 
in clinical trials makes it difficult to interpret and compare data. As a consequence, it can be 
expected that studies with less stringent definitions report higher MH rates. 
Histological remission (HR)
Histological remission (HR) as a recently defined treatment target is emerging in clinical trials. 
HR seems a good predictor of a favorable disease course, in particular in UC.50-54 However, at 
present there is no unified definition of HR,52, 54 which is pivotal for the design and comparability 
of clinical trials, but also for the use of HR as treatment target in daily practice. 
Cytomegalovirus (CMV) in IBD
The pathogenic role of CMV in IBD is unclear. The interpretation of the presence of CMV in blood 
or inflamed colonic mucosa remains controversial. It may either represent infection or simply 
represent colonization without changing the IBD disease course (‘innocent bystander’). CMV 
infection and clinically relevant intestinal disease (CMV colitis) are two different entities in IBD 
patients.55-57 However, in clinical trials and clinical practice these two are used interchangeably. 
Likewise it is difficult to compare data from different studies and to draw conclusions on 
prevalence data and treatment outcomes for use in clinical practice.
Aims
We aimed to answer the following questions:
- which definitions for MH in UC are used in literature? (Ch4)
- how do heterogeneous definitions for MH impact reported prevalence of MH? (Ch4)
- what is the efficacy of 5-ASA on MH in UC? (Ch4)
- which definitions for CMV colitis and CMV infection are used in IBD literature? (Ch5)
- what is the effect of different definitions for CMV infection and colitis on the reported 
prevalence of these entities? (Ch5)
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PART III Challenges in daily IBD care – 
Theory versus real-life data
Histological remission 
To date there is no gold standard to define HR, both in clinical UC trials as in daily practice.52-54 
This complicates clinical decision-making in daily practice as clinicians are struggling with the 
question whether or not to change UC medication. In addition to this ‘definition-issue’, inter-
observer variability between pathologists may be another important matter to take into account. 
Histological assessment of UC colonic biopsies is complex and some IBD studies have shown 
considerable interobserver variability between pathologists.58, 59
Adherence
Adherence to drug therapy is crucial for successful IBD treatment. According to the World 
Health Organization (WHO) adherence is ‘the extent to which a person’s behavior – taking 
medication, following a diet, and/or executing lifestyle changes-, corresponds with agreed 
recommendations from a health care provider.’ The WHO differentiates adherence from 
compliance, because adherence also requires the patient’s consent to the recommendations.60 
Adherence on maintenance therapy in UC resulted in clear benefits, and those who are not 
adherent showed higher risk of disease relapse61-64 leading to higher healthcare costs.65-67 
5-Aminosalicylic acid (5-ASA) is a central component in UC treatment, but the reported 
prevalence of drug nonadherence is high and varies from 40 to 91%.68-72 There is no gold 
standard to measure adherence in UC and assessing adherence has proven complex, with a 
lack of of simple, direct and objective tools to screen for and monitor nonadherence. Self-report 
measures for adherence have well-known limitations and may overestimate actual medication 
use.73, 74 Electronic monitoring systems are more reliable but costly and not easy to use in daily 
care.75, 76 Another more ‘objective’ way to measure adherence is to assess serum or urinary drug 
levels. High-Performance Liquid Chromatography (HPLC) can be reliably used to measure 
urinary 5-ASA and N-acetyl-5-ASA (Nac-5-ASA) metabolites.77-82 
Therapeutic drug monitoring (TDM) in daily IBD care
Tumor necrosis factor alpha blockers (anti-TNF) are an effective treatment for IBD.83 TDM 
for anti-TNF agents involves measurement of drug levels and anti-drug antibodies, and can be 
performed reactively or proactively. Reactive TDM reserves testing for primary or secondary 
treatment failures, whereas proactive TDM also consists of periodic TDM for all patients 
including those responding to anti-TNF therapy. Currently, TDM in daily practice is mostly 
used reactively, while recent data demonstrate that in selected patients proactive TDM and a 
treat-to-target therapeutic approach may more effectively optimise efficacy, safety and costs 
of anti-TNF therapy.84-89
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Aims
The following research questions are addressed:
-  what is the interobserver agreement of UC histological scores in colonic biopsies with MH 
that show limited histological inflammation? (Ch6)
-  does ‘daily practice’ histological assessment of UC colonic biopsies by a general pathologist 
correlate with expert reviews by gastrointestinal (GI)-pathologists? (Ch6)
-  is HPLC a feasible and reproducible method to detect urinary (NAc-) 5-ASA excretion as a 
measure of adherence in healthy volunteers taking MMX-mesalazine? (Ch7)
-  can we determine cut-off levels for adherence to 5-ASA, by measuring urinary (NAc-) 5-ASA 
excretion in volunteers taking MMX-mesalazine? (Ch7)
-  is spot (Nac-)5-ASA urinalysis by HPLC feasible to assess adherence in IBD patients in daily 
IBD care? (Ch7)
- does proactive TDM-based IFX treatment in real-life IBD practice result in better clinical 
response compared to conventional treatment after six months of follow-up? (Ch8)
 - is proactive TDM-based IFX treatment cost-effective in real-life IBD practice compared to 
conventional treatment after six months of follow-up? (Ch8)
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1THESIS OUTLINE
Part I Treatment targets in Inflammatory Bowel Disease (IBD)
In chapter 2 we describe a nation-wide structured survey among Dutch gastroenterologists on 
IBD management in daily practice. We investigated the current practice and used definitions of 
IBD treatment targets among Dutch gastroenterologists, and aimed to map factors that may 
influence decision-making in clinical practice. Chapter 3 describes a single-centre case–control 
study that examined different dimensions of fatigue by using the Piper Fatigue scale (PFS) and 
examined prevalence of fatigue in consecutive IBD patients, visiting the outpatient clinic of the 
gastroenterology department of the Radboud University medical center, with Lynch syndrome 
gene carriers (Lynch) as a control group. 
Part II Outcome in IBD trials – the effect of different definitions and cut-offs
It is difficult to translate evidence from clinical IBD trials towards efficacy and treatment targets 
due to variation in used definitions and cut-off values. Chapter 4 describes a systematic review 
and meta-analysis which we performed in order to review efficacy of 5-ASA on MH in UC and 
to describe and compare all used definitions for MH in UC. We conducted a structured search 
of PubMed and the Cochrane Central Register of Controlled Trials to identify English-language 
randomized controlled clinical trials with 5-ASA in UC providing data about MH. Studies were 
eligible if they had a randomized controlled design, reported on induction of endoscopic MH, 
studied 5-ASA preparations mono therapy and were performed in patients with mild to moderate 
active UC. Chapter 5 describes a systematic review concerning the impact of using different 
definitions and cut-offs in IBD literature for CMV colitis and CMV infection. We performed a 
structured search of the medical literature using MEDLINE, EMBASE and the Cochrane central 
register of controlled trials, according to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines. The search strategy was designed to identify English-
language (clinical) trials concerning diagnostics and prevalence of CMV in IBD. Studies were 
eligible if they reported on prevalence and/or diagnostic criteria to define CMV infection or 
CMV intestinal disease (colitis) in IBD.
Part III Difference in outcome between theory (studies) and daily IBD care
In chapter 6 we describe a retrospective single-centre cohort study concerning colonic biopsies 
from UC patients with MH (Mayo ≤ 1) and limited histological inflammation. We investigated 
the inter- and intraobserver variation and correlation of UC histological scores and compared 
the ‘daily practice’ histological assessment of a general pathologist with expert reviews by 
gastrointestinal (GI)-pathologists, by using cronbach’s alpha and spearman rho analysis.	
Chapter 7 describes two studies concerning MMX-mesalazine and the use of HPLC as a tool 
to evaluate adherence by measuring urinary (NAc-) 5-ASA excretion. First a prospective pilot 
study in healthy volunteers taking MMX-mesalazine was performed to investigate feasibility of 
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HPLC to detect urinary (NAc-) 5-ASA excretion and try to determine cut-off levels for adherence 
of 5-ASA. The second randomized prospective multi-centre study concerns UC patients taking 
MMX-mesalazine in daily practice. We investigated the feasibility of spot (Nac-)5-ASA urinalysis 
by HPLC to assess adherence in IBD patients. Chapter 8 describes a prospective single-centre 
cohort study that evaluated whether proactive TDM-based IFX treatment was cost-effective 
compared to conventional tratement and resulted in a better clinical response in a real-life IBD 
cohort compared to conventional treatment after six months of follow-up. To assess costs and 
effects for the proactive TDM-based treatment, prospective cohort data from IBD patients in 
the Jeroen Bosch hospital were used. For the conventional treatment strategy, costs and effects 
were calculated with a model, based on baseline variables and literature parameters.
In Chapter 9 the main findings of this thesis are summarized and discussed. Directions for 
further research and future perspectives are suggested.
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PATIENT CASE
Ms B is a 55-year-old woman known with ileal Crohn’s disease since 1978. At that time she was treated 
with glucocorticosteroids and mesalazine as induction and maintenance therapy. In 1980 she underwent 
an ileocaecal resection because of active and stenotic disease. Since then she has been in clinical remission 
without medication until 2017, and did not visit the IBD outpatient clinic. In 2017 she developed fatigue, 
abdominal cramps and weight loss. The laboratory results were consistent with an iron deficiency anemia 
and low levels of vitamin B12. Her fecal calprotectin was 530 μg/g. A colonoscopy showed active disease at 
the neoterminal ileum and a narrow lumen. An MR enterography was compatible with active and partially 
stenosing disease stretching 25 cm of the neoterminal ileum. Induction therapy with budesonide and 
thiopurines as maintenance therapy was started. Since then she was in clinical remission, but her fecal 
calprotectin remained 350 μg/g. An MR enterography after 6 months of initial presentation indicated active 
disease with progression of the stenosis and mild prestenotic dilation. We had many conversations about 
treatment targets and risk of complications and discussed all possible treatment options. However Ms B 
does not want any treatment, because she is feeling well and because she believes that achieved results in 
the past guarantee success for the future. So far it goes well ....
ABSTRACT
Background & Aims
Recently, treatment goals in inflammatory bowel disease (IBD) in clinical trials have shifted 
from mainly symptom-based to more mucosa-driven. Real world data on treatment priorities 
are lacking. We aimed to investigate the current practice and most commonly used definitions 
of IBD treatment targets among Dutch gastroenterologists.
Methods
Dutch gastroenterologists were asked to participate in a computer-based nation-wide survey. 
We asked questions on demographics, opinion and current practice regarding IBD treatment 
targets.
Results
Twenty-four percent (134/556) of the respondents completed the survey. For both Crohn’s 
disease (CD) (47.3%, 61/129) and ulcerative colitis (UC)(45%, 58/129) the main treatment 
goal was to achieve and maintain deep remission, defined as clinical, biochemical and 
endoscopic remission. Seventy-six percent of the participants use mucosal healing (MH) as 
a potential treatment target for IBD, whereas 22.6% use histological remission. There is no 
single definition for MH in IBD. The majority use Mayo score ≤ 1 in UC (52%) and ‘macroscopic 
normal mucosa’ in CD (66%).
Conclusion
More stringent and mucosa-driven treatment targets as ‘deep remission’ and ‘mucosal 
healing’ have found traction in clinical practice. The most commonly used definition for MH in 
routine practice is endoscopic MAYO score ≤ 1 in UC and ‘macroscopic normal mucosa’ in CD.
Key words: Inflammatory bowel disease; mucosal healing; treatment goals; deep remission; 
ulcerative colitis; Crohn’ s disease.
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INTRODUCTION
Treatment targets in Inflammatory Bowel Disease (IBD) have shifted over the recent years. 
Therapeutic strategies focusing on induction and maintenance of clinical remission, have no 
effect on the natural course of the disease.1, 2 In the late 1990s, the advent of biologic agents 
for the treatment of IBD has taught us that while patients may be in clinical remission, they may 
still have ongoing mucosal inflammation resulting in structural damage.3-8 This has led to the 
concept of mucosal healing (MH) as a more meaningful therapeutic target in clinical practice. 
Indeed, emerging data suggest that MH is strongly associated with a reduction in steroid use, 
complications, hospitalizations, and surgeries. This has fueled a shift in IBD trials and guidelines 
from mainly symptom-based management of IBD patients to more complex management 
considerations. Composite treatment targets including both patient reported outcome 
measures (PROMS) and mucosal healing are promoted.9-15,3 4 Despite the clinical relevance of 
MH, no standardized definition is available yet. In addition, definitions for newly defined, but not 
yet widely accepted targets, such as ‘deep remission’ or ‘histological remission’ are emerging in 
clinical trials. There are a number of endoscopic disease activity scores that assist endoscopists, 
but few have been properly evaluated and validated in large cohorts. Fine examples are the 
Ulcerative Colitis Endoscopic Index of Severity (UCEIS) for ulcerative colitis (UC)16, 17 and the 
Crohn’s Disease Endoscopic Index of Severity (CDEIS) and the Simple endoscopic score (SES-
CD) for Crohn’s disease (CD).18-20 Practical and commonly used definitions for MH such as 
‘the complete resolution of the visible alteration or lesions’,21 or endoscopic Mayo score ≤ 122 
have the disadvantage of higher interobserver variability and limited accuracy. 9, 23, 24 In view of 
the above, (inter)national guidelines are still unclear which treatment goals we should use in 
routine clinical practice, and how much efforts, risks and resources we should use to achieve 
implementation.25-28 This leads up to the question how endoscopic endpoints such as MH are 
used in real world IBD practices. 
Therefore, we conducted a survey to investigate the current practice and used definitions of 
IBD treatment targets among Dutch gastroenterologists. In addition, we aim to map factors that 
influence decision-making in clinical practice.
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METHODS
Survey development, testing and distribution
We developed a structured survey on IBD management in daily practice consisting of 23 multiple-
choice questions (Q1-23) including 3 clinical cases and 3 endoscopy images (Supplementary 
Appendix). The cases and images were mainly designed to monitor the internal consistency 
of the survey. Academic review of important literature and guidelines on this topic, as well as 
gastroenterologist ’s interviews guided the survey development. The survey was published at 
the professional survey website www.surveymonkey.com between June 2015 and October 
2015. In accordance with survey design guidelines,29 a pilot questionnaire was pre-tested on 
5 dedicated IBD gastroenterologists to examine for questionnaire applicability, clarity, and 
content validity. As a result of this pilot survey, the initial questionnaire was modified.
The questionnaire was shortened, questions asked on treatment targets were made more 
clear and specific, ‘other’ response options were included, and the clinical cases were refined. 
The questionnaire (Supplementary Appendix) led to collection of data on demographics of 
participants and their institutes (7 questions), their opinion and current clinical practice with 
respect to IBD treatment targets (13 questions, of which 3 contained endoscopy images) and 
the most relevant decision-making factors in their clinical IBD practice (3 cases). With respect 
to IBD treatment targets, we asked both general and more detailed questions. To ensure that 
participants should only answer for those relevant survey questions, we redirected those that 
answered negatively on general questions in a specific topic to the next cluster of questions on 
the subsequent topic. 
Participants
The survey and two reminders were distributed to potential participants through e-mail. A cover 
e-mail explained the purpose of the survey and provided a link to the survey. Responses were 
accepted up to 4 months from the initial survey distribution date. Participants comprised all 
Dutch gastroenterologists and gastroenterology (GI) fellows, who were members of the Dutch 
association for gastroenterologists. As the survey was based on voluntary participation and 
information disclosure, the study protocol did not need to undergo a formal review by an Ethics 
Committee. Voluntary survey return was taken as consent.
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Data collection and statistics
Data collection was anonymous and treated confidentially. Statistical analyses were performed 
using descriptive statistics, independent t-tests, and nonparametric tests. We used descriptive 
statistics to analyze the results using counts and proportions for categorical data and means 
and standard deviations for continuous variables. Missing values were not imputed. The 
answers to most questions regarding definition, treatment goals and the case descriptions 
were tested against the mean number of years of experience (t-test after dichotomization) 
and type of hospital (chi-square). We assumed a two-tailed p < 0.05 as statistically significant. 
We examined the consistency of the participants’ answers by testing associations between 
theoretical questions and clinical cases or endoscopy images concerning the same subject 
(chi-square). Interobserver agreement for endoscopy images was tested by kappa statistics. 
Statistical analysis was performed with IBM SPSS version 22, excel version 2007, and GraphPad 
Prism (GraphPad Software, version 5.03).
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RESULTS
Participants
The survey was sent to 556 eligible e-mail addresses. Overall, 134 physicians participated and 
completed the survey (24%). The response rate was 25% for gastroenterologists (n=97/396) 
and 23% for GI fellows (n=37/160). Table 1 contains the demographic characteristics of 
the participants and their working environment. Fifty-nine percent of the participants were 
male (79/134), mean age was 42.1 years and the mean duration of working experience as a 
gastroenterologist was 8.5 years (fellows reported 0 on this question).
Survey topics
Treatment goals (Q8-9)
All selectable treatment goals, and their range are depicted in Figure 1. The main overall 
treatment goal was to achieve and maintain deep remission for both CD (47.3%, 61/129) 
and UC (45%, 58/129). In this survey, this was defined as clinical, biochemical and endoscopic 
remission. Participants who indicated deep remission as a key treatment goal (N=61 in CD, N= 
58 in UC), had fewer years of working experience. This was significant for CD (11.5 ± 9.8 versus 
6.0 ± 7.3 years ; P= 0.001); for UC the same trend was seen but this did not reach the threshold 
for statistical significance (10.2 ± 9.5 versus 7.2 ± 8.5 years; P= 0.06).We found no association 
between treatment goals and the type of hospital (Table 2).
Mucosal healing and definitions (Q10-13)
Seventy-six percent (98/129) of the participants indicated that they used MH as a potential 
treatment target for IBD. Years of working experience or type of hospital were independent of 
the use of MH (Table 2). Ninety-four participants (73%) answered more detailed questions on 
MH. The majority (70%; 66/94) mentioned that they used MH as endpoints for both CD, IBD 
unclassified (IBDU) and UC. To define MH in UC, 52% (49/94) used the Mayo score, with 40% 
(38/94) using ‘macroscopic normal mucosa’ as a definition for MH (Figure 2a). For UC, we did not 
detect an association with the type of definition used for MH and years of working experience 
(Table 2). The majority of respondents (66%; 62/94) used ‘macroscopic normal mucosa’ to define 
MH in CD, with almost one-fifth (18.1%; 17/94) using the CDEIS, and 9.6% (9/94) the SES-CD 
(Figure 2b). Again, we found no association with the type of definition used for MH and years of 
working experience, but in university hospitals the MH definition ‘macroscopic normal mucosa’ 
was used significantly more often (p=0.043)(Table 2).
Histological remission (microscopic mucosal healing) and deep remission (Q14-Q17)
Histological remission (microscopic mucosal healing, MMH) as a possible treatment target for 
IBD was used by 22.6% (28/124) of the participants. Twenty-seven participants (22%) provided 
additional details on MMH. Fifty-nine percent (16/27) stated to use MMH for CD, as well as 
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for IBDU and UC, with 22.2% (6/27) using it only in UC. The most frequently used definition 
of MMH was ‘perfectly normal mucosa’ (44.4%; 12/27). This was followed by the criteria of 
Truelove and Richards (29.6%; 8/27) (Figure 2c). There was no association between the used 
definition of MMH and years of working experience or type of hospital (Table 2). The participants 
defined deep remission frequently as ‘clinical, biochemical and endoscopic remission’ (56.5%; 
70/124), with the definition ‘clinical, biochemical, endoscopic and histological remission’ (39.5%; 
49/124) following suit (Figure 2d). There was no association between the latter (most stringent 
definition of deep remission) and years of working experience or type of hospital (Table 2).
Endoscopy images (Q18-20)
One hundred and twenty-four participants (93%) assessed 3 endoscopy images of the colonic 
mucosa on MH, to monitor for internal consistency of the survey. The 3 images linked to circle 
diagrams indicating the opinion of the participants on MH are depicted in Supplementary 
Figures 3a-c. The interobserver agreement depicted as Fleiss generalized kappa was almost 
perfect for respectively image A (0.94) and image B (0.88) and moderate for image C (0.53). To 
control for internal consistency, we compared answers of Q12 (‘which definition do you use for 
mucosal healing?’) with the judgment of the endoscopic image C. For this purpose we created 
two groups: 1) MH defined as Mayo score 0 (answer Q12b); 2) MH defined as Mayo score ≤ 1 
(answer Q12c). Some 68% (43/63) of the participants in group 1 judged image C as MH, while 
48% (10/21) did from group 2 (p=0.09).
Clinical cases (Q21-23)
The survey comprised three clinical cases (Q21-23). The first 2 cases (Q21-22) dealt with the 
use of deep remission in UC patients (Supplementary Figures 4a-b), and were used to test 
internal consistency of the survey. Question 8 (Q8) is the theoretical part that complements 
these 2 cases ( ‘what do you consider the most important treatment target in your patients 
with UC’ ) and therefore we analyzed the internal consistency of the participants by comparing 
the answers of Q8 and Q21/22 (n=120). For both cases and Q8, we created two groups of 
respondents: 1) treatment target is deep remission (answer Q8e) versus 2) all other answers 
(answer Q8a-d). Most respondents chose to intensify their treatment in both cases (Q21: 75%; 
92/124 /Q22: 84%; 103/123 ), with a significant association with the answer ‘deep remission’ 
in Q8 for both Q21 (p=0.026) and Q22 (p=0.03). The third case (Q23) dealt with ‘stopping 
criteria’ for IBD medication after one year of deep remission in UC, an issue that is outside the 
scope of this article. Fifty-three percent (65/122) of the participants were willing to stop the 
immunosuppressive medication in a young male patient, who was in deep remission for 1.5 years, 
but was initially treated top-down because of severe pancolitis at presentation.
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DISCUSSION
This nationwide survey was designed to determine the current practice of IBD treatment targets 
among Dutch gastroenterologists and to assess factors that influence decision making. Almost 
half of all respondents use deep remission as a key treatment goal. Deep remission was mostly 
defined as ‘clinical, biochemical and endoscopic remission’. The majority are willing to intensify 
treatment to reach deep remission. Over three-quarters of the gastroenterologists use MH as a 
potential treatment target for IBD, whereas less than a quarter use histological remission. There 
is no single definition for MH in IBD. The majority use Mayo score ≤ 1 in UC and ‘macroscopic 
normal mucosa’ in CD. 
Nowadays, MH is an accepted treatment target in clinical IBD trials9, 15, 21 and has been 
accepted in the guidelines.25-28 We found that 75% of the gastroenterologists use MH in 
daily IBD practice, irrespective of experience or type of hospital. Our data suggest that the 
concept of MH is embraced by many IBD practices. This indicates a watershed with the 
situation in 2010 when a Swiss survey found that gastroenterologists judged clinical activity 
as more relevant than endoscopic severity or biomarkers.30 Worth noting, and probably 
partly explaining the discrepancy, is that the Swiss participants were all gastroenterologists, 
with on average, a longer working experience, with probably less IBD patients in their 
center. However, it remains important to realize that we cannot achieve MH in all IBD 
patients with the currently available therapies. In UC, varying data on achieving MH with 
the use of 5-ASA (36,9%-80%),31, 32 azathioprine (53%),33 and biologics 32%-62%34-37 exist, 
depending on the used definition of MH and duration of follow up. In the case of CD similar 
results for budesonide (24%),38 azathioprine (16.5-73%),38-40 combinations of azathioprine 
and biologics (43,9-70.4%),39, 40 and biologics (20%-63%)39-42 exist. Newly defined treatment 
targets, such as deep or histological remission come from endpoints defined for clinical IBD 
trials,40, 43-44 but are not widely accepted or integrated in the IBD guidelines.25-28 Surprisingly, 
almost half of all respondents used deep remission as a key treatment target in daily clinical 
practice, which suggests that practice is being shaped prior to development or revision 
of guidelines. Most guidelines date from around 2011 and are updated every 3 years.25-27 
Indeed, a recent consensus meeting initiated by the International Organization for the 
Study of Inflammatory Bowel Diseases (IOIBD) did define composite treatment targets 
for both UC and CD, combining both clinical and endoscopic remission.45 Also, the majority 
of these respondents have fewer years of working experience. Possibly, a greater focus on 
evolving treatment targets in the current training schemes of GI fellows plays a role here. 
Histological remission appears to be used less often in daily practice, with a preference for 
UC when used. This is in line with international guidelines that do not advise histological 
remission as a treatment target.25-27 Also, IOIBD experts agreed upon histological remission 
as an adjunctive goal that might come into view in the future, in particular in UC.45 A unified 
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single definition for MH in IBD is lacking. For UC, several endoscopic scoring systems have 
been developed but none were validated until recently.46-47 In 2012, the UCEIS has been 
developed and validated.16, 17 UCEIS is rather complex and time consuming, which makes 
it less attractive for routine use in daily practice.48 Currently, the IOIBD consensus group 
recommends the endoscopic Mayo score in UC because of its ease of use and established 
predictive value.45, 49-50 In line with this recommendation we found that more than half of 
the participants use the Mayo score (0 or ≤ 1) to define MH in UC. Of these, one-third 
defined MH as Mayo score 0. In the literature, the debate continues whether Mayo score 
0 or 1 qualifies as a definition for MH.45, 51 Still, in UC 40% of the participants indicated the 
definition of MH as ‘macroscopic normal mucosa’, and the same applied for 66% in CD. The 
latter is in accordance with the IOIBD consensus which agreed on the ‘absence of ulceration’ 
as an endoscopic target in CD.45 Both CDEIS and SES-CD are validated scoring systems for 
CD. Surprisingly, we found that only one-fifth use the CDEIS, and 9.6% the SES-CD, while the 
CDEIS is known as time consuming and complex.19, 20, 48 The participants went through three 
clinical UC cases dealing with treatment targets and stopping criteria of immunosuppressive 
medication. In line with their answers on the theoretical questions concerning treatment 
targets in UC, most respondents chose to intensify the treatment to reach deep remission. 
Our study has several strengths and some limitations. Mucosal healing has been a theme in 
clinical trial design but it was unknown whether this concept had been adopted in clinical 
practice. Our data suggest that it has. Secondly, this survey has been developed according 
to survey guidelines,29 and carried high internal consistency when comparing theoretical 
questions with practical cases. Naturally, the voluntary participation to this survey creates 
response bias. Since our target population was ‘gastroenterologists who treat IBD patients’, 
we chose a purposive sampling design and mentioned this element in the cover e-mail that 
was sent to possible participants. The purposive sampling, national design of our survey, 
and the inclusion of physicians from both general and academic hospitals, were in support 
of the external generalizability of our findings.
In conclusion we demonstrated that the use of MH, as a marker of treatment efficacy for both 
UC and CD, has made its way into routine practice. Although there is no single definition for 
MH, the majority of gastroenterologists use endoscopic MAYO score ≤ 1 in UC or ‘macroscopic 
normal mucosa’ in CD. This seems to be the least complex and most pragmatic definition for 
widespread use in clinical practice.
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TABLES
Table 1 Demographic characteristics of the participants
Variable n/N(%)
Responsrate GI fellows 37/160 (23%)
Responsrate gastroenterologists 97/396 (25%)
Male sex 79/134 (59%)
Age (years) (mean ± SD) 42.1 ± 9.8 (range 28-65)
Type of hospital
University hospital 44/134 (33%)
Teaching hospital 59/134 (44%)
General hospital 31/134 (23%)
IBD	population#
<400 10/134 (8%)
400-800 44/134 (33%)
800-1200 38/134 (28%)
>1200 42/134 (31%)
Treat IBD in practice 130/134 (97%)
IBD: inflammatory bowel disease; # total number of IBD patients in follow up at the outpatient clinic of 
the center
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Table 2 Survey answers tested against working experience and type of hospital
Question	(Q) (N) Workinga
Experience
P Type of hospital P
University Teaching General 
Q8 Treatment goal UC 
deep remission
58 10.3±9.5
0.06
21 (36%) 20(48%) 17(61%)
0.08
Q8 Treatment goal UC 
other answers
71 7.22±8.5 38 (64%) 22(52%) 11(39%)
Q9 Treatment goal 
CD deep remission
61 6.0±7.3
0.001
25(42%) 21(50%) 15(54%)
0.57
Q9 Treatment goal 
CD other answers
68 11.5±9.8 34(58%) 21(50%) 13(46%)
Q10 MH used as 
treatment goal - yes
98 8.6±9.0
0.57
49(83%) 31(74%) 18(64%)
0.15
Q10 MH used as 
treatment goal - no
31 9.7±9.6 10(17%) 11(26%) 10(36%)
Q12 Definition MH in 
UC-macr.normal
38 10.6±9.7
0.31
24(50%) 9(30%) 5(31%)
0.08
Q12 Definition MH in 
UC-Mayo 
50 7.8±8.8 22(46%) 20(67%) 8(50%)
Q12 Definition MH in 
UC-other
6 7.0±5.8 2(4%) 1(3%) 3(19%)
Q13 Definition MH in 
CD macr.normal
63 9.5±8.9
0.34
37(77%) 19(63%) 7(44%)
0.04b
Q13 Definition MH in 
CD other
31 7.6±9.4 11(23%) 11(37%) 9(56%)
Q14 Stringent 
definition deep 
remission 
49 9.0±8.9
0.92
24(42%) 16(39%) 9(35%)
0.81
Q14 Other definition 
deep remission-
75 9.2±9.4 33(58%) 25(61%) 17(65%)
Q15 MMH used as 
treatment goal –yes-
28 11.5±8.1
0.12
14(25%) 9(22%) 5(19%)
0.86
Q15 MMH used as 
treatment goal –no-
96 8.5±9.4 43(75%) 32(78%) 21(81%)
ayears; mean ± SD; bP0.013 University hospital versus general; MH: mucosal healing; UC: ulcerative colitis; 
CD: Crohn’s disease; MMH: histological remission
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FIGURES 
Figure 1 Selectable treatment targets in ulcerative colitis (1a) and Crohn’s disease (1b)
(*Defined as normal laboratory results and normal fecal calprotectin; **Defined as clinical, biochemical 
and endoscopic remission; MH: mucosal healing; UC: ulcerative colitis; CD: Crohn’ s disease; GE: 
gastroenterologist).
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Figure 2 Definitions used for mucosal healing in ulcerative colitis (2a), in Crohn’s disease (2b), for 
histological remission (2c) and for deep remission in inflammatory bowel disease (2d). (MH: mucosal 
healing; UC: ulcerative colitis; CD: Crohn’ s disease; MMH: histological remission)
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SUPPLEMENTARY FILES
Figure 3a-c Endoscopy images and % participants judging the image as mucosal healing
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Figure 4 Treatment targets and treatment options used to achieve treatment goals in case 1 (4a) and 
case 2 (4b)
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Supplementary Appendix Survey
1. Wat is uw geslacht? Which gender do you have?
	A. Man Male
	B. Vrouw Female
2. Wat is uw leeftijd? What is your age?
3. Wat is uw beroep? What is your profession?
	A. MDL-arts Gastroenterologist
	B. MDL-arts i.o. GI Fellow 
	C. Internist Internist
	D. Internist i.o. Internal medicine fellow
	E. Overige (geef nadere toelichting) Other (give explanation)
4. Hoeveel jaar bent u reeds medisch specialist? 
(Indien AIOS vul 0 in)
How many years have you been medical 
specialist? (If fellow fill in 0)
.. jaar .. years
5. In welk type ziekenhuis werkt u? In what type of hospital do you work?
	A. Academisch ziekenhuis University hospital
	B. Top klinisch ziekenhuis (STZ) Teaching hospital
	C. Algemeen perifeer ziekenhuis General hospital
	D. Overige (geef nadere toelichting) Other (give explanation)
6. Hoe groot is de IBD patiënten populatie in uw 
ziekenhuis?
How many IBD outpatients are treated in your 
center?
	A. <400 patiënten <400 patients
	B. 400-800 patiënten 400-800 patients
	C. 800-1200 patiënten 800-1200 patients
	D. >1200 patiënten >1200 patients
7. Behandelt u zelf IBD patiënten in de praktijk? Do you treat IBD patients in clinical practice?
	A. Ja Yes
	B. Nee No
8. Wat is voor u het belangrijkste behandeldoel 
bij uw patiënten met CU?
What is your most important treatment goal in 
UC patients? 
	A. Goede kwaliteit van leven induceren en 
handhaven
Induce and maintain a good quality of life
	B. Klinische remissie induceren en handhaven Induce and maintain clinical remission
	C. Biochemische remissie (normaal lab en faeces 
calprotectine) induceren en handhaven
Induce and maintain biochemical remission 
(normal laboratory results and feces calprotectin)
	D. Endoscopische remissie/ mucosal healing 
(MH) induceren en handhaven
Induce and maintain endoscopic remission (MH)
	E. Induceren en handhaven van diepe remissie 
(combinatie van B, C en D)
Induce and maintain deep remission 
(combination of B, C and D)
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9. Wat is voor u het belangrijkste behandeldoel 
bij uw patiënten met M. Crohn?
What is your most important treatment goal in 
CD patients? 
	A. Goede kwaliteit van leven induceren en 
handhaven
Induce and maintain a good quality of life
	B. Klinische remissie induceren en handhaven Induce and maintain clinical remission
	C. Biochemische remissie (normaal lab en faeces 
calprotectine) induceren en handhaven
Induce and maintain biochemical remission 
(normal laboratory results and feces calprotectin)
	D. Endoscopische remissie (MH) induceren en 
handhaven
Induce and maintain endoscopic remission (MH)
	E. Induceren en handhaven van diepe remissie 
(combinatie van B, C en D)
Induce and maintain deep remission 
(combination of B, C and D)
10. Gebruikt u endoscopische remissie (MH) wel 
eens als behandeldoel voor uw IBD patiënt?
Do you ever use endoscopic remission (MH) as a 
treatment target in your IBD patients?
	A. Ja Yes
	B. Nee No
11. In welke patiëntengroep gebruikt 
u endoscopische remissie (MH) als 
behandeldoel?
In which patients do you use endoscopic 
remission (MH) as a treatment target?
	A. M. Crohn CD
	B. CU UC
	C.	 IBD-U IBD-U
	D. Antwoord A en B Answer A and B
	E. Antwoord A en C Answer A and C
	F. Antwoord B en C Answer B and C
	G.	 Alle bovenstaande antwoorden All of the above answers
12. Welke definitie voor endoscopische remissie 
(MH) gebruikt u voor patiënten met CU?
Which definition do you use for endoscopic 
remission (MH) in UC patients?
	A. Macroscopisch volledig normale mucosa Macroscopic complete normal mucosa
	B. Mayo endoscopie score 0 Mayo endoscopy score 0
	C. Mayo endoscopie score ≤ 1 Mayo endoscopy score ≤ 1
	D. ‘D Haens scoreA ‘D Haens scoreA
	E. UCEISB score 0 UCEISB score 0
	F. UCEISB score < 4 UCEISB score < 4
	G. Overige (geef nadere toelichting) Other (give explanation)
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13. Welke definitie voor endoscopische remissie 
(MH) gebruikt u voor patiënten met M. 
Crohn?
Which definition do you use for endoscopic 
remission (MH) in CD patients? 
	A. Macroscopisch volledig normale mucosa Macroscopic complete normal mucosa
	B. CDEISC score 0 CDEISC score 0
	C. CDEISC score < 4 CDEISC score < 4
	D. SES-CDD SES-CDD
	E. Overige (geef nadere toelichting) Other (give explanation)
14. Wat betekent voor u 'diepe remissie' in IBD 
patiënten?
How do you define deep remission in your IBD 
patients?
	A. Klinische remissie Clinical remission
	B. Klinische en biochemische remissie Clinical and biochemical remission
	C. Klinische, biochemische en endoscopische 
remissie
Clinical, biochemical and endoscopic remission
	D.	 Klinische, biochemisch, endoscopische en 
histologische remissie
Clinical, biochemical endoscopic and histological 
remission
15. Gebruikt u histologische remissie/ 
microscopische mucosal healing (MMH) wel 
eens als behandeldoel voor uw IBD patiënt?
Do you ever use histological remission/
microscopic mucosal healing (MMH) as a 
treatment target in your IBD patients?
	A. Ja Yes
	B. Nee No
16. In welke patiëntengroep gebruikt u MMH wel 
eens als behandeldoel?
In which patient group do you use MMH as a 
treatment target?
	A. M. Crohn CD
	B. CU UC
	C.	 IBD-U IBD-U
	D. Antwoord A en B Answer A and B
	E. Antwoord A en C Answer A and C
	F. Antwoord B en C Answer B and C
	G.	 Alle bovenstaande antwoorden All of the above answers
17. Welke definitie voor MMH gebruikt u? Which definition for MMH do you use?
	A. Truelove and RichardsE Truelove and RichardsE
	B. Volledig normale mucosa Perfectly normal mucosa
	C. Criteria van RileyF Riley criteriaF
	D. Geboes scoreG Geboes scoreG
	E. Overige (geef nadere toelichting) Other (give explanation)
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18. Vindt u op deze foto dat er sprake is van 
endoscopische remissie?
Do you think this image shows endoscopic 
remission?
	A. Ja Yes
	B. Nee No
19. Vindt u op deze foto dat er sprake is van 
endoscopische remissie?
Do you think this image shows endoscopic 
remission?
	A. Ja Yes
	B. Nee No
20. Vindt u op deze foto dat er sprake is van 
endoscopische remissie?
Do you think this image shows endoscopic 
remission?
	A. Ja Yes
	B. Nee No
21. (1/3) Casus: 45-jarige vrouw, pancolitis 
ulcerosa sinds 1994, gebruikt 2 gram 
mesalazine/dag als onderhoudsdosering; geen 
klachten, normaal laboratoriumonderzoek, 
faeces calprotectine 200μg/g.
Bij surveillance endoscopie macroscopisch: 
sigmoïditis MAYO I. Wat is uw beleid?
(1/3) Case: 45 year old female; pancolitis 
ulcerosa since 1994, is on 2 grams mesalazine/
day maintenance dose; no symptoms, normal 
laboratory results, feces calprotectin 200µg/g. 
At surveillance colonoscopy: sigmoiditis MAYO I. 
What is your treatment? 
	A. Handhaven 5-ASA dosering gezien klinische 
en biochemische remissie
Maintain 5-ASA dose (patient is in clinical and 
biochemical remission)
	B. Ophogen 5-ASA dosering om diepe remissie 
te bewerkstelligen
Increase 5-ASA dose to achieve deep remission
	C. Topicale medicatie naast 5-ASA oraal geven 
om diepe remissie te bewerkstelligen
Add topical medication to oral 5-ASA to achieve 
deep remission
	D. Combinatie van B. en C. om diepe remissie te 
bewerkstelligen
Combination of B. and C. to achieve deep 
remission
	E. Immunomodulator toevoegen om diepe 
remissie te bewerkstelligen
Add an immunomodulator to achieve deep 
remission
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22. (2/3) Casus: 22-jarige man, pancolitis ulcerosa 
sinds 2011, top down behandeld i.v.m. ernstig 
ziektebeloop bij presentatie met infliximab 
5mg/kg inductieschema en nu 1x/8 weken 
gecombineerd met 6-mercaptopurine. Nu 
geen klachten, laboratoriumonderzoek: CRP 
10, verder normaal, faeces calprotectine 
250μg/g en bij scopie rectosigmoïditis MAYO 
II. Wat is uw beleid?
(2/3) Case: 22 year old male, pancolitis 
ulcerosa since 2011; Severe disease course 
at presentation: top down treatment with 
infliximab 5mg/kg induction scheme followed 
by maintenance therapy 1x/8 weeks combined 
with 6-mercaptopurine. Now: no symptoms, 
laboratory results: CRP 10, feces calprotectin 
250 µg/g and at colonoscopy rectosigmoiditis 
MAYO II. What is your treatment?
	A. Handhaven huidige medicatie gezien klinische 
remissie
Maintain current medication (patient is in clinical 
remission)
	B. Handhaven huidige medicatie gezien klinische 
en biochemische remissie
Maintain current medication (patient is in clinical 
and biochemical remission)
	C. Topicale medicatie naast huidige medicatie 
geven om diepe remissie te bewerkstelligen
Add topical medication to current medication to 
achieve deep remission
	D. Intensiveren/switchen huidige 
immuunmodulerende medicatie (na controle 
spiegels) om diepe remissie te bewerkstelligen
Intensify/switch current immunomodulators 
(after control levels) to achieve deep remission
	E. Combinatie van C. en D. Combination of C. and D. 
23. 3/3) Casus: 22-jarige man, pancolitis ulcerosa 
sinds 2011, top down behandeld i.v.m. ernstig 
ziektebeloop bij presentatie met infliximab 
5mg/kg inductieschema en nu 1x/8 weken 
gecombineerd met 6-mercaptopurine. Nu 1,5 
jaar geen klachten, laboratoriumonderzoek: 
normaal, CRP <5, faeces calprotectine 
250μg/g en bij scopie normale mucosa. Wat is 
uw beleid?
 (3/3) Case: 22 year old male, pancolitis 
ulcerosa since 2011; Severe disease course 
at presentation: top down treatment with 
infliximab 5mg/kg induction scheme followed 
by maintainance therapy 1x/8 weeks combined 
with 6-mercaptopurine. Since 1,5 years no 
symptoms, laboratory results: normal, CRP<5, 
feces calprotectin 250µg/g and normal mucosa 
at colonoscopy What is your treatment?
	A. Handhaven huidige medicatie gezien 
“prognostisch slechte” colitis ulcerosa
Maintain current medication because of to 
“prognostic poor” ulcerative colitis
	B. Stop anti-TNF therapie gezien >1 jaar 
klinische, biochemische en endoscopische 
remissie
Stop anti-TNF therapy because of >1 year clinical, 
biochemical and endoscopic remission
	C. Stop 6-mercaptopurine gezien >1 jaar 
klinische, biochemisch en endoscopische 
remissie
Stop 6-mercaptopurine because of >1 year 
clinical, biochemical and endoscopic remission
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A  ‘D Haens score = normaal ogende mucosa  zonder: 1) toegenomen kwetsbaarheid, 2) 
bloedingen, 3) erosies, 4) zweren. (‘D Haens score = normal-looking mucosa without: 1) 
increased vulnerability, 2) hemorrhages, 3) erosions, 4) ulcers)
B  UCEIS = Ulcerative Colitis Endoscopy Index of Severity
C  CDEIS = Crohn’s Disease Endoscopy Index of Severity
D  SES-CD = Simple Endoscopic Score for Crohn’s Disease
E  Truelove and Richards: graad 1: geen significante ontsteking, graad 2: mild-gemiddelde 
ontsteking,  graad 3: ernstige ontsteking (Truelove and Richards: grade 1: no significant 
inflammation, grade 2: mild-moderate inflammation, grade 3: severe inflammation)
F  Riley: score van 6 kenmerken: acuut ontstekingsinfiltraat, crypt abcessen, mucus depletie, 
epitheliale integriteit,  chronisch inflammatoir infiltraat, abnormaliteiten in crypte 
architectuur ( Riley: score of 6 features: acute inflammatory cell infiltrate, crypt abscesses, mucine 
depletion, surface epithelial integrity, chronic inflammatory cell infiltrate, crypt architectural 
irregularities) 
G  Geboes: score van 6 kenmerken: architecturele veranderingen, chronisch inflammatoir 
infiltraat, neutrofielen en eosinofielen in lamina propria, neutrofielen in epitheel, crypt 
destructie, erosie of ulceratie.  (Geboes: score of 6 features: architectural changes, chronic 
inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, 
crypt destruction, erosion or ulceration).
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REPLY – LETTER TO THE EDITOR
We thank Gheorghe and colleagues for their interest in our work and for their thoughtful 
comments. We appreciate their willingness to share the original data from their cohort of 66 
Crohn’s disease (CD) patients. The authors highlight the complexity of endoscopic scoring of 
apparently normal looking mucosa and show that the proportion of patients with ‘endoscopic 
remission’ depends on the used definition. The issue at stake is not only to formulate a lucid 
definition of mucosal healing (MH) in inflammatory bowel disease (IBD), but also to coin a 
clear definition of ‘macroscopic normal mucosa’. The aim of our nationwide survey was to map 
treatment targets in daily clinical IBD practice, not to propose new scoring systems for IBD. 
We found that more than half of the participants use the Mayo score (0 or ≤ 1) to define MH in 
ulcerative colitis (UC), with 40% of the participants indicating ‘macroscopic normal mucosa’ as 
MH in UC, and 66% in CD. In CD only one-fifth used validated scoring systems as CDEIS and 
SES-CD, probably because of their time-consuming and complex character.1 We agree with the 
comments of Dr. Gheorghe and colleagues, as mentioned in our discussion, that ‘macroscopic 
normal mucosa’ in CD must be interpreted in accordance with the IOIBD consensus2 as ‘absence 
of ulceration’. Clear definitions are indispensable to categorize IBD treatment targets.
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PATIENT CASE
Ms KA is a 35-year-old woman diagnosed in 1995 with Crohn’s disease located in colon and duodenum and 
presenting with perianal fistulae in 1996. She underwent a subtotal colectomy with ileostoma in 2000. Since 
then she suffered from many relapses and was treated with glucocorticosteroids, thiopurines, infliximab 
and adalimumab. She gave birth to a healthy daughter in 2011 and healthy son in 2013. Since 2015 she is 
in deep remission on methotrexate and weekly adalimumab. However, her most debilitating complaint did 
not disappear: extreme fatigue. Prior to the diagnosis of Crohn’s disease she was used to having a busy 
lifestyle, keeping 2 jobs, taking care of her family and running the household. Since her diagnosis she adapted 
her lifestyle in sync with her energy level with some help from a psychologist and her loving family. She has 
no vitamin, electrolyte or iron deficiencies. Still, however, she suffers every day and is not able to live a life 
befitting with a 35-year-old woman. Her physical appearance is healthy and she gets compliments every 
day about her appearance. People assume that she is fully employable.
ABSTRACT
Background and Aims
Many outpatients with Inflammatory Bowel Disease (IBD) complain about fatigue, even in 
quiescent disease. The aim of this study is to examine prevalence of fatigue in IBD outpatients 
and define possible determinants of fatigue.
Methods: 
A case–control study was conducted in consecutive IBD outpatients, with Lynch syndrome 
gene carriers (Lynch) as a control group. Demographics, laboratory results and Harvey 
Bradshaw Index (HBI) were obtained from medical records. Subjective fatigue was measured 
by the revised Piper Fatigue Scale (PFS). Mean PFS scores were compared between groups. 
Secondly, possible determinants of fatigue were assessed.
Results
Three hundred patients were enrolled. 74% returned the questionnaires (117 CD; 55 UC; and 
50 Lynch). Demographics were not different between groups. Mean overall PFS is 4.03. PFS 
score in IBD patients was significantly higher compared to Lynch. Mean (SD) PFS score was 
4.8 (2.09) for CD, 4.2 (2.3) for UC versus 1.9 (2.03) for Lynch (P<0.01). Fatigue was present 
in 40% of the IBD patients in remission. HBI was positively, but not significantly, correlated 
with PFS scores (r=0.37).
Conclusion
We found a high prevalence of fatigue in IBD patients, compared to a control group, even 
in quiescent disease. None of the studied determinants was significantly associated with 
fatigue.
Keywords: Ulcerative colitis; Crohn’s disease; IBD; Fatigue; Piper fatigue scale.
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INTRODUCTION
Inflammatory Bowel Disease (IBD) is a chronic condition characterized by inflammation and 
ulceration of the gastrointestinal tract and is comprised of two major disorders: ulcerative colitis 
(UC) and Crohn’s disease (CD). The disease course of IBD is characterized by both intestinal 
and extra intestinal complaints and episodes of active and quiescent disease.1 During a period 
of active bowel inflammation, patients frequently complain of fatigue. Still, even in remission 
more than 40% of IBD patients, suffer from fatigue.2 Nowadays, in international studies, Pipers 
definition of chronic fatigue is widely used: ‘chronic fatigue is perceived as unpleasant, unusual, 
abnormal or excessive whole-body tiredness, disproportionate to or unrelated to activity or 
exertion and present for more than one month. Chronic fatigue is constant or recurrent, which 
is not dispelled easily by sleep or rest and can have a profound negative impact on the person’s 
quality of life’.3,4 In previous studies in patients with cancer,5 and a variety of chronic diseases 6,7 
fatigue is one of the most frequently reported problems, which can have major implications in 
daily life.2,8 Many hypotheses exist concerning the etiology of chronic fatigue, which is probably 
multifactorial. Physical findings or biochemical and hematological tests alone seldom provide an 
explanation for its occurrence.6, 8–10 The Piper Fatigue Scale (PFS) has been described as one of 
the most well-developed and widely used instruments for assessing fatigue in cancer patients.5 
We used the PFS as a tool to measure fatigue in our IBD population. The primary aim of this 
study was to assess the prevalence of fatigue in consecutive IBD patients, visiting the outpatient 
clinic of the gastroenterology department, in comparison with a control group. Secondly, we 
defined possible determinants of fatigue in these patients.
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MATERIALS AND METHODS
Patients
This study was carried out at the department of gastroenterology and hepatology of a Dutch 
tertiary referral center. Consecutive outpatients, with a confirmed diagnosis of IBD were asked 
to participate in this study, regardless of their disease phenotype and disease activity. The 
control group consisted of consecutive outpatients with the Lynch syndrome (Lynch). Lynch 
patients have an inherited increased risk of (mainly gastrointestinal) cancer, but in this control 
group no cancer had developed yet. Informed consent was obtained and the study was approved 
by the local Medical Ethical Committee.
Assessment of phenotype and disease activity
Demographic variables, clinical history, use of medication and Montreal classification, were 
obtained from the medical records at inclusion.11 Patients with Crohn’s disease and ulcerative 
colitis were divided in separate groups. Disease activity in all IBD patients was measured by 
the Harvey Bradshaw Index (HBI), which is a validated index12 originally developed to measure 
the disease activity in patients with CD (Figure 1). Active disease was defined by HBI >5.13,14 In 
IBD patients, most laboratory results were obtained during the outpatient visit at the time of 
inclusion, or in case of missing values within 6 months of enrollment. Blood cell counts, serum 
hemoglobin (normal limits ≥8 mmol/l for men and ≥7 for women), C reactive protein (normal 
≤5 mg/l), serum albumen (normal 35–50 g/l) and vitamin B12 (normal 160–750 pmol/l) levels 
were assessed.
Piper fatigue scale questionnaire
During consultation an envelope with the revised Piper Fatigue Scale (PFS) questionnaire 
was handed to the patient to complete this at home and return to us. The revised PFS is a 22-
item self-report instrument designed to measure fatigue, which was originally developed for 
cancer patients. All items can be scored on a 0–10 numeric scale. The revised PFS measures 
four dimensions of subjective fatigue: behavioral/severity, relating to the severity distress, 
and degree of disruption in activity of daily living; affective meaning, relating to the emotional 
meaning attributed to fatigue; sensory, relating to the physical symptoms of fatigue; and 
cognitive/ mood, relating to mental and mood states. A total fatigue score can be calculated by 
adding the four subscale scores and dividing this sum by four. The results of the PFS are coded 
b4 as mild or none fatigue and N4 as moderate to severe fatigue.15
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Statistical analysis
Frequency tables were provided for baseline characteristics of the three studied groups, and 
were compared between patients with IBD and patients with Lynch syndrome, as well as 
between patients with Crohn’s disease and ulcerative colitis. Pearson’s chi-squared test was 
used to compare frequencies, and Student’s T-test and ANOVA for continuous variables. Factors 
associated with high scores on the Piper Fatigue Scale followed the same procedures. All data 
were analyzed using SAS Statistical Software Package, version 8.02. A two-sided P-value below 
0.05 was considered statistically significant.
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RESULTS
During a 3-month study period 300 consecutive outpatients were invited. Of these 222 
returned the questionnaires (117 CD; 55 UC; and 50 Lynch). Because of missing data in the 
PFS 6 patients (3 CD, 2 UC, and 1 Lynch) were excluded. Baseline patient characteristics and 
Montreal classification are presented in Table 1 and 1A. The three patient groups were not 
significantly different in age or gender. As expected, the used IBD medication differed. CD 
patients used more biologicals, whereas UC patients used significantly more 5-aminosalicylic 
acid (5-ASA) (65%; p=0.01). Twenty-two patients with CD (19%) and 9 patients with UC (19%) 
were free of any IBD medication at all. Laboratory results were not different between CD and 
UC patients. Overall, 64% of the IBD outpatients reported fatigue (PFSN4), with no significant 
difference between CD and UC. The mean total score of PFS in all patients was 4.03, with a 
mean PFS score of 4.8 (2.09) for CD patients, 4.2 (2.3) for UC patients versus 1.9 (2.03) for 
Lynch gene carriers (Figure 2). The PFS score was significantly higher in CD and UC patients 
(P<0.01) compared to Lynch patients in all 4 dimensions (Figure 3) In the subgroup of IBD 
patients in clinical remission (HBI≤5), even 40% reported a fatigue score above 4 (Figure 4). 
Table 2 shows that none of the mentioned determinants was significantly correlated with the 
presence of fatigue. The HBI score was >5, defined as active disease in 33 CD patients (29%) and 
10 UC patients (18%). Mean HBI was higher in the fatigue group (r=0.37), but this difference 
was non-significant.
Fatigue in Inflammatory Bowel Disease   |   75
3
DISCUSSION
Overall we found a high prevalence of fatigue in all IBD outpatients (64%), in comparison with 
our control group. Similar prevalence percentages were found earlier in smaller numbers of 
adult and pediatric IBD patients.2,8 Due to the relatively high number of IBD patients in our 
study and the high questionnaire response rate (74%), our results give a reliable reflection of 
fatigue in IBD outpatients. In our study we found an equal prevalence of fatigue for both UC and 
CD, which is in accordance with a study of Minderhoud et al.,2 but contradicts another study in 
which CD patients are more tired.16 
The exact etiology of fatigue in IBD is unknown, but it’s highly likely multifactorial. For this we 
looked for possible determinants of fatigue in our IBD population. As expected we found a higher 
prevalence of fatigue in patients with active disease (HBI>5) compared to remission. Still, we 
found that fatigue has major implications in the daily life of 40% of the IBD patients in remission, 
which accords to other studies.2,8 Abnormal laboratory results, especially inflammation markers 
and anemia are associated with fatigue in patients with chronic diseases and cancer and may 
therefore influence fatigue in IBD patients.17–20 In our study 28% (37/133) of the IBD patients 
had a CRP above the detection limit (5 mg/l) which may indicate disease activity. Of these 
patients, 57% suffered from fatigue (PFS>4) compared to 62% of the patients with a normal CRP 
(not significantly different). In a screening study for fatigue in cancer patients, fatigue inventory 
showed a weak negative correlation with albumin levels.21 In our study hypoalbuminemia (<35 
g/l) was found in 17% of the patients (26/154). We found a similar proportion of fatigue in 
patients with hypoalbuminemia (73%) compared to those with normal albumin values (61%). 
Anemia is a well known determinant for fatigue.22 In cancer patients less fatigue was reported 
with higher Hb-levels, and mostly symptoms of fatigue surface with very low Hb-levels.21,23 In 
our study 2/162 IBD patients suffered from severe anemia (Hb <6 mmol/l), which both had a 
PFS>4. Still, 62% of the patients with normal Hb levels suffered from fatigue, again supporting 
the concept that fatigue in IBD is a multifaceted symptom. Apart from somatic determinants, 
psychological factors are known to be related to fatigue in patients with chronic diseases and 
cancer, and sometimes even play a more important role than inflammation-related factors.6,18,24,25 
This finding likely applies to IBD as well, and could explain the high prevalence of fatigue in 
patients with low disease activity in our present study. Cognitive behavioral therapy (CBT) is 
known to be an appropriate treatment in reducing fatigue in various chronic conditions26–29 and 
showed to be feasible and preliminary effective in improving functioning in adolescents with 
IBD.30 Therefore CBT may be appropriate to treat IBD related fatigue, but further research in 
this topic is necessary. Our study has clear implications. First of all many IBD patients visiting the 
outpatient clinic suffer from fatigue, a finding that was emphasized by the case control design of 
our study in comparison with a control group. Therefore their treating physicians need to have 
adequate attention for this serious symptom of IBD. Secondly this study supports the theory 
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that fatigue is multifaceted, as no single investigated somatic determinant was shown to be 
positively correlated with fatigue. Next to somatic determinants, psychological factors are likely 
to influence fatigue. Theoretically CBT can be effective in treating fatigue in IBD patients, but 
this has to be studied. Finally, we used the Dutch translation of the revised PFS as a validated 
questionnaire to measure fatigue. This instrument can be used in chronic patients as well as in 
controls; the present study demonstrates the feasibility of its use in IBD.2,5,8 Limitations of this 
study are as follows. First of all it establishes associations, but no causal links with the various 
determinants of fatigue. Furthermore the HBI was originally developed for evaluating disease 
activity of CD patients only, but, similar to earlier studies, we used it to evaluate disease activity 
in the total IBD patient group.31,32 In our study patients with Lynch syndrome, instead of healthy 
controls, served as control group for the following reasons. Lynch patients are in general healthy 
without chronic diseases and are of comparable age to patients visiting the outpatient IBD clinic. 
They have the same burden as IBD patients of frequently visiting an outpatient clinic, and of the 
feeling of an indistinct future.
In conclusion a large proportion of IBD patients suffer from fatigue, with the highest prevalence 
in patients with active disease. However 40% of the IBD patients with low disease activity 
suffer from fatigue, supporting the assumption that the etiology of fatigue in IBD patients is 
multifactorial, and that psychosocial factors may also play an important role.
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TABLES
Table 1 Baseline characteristics (N= 216)
Crohn’s 
disease 
(N=114)
Ulcerative 
colitis 
(N=53)
Lynch 
Syndrome 
(N=49)
CD 
vs UC 
(p-value)
IBD 
vs Lynch 
(p-value)
Male gender 40 (35) 23 (43) 19 (39) 0.30 0.89
Mean age (yrs)(SD) 42.7 (14.0) 45.7 (14.4) 44.4 (9.2) 0.21 0.72
Mean HBI (SD) 4.5 (3.6) 3.9 (3.3)
HBI ≥ 5 33 (29) 10 (18) 0.32
Steroids 21 (19) 17 (35) 0.04
Immunosuppressives 48 (44) 17 (35 0.27
Biologicals 19 (17) 0 (0) N/A
5 ASA medication 33 (30) 32 (65) <0.01
Mean Hb (mmol/l)(SD) 7.8 (0.8) 8.1 (0.9) 0.03
Anemia 34 (31) 14 (26) 0.53
CRP > 5 mg/l 30 (32) 9 (24) 0.34
Albumen < 35 g/l 22 (21) 4 (8) 0.04
Mean vit.B12 (pmol/l) 395 ±189 389 ±211 0.89
Auto immune disease 9 (8) 9 (17) 0.06
Vascular disease 11 (10) 5 (9) 0.95
Carcinoma 5 (4) 2 (4) 0.85
Surgery 59 (52) 9 (17) <0.01
Data are given as number of patients (%) or mean (SD) where indicated; HBI: Harvey Bradshaw Index; 
CRP: C-reactive protein; aAnemia is defined as Hemoglobin < 8.1 mmol/l in males and < 7.3 mmol/l in 
females
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Table 1a Baseline characteristics – Montreal Classification IBD patients 
Crohn’s disease (N=113) Ulcerative colitis (N=53)
Montreal class (B)
0 36 (32)
1 61 (54)
2 4 (3)
3 12 (11)
Montreal class (L)
1 25 (22)
1+4 2 (2)
1+p 12 (11)
2 28 (25)
2+4 2 (2)
2+p 11 (10)
3 21 (19)
3+4 1 (1)
3+p 10 (9)
4 1 (1)
Montreal class (S)
0 18 (34)
1 22 (42)
2 10 (19)
3 3 (6)
 Data are given as number of patients (%) or mean (SD) where indicated 
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Table 2 Potential determinants of fatigue in patients with IBD (n=167)
Fatigue ( PFS >4) (N=101) No fatigue (PFS <4) (N=66) p-value
Male gender 38 (37) 25 (38) 0.97
Mean age in years (SD) 44.1 (14.4) 42.9 (14.0) 0.59
Mean HBI (SD) 4.8 (3.7) 3.4 (3.1)
HBI ≥ 5 42 (80) 11 (20) 0.08
Steroids 23 (23) 15 (25) 0.76
Immunosuppressives 45 (45) 20 (34) 0.15
Biologicals 14 (14) 5 (8) 0.29
5 ASA medication 38 (39) 27 (46) 0.36
Mean Hb (mmol/l)(SD) 103 (7.8) 59 (8.0)
Anemiaa 28 (29) 20 (31) 0.80
CRP > 5 mg/l 21 (28) 18 (32) 0.66
Albumen < 35 g/l 18 (20) 8 (13) 0.25
Mean vit. B12 (pmol/l) 403 ± 206 383 ±189 0.70
Data are given as number of patients (%) or mean (SD) where indicated; PFS: Piper fatigue Scale; HBI 
:Harvey Bradshaw Index; CRP: C-reactive protein; aAnemia is defined as Hemoglobin < 8.1 mmol/l in 
males and < 7.3 mmol/l in females
82   |   Chapter 3
FIGURES 
General well-being 0 very well
1 slightly below par
2 poor
3 very poor
4 terrible
Abdominal pain 0 none
1 mild
2 moderate
3 severe
Number of liquid stools per day ……………
Abdominal mass 0 none
1 dubious
2 definite
3 definite and tender
Complications Arthralgia, uveitis, erythema nodosum, aphtous 
ulcers, pyoderma gangrenosum, anal fissure, new 
fistula, abscess
Figure 1 The Harvey Bradshaw Index
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ABSTRACT
Background
Recently, mucosal healing (MH) is regarded as an important treatment goal in ulcerative 
colitis (UC). 5-Aminosalicylates (5-ASA) are the standard treatment in mild-to-moderate UC, 
but the effect on MH is less known. The aim of this study was to systematically review the 
medical literature in order to compare different preparations of 5-ASA for the effect on MH.
Methods
We conducted a structured search of PubMed and the Cochrane Central Register of 
Controlled Trials to identify randomized controlled clinical trials with 5-ASA in UC providing 
data about MH. We calculated the sample size-weighted pooled proportion of patients with 
MH, and performed meta-analysis of head-to-head comparisons.
Results
Out of 645 hits, we included 90 treatment arms, involving 3977 patients using oral 5-ASA 
(granulate and tablets) and 2513 patients using rectal 5-ASA (suppositories, enema, and 
foam). Overall, 43,7% of 5-ASA treated patients achieved MH (oral 36,9%; rectal 50,3%). In 
oral studies, 49% of patients using granulate (7 treatment-arms) achieved MH compared to 
34,9% using tablets (43 treatment-arms). In rectal studies the proportion of MH was 62% 
for suppositories (eight treatment arms), 51% for foam (nine treatment arms), and 46% for 
enema (23 treatment arms), respectively.
Conclusions
5-ASA preparations achieved MH in nearly 50% of UC patients. There were no significant 
differences in MH between the various 5-ASA agents, either in the oral or the rectal treatment 
groups.
Key words: 5-ASA, mucosal healing, ulcerative colitis, systematic review, clinical trials.
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INTRODUCTION
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) limited to the colonic 
mucosa with an unknown etiology. It is characterized by diarrhea, rectal bleeding, abdominal 
pain, and, without treatment, usually follows a relapsing-remitting course. The degree of disease 
activity can vary from mild to highly severe.1–3 Formulations containing 5-aminosalicylic acid 
(5-ASA) are the keystone for induction and subsequent maintenance of remission in mild-to-
moderate active UC.4–7 The exact mechanism of action of 5-ASA remains unclear. However, the 
anti-inflammatory effect in UC appears to be related to local exposure to the mucosal surfaces of 
the colon.8,9 Over the years a variety of scoring systems have been developed to assess disease 
activity in UC patients, based both on clinical symptoms as well as on endoscopic healing and 
remission. In the late 1990s greater interest in the latter scoring system was raised by the 
finding that the biological agent infliximab could possibly achieve endoscopic healing of mucosal 
ulcerations in both Crohn’s disease (CD) and UC.10–14 Since then mucosal healing(MH) has been 
more often proposed as an important goal in the biological treatment of CD and UC patients. 
Subsequently, numerous studies provided convincing evidence that 5-ASA formulations also 
may possess the ability to heal the colonic mucosa.4,14,15 Indeed, when achieved, MH is associated 
with a lower risk of relapse, or future surgical interventions, a reduced risk of colorectal 
malignancy, and improved quality of life. These key elements emphasize the significance of MH 
in UC as an indicator of treatment efficacy and a marker of long-term prognosis.4,15 In addition, 
the use of MH may facilitate standardization of scoring systems and might serve as an objective 
determinant of treatment response in future clinical trials. We performed the present study 
predominantly to assess the ability of 5-ASA preparations to accomplish MH in UC patients. 
Furthermore, we were interested in possible differences in efficacy between various 5-ASA 
formulations and dosages in inducing MH. We hypothesized that both local and oral 5-ASA-
formulations are effective in inducing MH in UC patients with mild to moderate active disease.
The aims of the present study were to systematically review 1) the efficacy on MH of oral and 
rectal formulations of 5-ASA in UC; 2) definitions for MH in UC; and 3) to perform meta analyses 
for different formulations and dosages of 5-ASA on MH.
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METHODS 
Search Strategy
The search strategy was designed to identify English-language randomized controlled 
clinical trials (RCT) of 5-ASA in adult UC patients that provided data about induction of 
MH. We performed a structured search of PubMed and the Cochrane Central Register of 
Controlled Trials. The following search terms and MeSH terms were used: ‘5-aminosalicylic 
acid,’ ‘5-ASA,’ ‘mesalamine,’ ‘mesalazine,’ ‘olsalazine,’ ‘balsalazide,’ ‘inflammatory bowel 
disease,’ and ‘IBD.’
Study Selection
Studies were eligible if they were 1) of randomized controlled design; 2) reported on 
induction of endoscopic MH; 3) studied 5-ASA preparations monotherapy; and 4) in patients 
with mild to moderate active UC. Studies were excluded if they 1) reported on maintenance 
of remission only; 2) studied combination therapy; or 3) studied combined populations of 
UC and CD. Only studies in the English language were included. Two independent reviewers 
(T.R. and M.K.) screened the titles and abstracts of the articles identified by the electronic 
searches and completed an inclusion form for eligible studies. We applied a preliminary 
screen and we identified studies that could meet the inclusion criteria for full review. Full 
copies of all included studies were retrieved and reviewed by two authors (T.R. and M.K.). In 
case of disagreement they discussed with a third author (M.vO.) in order to reach consensus.
Data Extraction and Quality Assessment
Full papers were reviewed for quality and extracted data using a purpose-designed database. 
Demographic variables extracted were study design, participating countries, description of 
patients, description of severity of disease, type and dose of medication, and definition of 
MH. The extracted outcome data were frequencies regarding different definitions, scores, 
and cut-offs for MH, number of patients with MH, and comparison of the proportion of 
MH between these definitions. Important quality criteria for studies concerning MH in 
UC were the availability of an endoscopic measurement of MH and the use of a reliable 
definition for MH.
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Data Synthesis and Analysis
All abstracted data were entered into a structured database and analyses were performed 
using SAS Statistical Software, v. 8.2 (Cary, NC), and Cochrane Review Manager 5. Kappa 
statistics were used to analyze agreement among reviewers for every step in literature 
acquisition. Frequency and evidence tables were provided for characteristics of the study 
treatment arms. For analysis of the primary outcome, we calculated the sample size-
weighted pooled proportion of patients with MH and compared that between different 
formulations in oral and rectal treatment arms of the included studies. We carried out a 
meta-analysis of head-to-head comparisons of formulations or dosages within the oral and 
rectal treatment arms. Based on heterogeneity between included studies, we used random 
effect models. For all comparisons forest plots were provided.
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RESULTS
Included Studies
Our literature search is summarized in a flow diagram (Figure 1). Our initial search identified 645 
studies, of which we excluded 459 studies for various reasons. We applied full-text screening 
for 186 articles. The main reasons for exclusion were inappropriate data on induction of MH, 
inclusion of both CD and UC patients in one statistical analysis without presenting separate data, 
or structural use of co medication for IBD. Eventually, we included 49 articles (90 treatment 
arms) in our meta-analysis, involving 6490 patients using 5-ASA preparations (n = 3977 oral; n 
= 2513 rectal). All essential details of the included studies are depicted in the Appendix.1–9,16–55
In each step of the literature search, presented in Figure 1, the calculated kappa for agreement 
between both reviewers was above 0.8, indicating good agreement. Figure 2 shows the 
distribution of the various 5-ASA formulations over the 90 study arms. The overall baseline 
characteristics of oral and rectal treated UC patients are depicted in Table 1. As expected, the 
proportion of patients with pancolitis was higher in the oral-treated UC patient group compared 
with the rectal group. There were no other major differences between groups, although patients 
treated with rectal 5-ASA were slightly younger.
Mucosal Healing
Table 2 displays all definitions and cut-offs used for MH in the included study arms. We identified 
19 different definitions and cut-offs for MH. Overall, by using the MH definition of the original 
articles, 43.7% of UC patients treated with 5-ASA achieved MH. This was 36.9% in the oral group 
and 50.3% in the rectal group. Pooled data from head-to-head comparisons showed a higher 
proportion of MH in patients treated with a higher mean dose of 5-ASA (Figure 4a,b), although 
this was only statistically significantly different in the oral group. Head-to-head comparisons of 
treatment duration of 5-ASA and efficacy in terms of MH are not available from the included 
studies. In the rectal-treated group MH seemed comparable in studies with a short treatment 
period (<6 weeks) to studies with a longer treatment period (>6 weeks); in the oral group MH 
rates seemed slightly higher when longer treated.
Oral 5-ASA
Using the original articles definition of MH, granulate treatment seemed associated with higher 
MH rates compared with treatment with tablets in the oral-treated group (49% vs. 34.9%), using 
comparable dosage of 5-ASA (mean dose 3.5 g in granulate vs. 3.4 g/day in tablets) (Figure 3). 
However, head-to-head comparisons of the few studies using both 5-ASA tablets and granulate 
revealed no significance difference between the treatments (Figure 5a). In addition, we looked 
at the effect of the various brands and delivery systems of the oral 5-ASA agents with respect to 
MH, which seemed comparable. Between these groups there are no head-to-head data available 
and extensive subgroup analyses in these small numbers of patients may be misleading.
Mucosal healing and 5-ASA in Ulcerative Colitis   |   93
4
Rectal 5-ASA
Similarly, in the rectal 5-ASA treatment group induction of MH differed between the various 
preparations using the original articles definitions. Suppositories achieved MH in 62% of UC 
patients versus 51% in foam and 46% in enema (Figure 3) (mean dose respectively 1.2 vs. 2.1 
vs. 2.7 g/day). Naturally, patients with proctitis, using only suppositories, represent a different 
patient group with different characteristics. Therefore, only head-to-head comparisons 
of studies using both 5-ASA foam and enema were performed. Again, MH rates were not 
statistically significantly different between these rectal 5-ASA preparations (Figure 5b).
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DISCUSSION
Based on this meta-analysis, we conclude that 5-ASA formulations are able to heal the colonic 
mucosa in nearly half of all patients with mild-to-moderate UC, regardless of the used definition 
of MH or the 5-ASA formulations. Theoretically, the different dose and delivery systems of 
5-ASA formulations used may influence treatment distribution and efficacy. However, in our 
analysis in mild to moderate UC we found no difference in MH between the various 5-ASA 
agents and delivery systems, either in oral and rectal 5-ASA-treated patients. In the head-to-
head comparisons of rectal 5-ASA, patients with proctitis only, using suppositories, were not 
included because this is a different patient group with different characteristics. Our finding that 
different 5-ASA agents and delivery systems have no differential effect on MH is in concordance 
with a recently published Cochrane review.59 There the authors conclude that future trials 
should focus more on improving patient adherence rather than detecting differences in 
efficacy. We found a significant 5-ASA dose–response relationship in the oral group, but only 
a trend in the rectal treatment group. A previous meta-analysis for rectal 5-ASA preparations 
is in concurrence with our findings and similarly failed to detect a significant dose–response 
relationship.56 On the other hand, an advantage for higher oral 5-ASA doses was demonstrated 
earlier for UC patients with more severe disease activity.31,58 This detailed patient information 
could not be subtracted from the original articles analyzed in our meta-analysis. Furthermore, 
a recently published British guideline on UC indicates comparable remission rates on high-dose 
versus low-dose 5-ASA. This guideline does not elaborate on which 5-ASA formulation to use 
and mentions that ‘a greater clinical improvement,’ but not necessarily remission, is associated 
with 5-ASA doses >3 g/day.57 In summary, in our study both rectal and oral treatment with 
5-ASA shows MH rates of nearly 50%, irrespective of the formulations used in the head-to-head 
comparison. Therefore, we recommend first-line topical 5-ASA treatment in cases of patients 
with mild to moderate proctitis or proctosigmoiditis, irrespective of the used formulation and 
dosage. In cases of mild to moderate left-sided or pancolitis, oral 5-ASA is recommended as 
first-line treatment, with no significant difference between the different formulations, but with 
higher MH rates by using ≥ 3g/day. 
The therapeutic goals for UC have changed from predominantly treatment of symptoms 
toward achievement of endoscopic remission. The use of MH in the treatment of UC patients 
may facilitate standardization of scoring systems and might serve as an objective determinant 
of treatment response in future clinical trials. However, before MH can be introduced as a 
treatment goal, a uniform definition for MH must be developed and validated. Unfortunately, 
at this moment this uniform accepted definition is lacking. Between all the included RCTs in our 
study we identified 19 different definitions and cut-offs for endoscopic MH. In 2007, the clinical 
trials task force of the International Organization of Inflammatory Bowel Disease (IOIBD) 
recommended a definition of genuine endoscopic healing in UC as the absence of friability, 
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blood, erosions, and ulcers in all visualized segments, whereby an abnormal vascular pattern in 
the absence of these other features is still compatible with endoscopic healing.60 We support 
this and call for acceptance of this definition for future studies in order to compare efficacy data. 
However, because until now authors used heterogeneous definitions on MH in UC, we accepted 
the definitions of MH as indicated in the individual articles to facilitate quantitative pooling of 
results in our analysis. Naturally, it would have been preferable to convert the definition for MH 
from each trial to reduce inter-study heterogeneity and improve the accuracy of the MH rate in 
this meta-analysis, but this would have implied a completely different study strategy. As might 
be expected, studies with less stringent definitions reported higher MH rates.1,7,20,21,24,36,37,44,52
Our study has several strengths and some limitations. First, our study provides the most 
extended overview of the efficacy of various 5-ASA formulations in UC patients on MH. 
Therefore, according to us, we present substantial data on this issue. Second, by broadening 
the primary search term to ‘inflammatory bowel disease’, we made attempts to identify all useful 
trials to obtain data that strengthened our analysis. ‘Sulfasalazine’ was not used as a separate 
search term, but no RCT that met the inclusion criteria was excluded. Third, two independent 
reviewers reviewed all eligible studies, with very good agreement scores based on the presented 
kappa value, which was calculated in every literature review step, presented in Figure 1. Finally, 
we only included RCTs published as full articles, without restrictions by year of publication. 
Although we restricted our analysis to English-language RCTs, there was no large trial excluded. 
In the primary search we found 53 non-English studies in both the Cochrane database and 
PubMed database. None of them were available as full text. By selection on title and abstract, 
only one controlled study in 50 UC patients using 5-ASA mentions data on MH.61 In general, it 
can be misleading to draw conclusions by pooling data of several partly heterogenic studies, as 
we did. Using different definitions, dosage, type of delivery system, and duration of treatment 
can alter the result. We tried to overcome this problem as much as we could by performing 
head-to-head comparisons of available data on the mentioned topics, which showed no major 
differences, except for dosage. Statistical heterogeneity between the included studies was low, 
according to the I2 in the presented Forest plots. Still, heterogeneity of the included studies 
must be taken into account by interpreting the results. In addition, possible confounding aspects 
in this meta-analysis are the permitted comedication, comorbidity, the length of treatment, 
and nonuniformity in the definition of the extent of disease. Single trials that reported interim 
endpoints at different time intervals observed higher endoscopic remission rates with prolonged 
treatment.16,17 In our study the duration of treatment among the accepted trials ranged from 
2–12 weeks. There seemed to be no major differences in the rectal-treated group, but in the 
oral group MH rates seemed to be slightly higher in patients with longer treatment, but head-
to-head-comparisons of different treatment durations and the effect on MH are not available 
from the included studies. 
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In summary, we showed that 5-ASA preparations are highly effective in inducing MH in mild 
to moderate UC. For this reason, 5-ASA remains to be considered the first-line therapy for 
patients with mild to moderately active UC, irrespective of disease extension and of 5-ASA 
formulations used.
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TABLES
Table 1 Baseline patient characteristics
Patients Characteristics
Baseline
Oral arms (N=50)
(3977 patients)
Rectal arms (N=40)
(2513 patients)
Mean age (yrs) 42.3 40.2
Mean % males 53.2 52.6
Mean duration UC (months) 63.9 62.4
Mean % pancolitis 27.3 0 
Mean % smoking 10.1 8.9
Industry funded (n (%)) 46 (92) 27 (67.5)
Table 2 Definitions and Cut-offs for Mucosal Healing
Endoscopic score Treatment arms (N) % mucosal healing
(Range)
Rachmilewitz
Endoscopic index ≤ 1
Endoscopic index <3
Endoscopic index ≤4
2
6
9
50,5 (48,4-52,2)
36,5 (28,9-45)
57,2 (42-72,7)
(UC)DAI
Sigmoidoscopy score of 0
Sigmoidoscopy score ≤1
5
6
55,2 (17-80)
67,2 (53-77,6)
Baron Score 11 45,3 (14,3-65)
Truelove and Richards 6 61,9 (43,3-93)
Combined clinical and endoscopic score 27 30,7 (0-74)
Remaining 18 40,1 (9,5-66)
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FIGURES
Total 645 articles 
screened on title 
350 articles screened 
on abstract 
186 articles to be read fulltext 
49 articles included in meta analyses 
137 articles excluded by fulltext reading* 
41 articles excluded various reasons* 
 
123 ‘double’ articles excluded 
Hits Pubmed 266 articles 
Hits Cochrane 379 articles 
295 articles exluded based on title* 
Pubmed 107, Cochrane 188 articles 
*Main Exclusion reasons: remission studies, combinationtherapy, Crohn’s disease, no English language, only abstract available 
Figure 1 Algorithm of inclusion
Mucosal healing and 5-ASA in Ulcerative Colitis   |   103
4
90 arms 
40 rectal 
arms 
9 foam 
8 supp 
23 
enema 
50 oral 
arms 
43 
tablets 
7 granulate 
Figure 2 Distribution of study arms of various 5-ASA formulations
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Figure 3 Mucosal healing in oral and rectal 5-ASA-treated UC patients
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a.
b.
Figure 4 Forest plots of head to head comparisons of 5-ASA doses (a) Oral 5-ASA in UC: MH < 3 gram 
versus ≥ 3 gram (b). Rectal 5-ASA: 1 gram versus 4 gram enema 
a.
b.
Figure 5 Forest plots of head to head comparisons 5 ASA formulations (a) Oral 5-ASA: granulate versus 
tablets (b). Rectal 5-ASA: enema versus foam
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APPENDIX
Evidence Tables
1a Evidence Table oral 5-ASA
1b Evidence Table of rectal 5-ASA
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Appendix 1a Evidence Table oral 5-ASA Dosage Form (1a= tablets; 1b=pellets); Definition mucosal 
healing (1= Baron; 2=Rachmilewitz; 3= UC-DAI; 4= other; 5= combined clinical and endoscopic score; 
6= Truelove and Richards)
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Cobden, 1991 y n steroid enema y y 18 y 33,3% 38,3 4 38,8% 55,6%
Sninsky, 1991 y y asacol 2,4 g y y 53 y 47,0% 43,3 84,0 6 15,0% 47,0%
Sninsky, 1991 y y asacol 1,6 g y y 53 y 45,0% 43,1 86,4 6 17,0% 38,0%
Fleig, 1988 y n benzalazine y y 21 y 66,7% 41,1 51,0 6 23,8% 28,6%
Fleig, 1988 y n sulfasalazine y y 22 y 45,5% 42,4 88,0 6 27,3% 22,7%
Hanauer, 1993 y y none y y 92 y 53,0% 39,9 85,2 8
Hanauer, 1993 y y none y y 95 y 44,0% 40,9 94,8 8
Hanauer, 1993 y y none y y 97 y 51,0% 40,1 70,8 8
Kam, 1996 y n rectal mesalamine y y 18 y 38,9% 36,2 6
Gionchetti, 1998 y n mesalazine suppositories n y 29 n 55,2% 36 74,4 4 100,0%
Kruis, 1998 y n dipentum y y 80 y 57,5% 38,5 63,6 12 25,0%
Kruis, 1998 y n claversal y y 88 y 59,0% 41,9 66,0 12 30,0%
Vernia, 2000 y n sodium butyrate and mesalazine y y 15 y 66,7% 45,6 6 0,0% 0,0%
Vecchi, 2001 y n combined oral and rectal 5-ASA y y 67 y 56,7% 43 74,0 6 49,0%
Farup, 2001 y n pentasa prolonged-release granules n n 77 y 62,0% 43 8 53,3%
Farup, 2001 y n pentasa prolonged-release tablets n n 74 y 68,0% 43 8,0 8 44,6%
Farup, 2001 y n pentasa prolonged-release tablets n n 76 y 58,0% 45 8,0 8 43,4%
Green, 2002 y n sulfalazide y y 28 y 67,8% 43 60,0 12
Green, 2002 y n balsalazide y y 29 y 44,8% 40 55,2 12
Mansfield, 2002 y n balsalazide y y 24 y 66,7% 43 18,0 8 45,8%
Mansfield, 2002 y n sulfasalazine y y 26 y 65,4% 46 18,0 8 38,5%
Levine, 2002 y n balsalazide 6,75 g y y 51 y 46,9% 42,8 80,7 8
Levine, 2002 y n balsalazide 6,75 g y y 50 y 53,1% 40,7 67,6 8
Levine, 2002 y n balsalazide 2,25 g; asacol 2.4 g y y 53 y 51,0% 42,3 64,0 8
Pruitt, 2002 y n mesalamine y y 84 y 54,0% 41,6 58,0 8 0,0%
Pruitt, 2002 y n balsalazide y y 89 y 56,0% 40,5 62,8 8 0,0%
Raedler, 2004 y n mesalazine pellets y y 178 y 48,3% 44 105,2 8
Raedler, 2004 y n mesalazine tablets y y 179 y 43,0% 44 105,2 8
Marakhouski, 2005 y n eudragit-L-coated 5-ASA tablets y y 114 y 41,0% 41,9 103,2 8 45,0%
Forbes, 2005 y n ipocol y y 88 y 59,5% 44,8 8
Forbes, 2005 y n asacol y y 88 y 58,7% 47,9 8
Prantera, 2005 y n 5-ASA enema 4 g y y 40 y 60,0% 41,1 70,0 8 67,5%
Marteau, 2005 y n combined oral and rectal 5-ASA y y 53 y 57,0% 47 8
Hanauer, 2005 y n asacol y y 129 y 41,9% 42 6 16,3% 24,8%
Hanauer, 2005 y n asacol y y 139 y 44,6% 42,3 6 14,4% 35,3%
Gibson, 2006 y n eudragit-L  coated 5-ASA y y 127 y 53,0% 40 70,8 8 50,0%
Gibson, 2006 y n ethylcellulose coated 5-ASA y y 131 y 52,0% 40 78,0 8 54,0%
D’Haens, 2006 y n MMX 1,2 g; 2,4 g y y 11 y 72,7% 48 22,3 8
D’Haens, 2006 y n MMX 4,8 g; 2,4 g y y 13 y 69,2% 41 28,3 8
D’Haens, 2006 y n MMX 1,2 g; 4,8 g y y 14 y 50,0% 39 47,0 8
Lichtenstein, 2007 y y MMX 4,8 g y y 88 y 52,3% 40,2 54,0 8
Lichtenstein, 2007 y y MMX 2,4 g y y 89 y 53,9% 41,8 66,7 8
Kamm, 2007 y y none y y 84 n 46,6% 43,3 83,4 8
Kamm, 2007 y y none y y 85 n 45,9% 44,6 95,2 8
Kamm, 2007 y y none y y 86 n 47,7% 41,9 65,1 8
Hanauer, 2007 y n asacol y y 136 y 54,4% 45,9 6 19,7% 25,9%
Hanauer, 2007 y n asacol y y 150 y 48,7% 43,5 6 16,2% 29,2%
Kruis, 2009 y n mesalazine granulate 3 g od y y 189 y 50,8% 43,3 37,2 8 52,9%
Kruis, 2009 y n mesalazine granulate 1g tid y y 191 y 49,2% 41,8 33,6 8 50,8%
Scherl, 2009 y y none y y 166 y 48,8% 43,6 88,1 8
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5,6% mesalazine unknown 3,2 1 1 50,0% 4
pH-dependent, delayed-release mesalamine asacol 1,6 1 1 1,5 13,6% 5
pH-dependent, delayed-release mesalamine asacol 2,4 1 1 1,5 13,9% 5
19,0% 28,6% sulfasalazine 3 1 1 1,5 14,3% 1
36,4% 13,6% benzalazine salicylazobenzoic acid 2,16 1 1 1,5 22,7% 1
65,0% 35,0% mesalazine, prolonged release pentasa 1 1 1 2 5,4% 40,0% 4
72,0% 28,0% mesalazine, prolonged release pentasa 4 1 1 2 7,4% 48,0% 4
68,0% 32,0% mesalazine, prolonged release pentasa 2 1 1 2 9,3% 44,0% 4
0,0% sulfasalazine 4 1 1 1,5 16,7% 22,0% 5
pH-dependent, delayed-release mesalamine asacol 2,4 1 1 1 0,0% 34,5% 3
34,0% 41,0% eudragit-L-coated mesalazine claversal 3 1 1 3 11,3% 48,8% 2
35,0% 35,0% olsalazine dipentum 3 1 1 3 12,5% 52,2% 2
mesalazine eudragit S-coated 2,4 1 1 1,5 0,0% 33,3% 5
25,5% 25,5% mesalazine salofalk 4 1 1 1,5 1,5% 53,7% 2
46,8% mesalazine, prolonged release pentasa 4 1 1 2 31,0% 5
55,4% mesalazine, prolonged release pentasa 4 1 1 2 39,0% 5
56,6% mesalazine, prolonged release pentasa 4 1 1 2 37,0% 5
17,9% 5-ASA-derivate balsalazide 6,75 1 1 3 7,1% 35,7% 4
6,9% sulfasalazine sulfasalazine 3 1 1 3 31,0% 31,0% 4
20,8% 12,5% sulfasalazine 3 1 1 2 38,0% 37,5% 4
30,8% 11,5% balsalazide 6,75 1 1 2 4,0% 50,0% 4
30,6% pH-dependent, delayed-release mesalamine asacol 2,4 1 1 2 9,8% 19,4% 5
24,5% balsalazide 2,25 1 1 2 10,0% 20,0% 5
22,4% balsalazide 6,75 1 1 2 1,9% 22,9% 5
balsalazide colazal 6,75 1 1 2 3,6% 46,0% 5
pH-dependent, delayed-release mesalamine asacol 2,4 1 1 2 5,6% 41,0% 5
mesalazine tablets claversal 3 1 1 2 0,6% 39,9% 2
mesalazine pellets Merckle 3 1 1 2 2,8% 37,4% 2
40,0% 16,0% mesalazine rohm 1,5 1 1 2 0,9% 50,0% 2
39,0% pH-dependent, delayed-release mesalamine asacol 2,4 1 1 2 0,0% 26,2% 4
38,0% mesalazine ipocol 2,4 1 1 2 0,0% 26,1% 4
32,5% mesalazine, multi matrix system MMX 3,6 1 1 2 0,0% 45,0% 2
100,0% mesalazine, prolonged release pentasa 4 1 1 2 37,7% 5
38,0% 20,9% pH-dependent, delayed-release mesalamine asacol 4,8 1 1 1,5 3,2% 20,1% 5
30,2% 20,1% pH-dependent, delayed-release mesalamine asacol 2,4 1 1 1,5 3,0% 17,7% 5
25,0% 18,0% mesalazine ethylcellulose L-coated 3 1 1 2 43,0% 2
21,0% 18,0% mesalazine eudragit L-coated 3 1 1 2 42,0% 2
63,6% 36,4% mesalazine, multi matrix system MMX 4,8 1 1 2 0,0% 18,2% 5
83,3% 16,7% mesalazine, multi matrix system MMX 1,2 1 1 2 0,0% 0,0% 5
78,6% 21,4% mesalazine, multi matrix system MMX 2,4 1 1 2 0,0% 28,6% 5
88,6% 11,4% mesalazine, multi matrix system MMX 2,4 1 1 2 5,4% 34,1% 5
79,8% 19,1% mesalazine, multi matrix system MMX 4,8 1 1 2 2,1% 29,2% 5
70,2% 29,8% mesalazine, multi matrix system MMX 2,4 1 1 2 1,1% 69,0% 3
78,8% 21,2% mesalazine, multi matrix system MMX 4,8 1 1 2 0,0% 77,6% 3
80,2% 19,8% pH-dependent, delayed-release mesalamine asacol 2,4 1 1 2 1,2% 61,6% 3
31,3% 23,1% pH-dependent, delayed-release mesalamine asacol 4,8 1 1 1,5 3,4% 25,7% 5
29,2% 25,3% pH-dependent, delayed-release mesalamine asacol 2,4 1 1 1,5 5,2% 20,0% 5
21,2% 25,9% mesalazine salofalk 3 1 1 2 3,7% 70,0% 2
28,8% 20,4% mesalazine salofalk 3 1 1 2 3,7% 71,0% 2
balsalazide colazal 6,6 1 1 2 4,5% 53,0% 3
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Appendix 1b Evidence Table of rectal 5-ASA Dosage Form (2= suppositories; 3= enema; 4= foam); 
Definition mucosal healing (1= Baron; 2=Rachmilewitz; 3= UC-DAI; 4= other; 5= combined clinical and 
endoscopic score; 6= Truelove and Richards
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Campieri, 1991 Gut y y 2 and 4 g 5-ASA  enema y y 27 y 48,10% 36,0 4
Campieri, 1991 Gut y y 1 and 2 g 5-ASA  enema y y 29 y 44,80% 37,0 4
Campieri, 1991 Gut y y 1 and 4 g 5-ASA enema y y 30 y 40,00% 42,0 4
Campieri, 1990, Int J colorect dis y y none y y 32 n 56,25% 37,0 4
Campieri, 1990 Scan J of Gastro y y mesalazine 1 g y y 31 y 42,00% 37,1 55,2 4
Campieri, 1990 Scan J of Gastro y y mesalazine 1.5 g y y 32 y 75,00% 42,1 55,2 4
Danish 5-ASA group, 1987 y n prednisolone 25 mg y y 61 n 39,60% 36,0 48 4
Campieri, 1988 y n 5-asa enema n y 19 y 36,80% 40,0 4
Campieri, 1988 y n 5-asa supp n y 20 y 75,00% 40,0 4
Campieri, 1981 y n 100 mg hydrocortisone enema y y 44 y 56,80% 40,0 2
Farup, 1995 y n hydrocortisone foam n n 41 y 65,80% 40,0 4
Campieri, 1993 y n asacol foam n y 54 n 55,50% 36,0 50,4 3
Campieri, 1993 y n asacol foam n y 56 n 66,10% 40,0 66 3
Campieri, 1993 y n asacol enema n y 60 n 76,66% 40,0 67,2 3
Campieri, 1993 y n asacol enema n y 63 n 42,85% 38,0 52,8 3
Pullan, 1993 y n bismuthcitrate and polyacrylate y y 32 y 37,50% 42,0 92 4
Lémann, 1995 y n budesonide enema n y 49 y 51,00% 38,0 52,8 4
Kam, 1996 y n sulfalazine tablets y y 19 y 52,60% 37,6 6
Lee, 1996 y n prednisolone foam n y 167 y 51,00% 44,0 4
Mulder, 1996 Y n beclomethason enema y y 21 n 42,85% 43,0 64,8 4
Gionchetti, 1998 y n mesalazine tablets n y 29 n 51,70% 34,0 67,2 4
Hanauer, 1998 y y pentasa 1 and 4 g y y 71 n 45,00% 42,4 72 8 7,0%
Hanauer, 1998 y y pentasa 2 and 4 g y y 73 n 40,00% 40,7 69,6 8 4,0%
Hanauer, 1998 y y pentasa 1 and 2 g y y 73 n 34,00% 37,7 68,4 8 8,0%
Gionchetti, 1997 y n claversal supp n y 25 y 60,00% 38,0 64,8 4
Gionchetti, 1997 y n pentasa supp n y 25 y 52,00% 40,0 56,4 4
Gionchetti, 1999 y n mesalazine foam n y 50 y 72,00% 42,2 70,8 4
Gionchetti, 1999 y n mesalazine gel enema n y 53 y 57,00% 37,4 69,6 4
Pokrotnieks, 2000 y y none y y 54 y 43,00% 44,1 89,2 6 4,0%
Malchow, 2002 y n claversyl foam n y 128 y 59,30% 4 9,0%
Malchow, 2002 y n salofalk enema n y 128 y 52,30% 4 8,3%
Gionchetti, 2005 y n beclomethason enema n y 100 y 69,81% 41,0 65,4 6
Prantera, 2005 y n 5-asa MMX tablets y y 38 y 59,00% 41,3 76,7 8 21,1%
Miner, 2006 y n alicaforsen y y 54 y 46,30% 46,0 113 6
Eliakim, 2007 y n salofalk foam n y 167 y 41,00% 42,0 42 6 12,0%
Eliakim, 2007 y n claversal foam n y 163 y 49,00% 43,9 50,4 6 7,0%
Cortot, 2008 y n pentasa foam n y 179 y 46,40% 41,0 24 4 7,3%
Cortot, 2008 y n pentasa enema n y 189 y 59,80% 44,0 20 4 10,1%
Basilisco, 1987 y sulfasalazine enema n y 13 n 46,20% 47,0 4
Basilisco, 1987 y 5-asa enema n y 14 n 64,30% 39,0 4
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25,9% 29,6% 44,4% 5-ASA methyl-cellulose 1,0 3 12 44,4% 6
27,6% 41,4% 31,0% 5-ASA methyl-cellulose 4,0 3 15 51,7% 6
33,0% 30,0% 36,7% 5-ASA methyl-cellulose 2,0 3 13 43,3% 6
100,0% mesalazine asacol 1,5 2 0,0% 13 40,6% 4
28,0% 39,0% mesalazine asacol 1,5 2 0,0% 17 54,8% 1
72,0% 61,0% mesalazine asacol 1,0 2 3,1% 19 59,4% 1
0,0% mesalazine pentasa 1,0 3 4,9% 31 50,8% 4
0,0% 5-asa supp gottefosse 2,0 2 14 73,7% 6
0,0% 5-asa enema 2,0 3 13 65,0% 6
18,1% 36,4% 45,5% 5-asa 4,0 3 41 93,2% 6
58,5% 41,5% mesalazine mesasal 1,0 2 17 41,5% 5
88,9% 11,1% mesalazine asacol 2,0 3 30 55,6% 1
50,0% 50,0% mesalazine asacol 4,0 3 1,8% 19 33,9% 1
60,0% 40,0% mesalazine asacol 4,0 4 1,7% 23 38,3% 1
87,3% 12,7% mesalazine asacol 2,0 4 1,6% 41 65,1% 1
5-asa 2,0 3 0,0% 20 62,5% 1
mesalazine pentasa 1,0 3 6 12,2% 4
5-asa Rowasa 4,0 3 0,0% 4 21,1% 5
9,0% 66,0% 25,0% mesalazine asacol 2,0 4 1,8% 50 29,9% 4
100,0% 5 asa henning 2,0 3 2 9,5% 4
100,0% mesalazine 1,2 2 0,0% 21 72,4% 3
0,0% mesalamine pentasa 2,0 3 46 64,8% 4
0,0% mesalamine pentasa 1,0 3 43 58,9% 4
0,0% mesalamine pentasa 4,0 3 48 65,8% 4
100,0% mesalazine pentasa 1,0 2 20 80,0% 3
100,0% mesalazine claversal 0,5 2 18 72,0% 3
76,0% 24,0% mesalazine gel mesalazine 2,0 3 25 50,0% 1
68,0% 32,0% mesalazine mesalazine 2,0 4 22 41,5% 1
24,0% 57,0% 19,0% mesalazine mesalazine 2,0 4 1,9% 26 48,1% 2
mesalazine Salofalk 4,0 3 40 31,3% 2
mesalazine claversal 2,0 4 37 28,9% 2
29,3% 56,6% 14,1% 5asa 5asa 1,0 3 29 29,2% 5
82,1% 17,9% mesalazine asacol 4,0 3 2,6% 14 36,8% 2
100,0% mesalazine Rowasa 4,0 3 9 17,0% 3
51,0% 49,0% mesalazine claversal 2,0 4 3,0% 119 71,0% 3
56,0% 44,0% mesalazine salofalk 2,0 4 4,9% 116 71,0% 3
45,8% 50,8% 3,4% mesalamine pentasa 1,0 3 6,6% 130 72,7% 2
42,9% 51,3% 5,8% mesalamine pentasa 1,0 4 7,3% 121 64,2% 2
38,5% 61,5% 5-asa 3,0 3 0,0% 9 69,2% 5
71,4% 28,6% sulfasalazine 3,0 3 0,0% 3 21,4% 5
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PATIENT CASE
Ms AB is a 53-year-old woman diagnosed with left-sided ulcerative colitis in 1985. She was treated 
consecutively with topical therapy, glucocorticosteroids and remained in remission on mesalazine 
monotherapy since. In 2013 she relapsed and was treated with glucocorticosteroids induction followed 
by mercaptopurine as maintenance treatment. Since then, her disease was in deep remission with fecal 
calprotectin < 30 μg/g and mucosal healing at endoscopy (Mayo 0). In 2015 her fecal calprotectin increased 
to 1100 μg/g and remained at this level. Initially she reported no symptoms, but after a few weeks she 
developed bloody diarrhea, and abdominal cramps. A colonoscopy was performed showing active ulcerative 
colitis (mayo II-III), with deep ulcers. Pathological investigation of the biopsies showed active chronic 
inflammation but also inclusion bodies suggestive of a CMV infection. A quantitative PCR was positive 
on the same biopsies and she was diagnosed with active CMV colitis. Her immunosuppressive medication 
was continued and she was treated with ganciclovir. Soon she was in clinical remission again and also her 
fecal calprotectin normalized. A colonoscopy was performed showing mucosal healing. Since then she has 
remained in deep remission on monotherapy thiopurines.
ABSTRACT
Aim
To identify definitions of cytomegalovirus (CMV) infection and intestinal disease, in 
inflammatory bowel disease (IBD), to determine the prevalence associated with these 
definitions.
Methods
We conducted a systematic review and interrogated PubMed, EMBASE and Cochrane for 
literature on prevalence and diagnostics of CMV infection and intestinal disease in IBD 
patients. As medical headings we used ‘cytomegalovirus’ OR ‘CMV’ OR ‘cytomegalo virus’ 
AND ‘inflammatory bowel disease’ OR ‘IBD’ OR ‘ulcerative colitis’ OR ‘colitis ulcerosa’ OR 
‘Crohn’s disease’. Both MeSH-terms and free searches were performed. We included all types 
of English-language (clinical) trials concerning diagnostics and prevalence of CMV in IBD.
Results
The search strategy identified 924 citations, and 52 articles were eligible for inclusion. We 
identified 21 different definitions for CMV infection, 8 definitions for CMV intestinal disease 
and 3 definitions for CMV reactivation. Prevalence numbers depend on used definition, 
studied population and region. The highest prevalence for CMV infection was found when 
using positive serum PCR as a definition, whereas for CMV intestinal disease this applies to 
the use of tissue PCR > 10 copies/mg tissue. Most patients with CMV infection and intestinal 
disease had steroid refractory disease and came from East Asia.
Conclusion
We detected multiple different definitions used for CMV infection and intestinal disease 
in IBD patients, which has an effect on prevalence numbers and eventually on outcome in 
different trials.
Key words:	Inflammatory bowel disease; Cytomegalovirus; Ulcerative colitis; Crohn’s disease; 
Systematic review.
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INTRODUCTION
Cytomegalovirus (CMV) is a member of human herpesvirus family.1 CMV infection is 
common and mostly asymptomatic in healthy people. Seroprevalence data differ depending 
on the healthcare circumstances or immunocompetency of the host, but most studies give 
a seroprevalence of 40%-100% in adults,2-4 with the highest prevalence in non-western 
countries.5,6 In immunocompromised patients CMV infection may follow a complicated course 
resulting in retinitis, pneumonia and intestinal disease (mostly colitis) or other organ specific 
disease.7-9 The role of cytomegalovirus (CMV) in inflammatory bowel disease (IBD) is under 
scrutiny. Here, the discussion mainly focuses on either the association or causation of CMV 
infection and intestinal disease in adverse outcomes in IBD patients. The applied definitions 
for both CMV infection and CMV intestinal disease, are crucial in this issue, and the answer 
to the above key question can only be given when there is a unified gold standard definition 
of clinical relevant CMV infection and intestinal disease, which is lacking at this moment. Our 
aim was to perform a systematic review of the literature to identify the different definitions for 
CMV infection and intestinal disease in IBD patients, and to connect the used definitions to the 
reported prevalence. In addition we summarize the different diagnostic strategies for CMV 
infection and intestinal disease.
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MATERIALS AND METHODS
Search strategy and study selection
A search of the medical literature was conducted using MEDLINE, EMBASE and the Cochrane 
central register of controlled trials, until December 2014, according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.10,11 The 
study was registered in the PROSPERO database registry (PROSPERO registration number 
CRD 42015017451).The search strategy was designed to identify English language (clinical) 
trials concerning diagnostics and prevalence of CMV in IBD. The following medical search 
headings were used: ‘cytomegalovirus’ OR ‘CMV’ OR ‘cytomegalo virus’ AND ‘Inflammatory 
Bowel Disease’ OR ‘IBD’ OR ‘ulcerative colitis’ OR ‘colitis ulcerosa’ OR ‘Crohn’s Disease’. Both 
MeSH-terms and free searches were performed. Studies were eligible if reported on prevalence 
and/or diagnostic criteria to define CMV infection or CMV intestinal disease in IBD (Table 1). 
Because of the paucity of prospective, randomized, controlled trials on this subject, we aimed to 
consider all types of evidence available. To this end, we also included observational studies, case-
control studies and retrospective studies. We excluded non-English literature, case reports, 
case series with n < 10 cases and review articles. We also excluded studies that concerned 
CMV and pouchitis, or studies that concerned the causative relationship of CMV and IBD. Two 
independent reviewers (Römkens TEH, Bulte GJ) performed the first selection, and screened 
title and abstract of the papers identified by electronic search. They completed an inclusion form 
for eligible studies. Additional articles were obtained through citation snowballing to locate 
primary sources. When no abstract was available, the article was always screened by full text. 
Three investigators read all full text papers, and disagreements were resolved by consensus 
(Römkens TEH, Bulte GJ and Nissen LHC).
Outcome assessment
The primary outcomes were: (1) a list with all used definitions of CMV infection or CMV 
intestinal disease in IBD patients; and (2) prevalence numbers to assess the effect that the 
applied definition has on the reported prevalence of CMV in IBD patients. Secondary outcomes 
were: (1) prevalence of CMV in subpopulations as ulcerative colitis (UC), Crohn’s disease (CD), 
and steroid refractory disease; (2) prevalence of CMV in different regions of the world. We also 
summarized different diagnostic strategies for CMV infection in IBD patients.
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Data extraction and assessment of risk of bias
The data extraction process was carried out using a pre-established protocol. Full papers were 
reviewed using a purpose-designed database. The following clinical data were extracted for 
each trial: single- or multicenter, country of origin, duration of follow up, study period, sample 
size, characteristics of the studied population, medication at baseline, used diagnostics for 
CMV infection, criteria used to define CMV infection, criteria used to define CMV intestinal 
disease, CMV prevalence and authors conclusion. Assessment of risk of bias was performed 
independently by three investigators, with disagreements resolved by discussion. Risk of bias 
was assessed by recording of study type, retrospective or prospective design, sample size, 
study period and follow up, whether or not randomization or blinding was used, and recording 
specific population characteristics that pose a risk for selection bias (type and severity of IBD, 
medication use, exclusion criteria).
Statistical analysis
All abstracted data were entered into a structured database. We displayed the results for both 
CMV infection and intestinal disease in IBD patients separately, in line with the fact that these are 
two different entities. In addition to detailed tables, we provide the main results in scatterplots 
in order to give more insight in sample size, median and range of the various definitions. Next 
to this, we provide scatterplots of prevalence by definition in different subgroups as UC, CD, 
steroid refractory IBD, and IBD patients in different regions of the world. Kappa statistics 
were used to analyze agreement among the reviewers. Evidence-tables were provided for all 
characteristics of the included studies. We could not carry out a meta-analysis because head-
to-head comparison of the included studies was impossible due to heterogeneity.
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RESULTS
Selected studies
Our search strategy generated a total of 924 citations, of which 190 (168 + 22) published 
articles appeared to be relevant, and were retrieved for further assessment (Figure 1). Of these, 
138 (118 + 20) articles were excluded for various reasons, leaving 52 eligible articles. The main 
reasons for exclusion were case reports; reviews; non-IBD patients; no information on CMV 
(intestinal) infection and non-English literature. Agreement in this step between reviewers 
was 88% (Cohen’s Kappa 0.73) before consensus meeting. Study (risk of bias) variables are 
shown in Appendix 1. Most of the included studies have small sample sizes. None of the included 
studies was randomized and most of the study designs were single centre (n = 42/50) with more 
than half of them using a retrospective design (26/48). Some used blinding for the reviewing 
pathologist (6/43) or endoscopist (2/43).
Definitions and prevalence
We identified 21 different definitions for CMV infection, and 8 definitions for CMV intestinal 
disease (Tables 2 and 3). Three definitions for reactivation of CMV are listed in Table 4. Some 
studies do not mention or define CMV infection, but report prevalence numbers of ‘mucosal 
expression’, 12 or ‘presence of CMV’ 13,14 and some provide a prevalence rate without defining 
CMV infection.15-62 Prevalence data for definitions used more than once for respectively CMV 
infection and intestinal disease are listed in a scatter plot (Figures 2 and 3). By using the authors’ 
definition of either CMV infection or intestinal disease, we found different prevalence numbers 
in various regions of the world and in different subpopulations, which are depicted in scatterplots 
for CMV infection in Figures 4 and 5. If available CMV seroprevalence data are depicted in 
Figure 6. More detailed information on this topic and prevalence numbers for CMV intestinal 
disease are given in supplementary files (Appendix 2 A,B and Appendix 3 A, B). In general, the 
prevalence is negligible in healthy controls. We found a higher prevalence in UC than in CD both 
for CMV infection (median 14% vs 2.5%) and CMV intestinal disease (median 19.5% vs 11%). 
The prevalence is highest in steroid refractory disease for CMV infection (median 32.5%) and 
intestinal disease (median 32.5%). 
Diagnostic tests for CMV
More than 10 different tests were used to diagnose CMV (active) infection and intestinal 
disease, which can be found in the definition Tables 2 and 3. Histology, with or without 
immunohistochemistry (IHC), is most widely used to diagnose CMV disease (infection and/or 
intestinal disease; n = 30/48). PCR on tissue is used in almost one third of the included studies 
(14/48). In Table 5 we present an overview of the test characteristics as described earlier in 
literature.24,63-70
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DISCUSSION
This systematic review maps the prevalence of both CMV infection and intestinal disease in IBD 
patients. We found that the prevalence greatly depends on the used definition. Studies reporting 
the highest prevalence of CMV infection use positive serum PCR as test, while studies that 
use positive antigenemia follow suit. In case of diagnosing CMV intestinal disease, the highest 
prevalence applies for tissue PCR (> 10 copies/ mg tissue). IBD patients with steroid refractory 
disease and those coming from East Asia have the highest prevalence of CMV infection and/
or intestinal disease. 
In general CMV infection or intestinal disease is seen more frequently in UC compared to CD. The 
difference of CMV infection and clinically relevant intestinal disease has been outlined earlier in 
literature. There, CMV infection is described as (incidental) finding of positive PCR or detection 
of CMV antigens or antibodies in serum, whereas CMV disease is a clinical syndrome where CMV 
infection is accompanied by manifest clinical symptoms.67,69,71,72 Subclinical reactivation of CMV, 
without symptoms, is seen in approximately 50% of active UC cases on immunosuppressive 
therapy.62 In practice however, the different entities described above, are used interchangeably. 
Likewise, no unified definitions have been used in clinical trials, and our study documents that 
the terms CMV infection and CMV intestinal disease are used reciprocally. This makes it difficult 
to compare data from different studies and to draw conclusions for outcome. Interestingly, by 
using the author’s definition, we found the highest prevalence of CMV infection and intestinal 
disease in East Asia. Population based CMV seroprevalence studies are lacking, but a review on 
this topic found that seroprevalence tended to be highest in South America, Africa and Asia, and 
was also higher in parts of Europe and the Middle East.6 The most likely explanation is the use of 
different diagnostic methods for CMV infection in different regions of the world. We show high 
prevalence numbers for CMV infection when antigenemia is used as test (Table 2), where 80% 
of these studies appear to come from Japan. CMV infection and more importantly CMV colitis 
is unusual in the healthy population13,28,29,54 as described before in a systematic review.71 Only 
one study reported presence of CMV DNA in 29% of asymptomatic control samples, but robust 
replication studies to confirm this unusual finding are lacking.14 We found lower prevalence of 
CMV infection (and to a lesser extent in intestinal disease) for CD compared to UC13,34 (Appendix 
3AB). The most frequently studied population in relation to CMV is those with steroid resistant 
IBD or refractory UC. Apropos it should be noted that these studies use different definitions 
for steroid resistant IBD or refractory UC which may affect the prevalence.71,73 We found the 
highest prevalence of CMV infection and CMV intestinal disease in steroid refractory disease, 
for each definition of CMV used 54 (Appendix 3AB). Whether or not CMV reactivation has a role 
in the process of steroid resistance, is still under debate.57,73-75 
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The surveyed literature contains 29 different methods to diagnose CMV infection and/
or intestinal disease, probably mainly caused by the fact that still no single gold standard 
exists for (clinically relevant) CMV infection in IBD. In general, the literature recommends 
to process biopsies for HE and IHC33,63,71,76 and/or if available by CMV DNA real-time PCR, 
with a cut-off value that is yet to be identified.76 The recent ECCO guideline72 mentions that 
different techniques for diagnosis of CMV infection are available, but stops short of defining 
a gold standard. The guideline refers to histopathology combined with IHC (using monoclonal 
antibodies) as highly specific and sensitive for verifying CMV infection in tissue. In addition the 
guideline describes quantitative PCR in tissue and in blood as the most commonly used and 
advantageous technique for diagnosis of CMV infection. Quantitative PCR has a low sensitivity 
for diagnosing CMV colitis in patients with moderate to severe UC, and cannot substitute 
histopathology diagnosis.44 
Already in the nineties consensus meetings were held to formulate the definition for CMV 
infection in general and for all organ specific involvements in transplant recipients. These 
definitions were updated again in 2002.67 CMV infection was defined as isolation of the CMV 
virus or detection of viral proteins or nucleic acid in any body fluid or tissue specimen. There 
CMV (gastro)intestinal disease was defined by identification of a combination of (1) clinical 
symptoms; (2) findings of macroscopic mucosal lesions on endoscopy; and (3) demonstration of 
CMV infection (by culture, histopathology, IHC, or in situ hybridization) in a (gastro)intestinal 
tract biopsy specimen. According to this guideline detection of CMV by PCR alone is insufficient 
for diagnosis of CMV gastrointestinal disease. Applying these criteria to IBD patients can be 
more complicated, since ulceration can also be caused by the underlying IBD. Since then, 
multiple more sensitive diagnostic tests have been developed to detect CMV, but a threshold 
or definition of clinical relevant CMV infection or intestinal disease remains to be established. 
We suggest that a global multidisciplinary consensus meeting on CMV and IBD should be held, 
in order to develop one unified definition of clinically relevant CMV intestinal disease. In this 
context, clinically relevant describes the situation that symptoms appear, clinical deterioration 
occurs, and (antiviral) treatment should be initiated. This single definition could be used in clinical 
practice, but also in future trials, to serve as a gold standard in the discussion on outcome and 
optimal (antiviral) treatment of CMV in IBD patients. 
Our study has several strengths. First of all, we show that the use of different definitions of 
CMV infection impacts reported prevalence rates. Second, we provide CMV prevalence data 
for several important sub populations, as UC, CD, steroid refractory disease, and patients 
in different continents of the world. Third, two independent reviewers reviewed all eligible 
studies, and three reviewers read all full text papers, with good agreement scores based on the 
presented kappa value. Our study comes with some limitations. None of the included studies 
were randomized, most of them had a retrospective design and only some used blinding of 
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endoscopists or pathologists. The heterogeneity of the design of included studies and wide 
variations in used definitions for both CMV infection and intestinal disease made it impossible 
to perform a meta-analysis on these data. 
In conclusion we find a wide variety in definitions used for CMV infection and intestinal disease 
in IBD patients, which impacts corresponding prevalence rates and eventually the outcome 
in different trials. A global consensus meeting is pivotal to develop one unified gold standard 
definition for clinically relevant CMV, to be used in clinical practice as well as in future trials.
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TABLES
Table 1 Eligibility criteria for inclusion
Eligibility criteria 
Adults
Diagnosis of IBD, according to international guidelines
English language
Prevalence and/or diagnostics CMV infection or intestinal disease reported
Minimal sample size 10 patients
IBD: Inflammatory bowel disease; CMV: Cytomegalovirus.
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Table2  Prevalence by definition of CMV-infection
Definition Studies	(n) Median Range
Antigenemia 17-21 5 32% 6%-34%
Tissue PCR 22-25 4 11% 1%-32%
IHC a, 26-29 4 13% 9%-23%
HE 30-32 3 17% 5%-36%
HE OR IHC 33, 34 2 8% 5%-11%
HE AND IHC 35, 36 2 19% 12%-27%
IgM OR HE OR IHC b 37, 38 2 9% 5%-13%
Antigenemia OR Tissue PCR 39 1 n/a n/a
Serum PCR 40 1 84% -
(HE AND IHC) OR tissue PCR 41 1 4% -
Tissue PCR 10 copies/μg; OR histology OR Antigenemia 42 1 54% -
Antigenemia (2tests: C7-HRP OR C10/C11) OR histology 43 1 9% -
Antigenemia OR blood PCR
quantitative 
44 1 36% -
IgM OR serum PCR OR HE 45 1 78% -
IgM OR tissue PCR
qualitative
 OR HE 46 1 16% -
IgG AND (blood culture, antigenemia OR histology OR IgM 
OR urine culture) 47
1 6% -
IgM OR serum PCR
qualitative
 OR feces PCR 48 1 5% -
Inclusions: HE 49 1 13% -
Active infection: tissue PCR 50 1 13% -
Active replication: (HE/ IHC) AND antigenemia 51 1 36% -
Blood dissemination: (viremia, antigenemia, RNAemia) OR 
(viremia OR tissue culture) 52
1 16% -
Total:	21 Total:	36
a: one study defined a ‘clinically relevant infection as >10 IHC + cells/section but also 
recognized ‘scattered’ positivity as 1-9 cells per section 29; b once mentioned as ‘acute infection’; 
PCR=polymerase chain reaction, IHC=immunohistochemistry, HE=Hematoxylin and eosin staining, 
IgM=immunoglobulin M, IgG=immunoglobulin G, N referring to number of studies using this 
definition.
Cytomegalovirus in Inflammatory Bowel Disease   |   129
5
Table3   Prevalence by definition of cytomegalovirus-intestinal disease
Definition Studies 
(n)
Median 
(%)	
Range 
(%)
HE OR IHC 1,2 38, 44, 53, 54 4 6 2-29
HE 20, 55 2 9 0-17
Tissue PCR
quantitative
 >10 copies/mg 56, 57 2 34 30-38
Serology AND (IHC OR antigenemia OR serum PCR OR tissue PCR) 58 1 6 -
IHC 59 1 0 -
HE OR IHC OR tissue PCR 51 1 33 -
(Pp65 antigenemia OR tissue PCR
quantitative
) AND IHC AND intestinal 
symptoms 39
1 n/a3 -
IHC positive when inflammation present 52 1 1 -
Total:	8 Total:	13
1One study tested both before and after iv-steroid administration; 2No data on prevalence: definition is 
used as the gold standard to compare other diagnostics; 3 No prevalence is reported in this study. PCR: 
Polymerase chain reaction; HE: Hematoxylin and eosin staining; IHC: Immunohistochemistry
Table 4 Prevalence by definition of cytomegalovirus reactivation
Definition Studies	(n) Median	(%) Range	(%)
IgM OR HE OR PCR 1,60 1 10 -
Serum PCR in IgG positive patients 61 1  0 -
Antigenemia OR plasma PCR 62 1 36 -
Total:	3 Total:	3
1Not specified what material is used for PCR testing. PCR: Polymerase chain reaction; HE: Hematoxylin 
and eosin staining; IgM: Immunoglobulin M; IgG: Immunoglobulin G.
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Table 5 Test characteristics different diagnostic tools for cytomegalovirus
Test Pro Con
Sens 
(%)
Spec 
(%)
Serology Fast, quantification possible Systemic, not proving 
intestinal disease;
98-100 96-99
Antigenemia Fast, quantification possible Systemic, not proving 
intestinal disease labor 
intensive
60-100 83-100
Serum PCR Fast, quantification possible Systemic, not proving 
intestinal disease
65-100 40-94
H&E Histology 
(gold standard?)
Specific, proofs intestinal 
disease 
Slow; low sensitivity 10-87 92-100
Histology with IHC Specific, proofs intestinal 
disease
Slow 93 92-100
Tissue PCR Quantification possible Cut-off point unclear, 
uncertain clinical 
significance
65-100 40-100
Stool PCR Quantification possible Little experience 83 93
Viral Culture Very specific Very slow 45-78 89-100
Rapid Vial culture Very specific Little experience 68-100 89-100
Sens=sensitivity, Spec=specificity, PCR=polymerase chain reaction, H&E=Hematoxylin and eosin staining, 
IHC=immunohistochemistry
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FIGURES
Initial search: 924 results 
Removal of duplicates: 857 left 
Selection by title: 216 left 
Selection by abstract: 168 left 
Selection by full text: 50 left 
Excluded: 
Reviews: 15 
Case reports: 31 
Editorials/letters/comments: 281 
Etiology: 2 
No CMV colitis or IBD: 19 
No prevalence: 20 
Duplicates: 3 
Total: 118 
1: letters/comments presenting original data were included in the review, and therefore not in this number 
Final selection:52 results 
Reference snowballing: 58 
results 
Selection by abstract: 22 results 
Excluded: 
No CMV colitis:  3 
No IBD:  9 
Case reports: 3 
Non-English: 1 
Congress abstract: 1 
Duplicates: 1 
Guidelines: 2  
Total: 20 
Selection by full text: 2 left 
Figure 1 Algorithm of inclusion
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 
 


  
  
    
     
 
Figure 2 Prevalence cytomegalovirus infection by authors definition. Size of the squares corresponds 
with the population size in 5 categories (n = 0-25, n = 25-50, n = 50-100, n = 100-250, n > 250). Median 
depicted as dotted line.
    
  

   
     
 
Figure 3 Prevalence cytomegalovirus intestinal disease by authors definition. Size of the squares 
corresponds with the population size in 5 categories (n = 0-25, n = 25-50, n = 50-100, n = 100-250, n > 
250). Median depicted as dotted line. 
Cytomegalovirus in Inflammatory Bowel Disease   |   133
5
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 
 
 
 
 
     

 
Figure 4 Prevalence cytomegalovirus infection in different global regions by authors definition. Size of 
the squares corresponds with the population size in 5 categories (n = 0-25, n = 25-50, n = 50-100, n = 
100-250, n > 250). Median depicted as dotted line.
    

 
 
  
  
   
     
 
Figure 5 Prevalence cytomegalovirus infection in different subpopulations, by authors definition. Size 
of the squares corresponds with the population size in 5 categories (n = 0-25, n = 25-50, n = 50-100, n = 
100-250, n> 250). Median depicted as dotted line.
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Figure 6 Cytomegalovirus seroprevalence data in different regions of the world. Size of the squares 
corresponds with the population size in 5 categories (n = 0-25, n = 25-50, n = 50-100, n = 100-250, n > 
250). Median depicted as dotted line.
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SUPPLEMENTARY FILES
Appendix 1 Characteristics of included studies.
Appendix 2a Prevalence by region, author’s definition of CMV-infection.
Appendix 2b Prevalence by region, author’s definition of CMV-intestinal disease.
Appendix 3a Prevalence by subpopulation, author’s definition of CMV-infection.
Appendix 3b Prevalence by subpopulation, author’s definition of CMV-intestinal disease.
Appendix 1 Characteristics of included studies ; ns: not specified, n/a not applicable
Author Year Country Study period Study type Follow	up	(months) Multi-center Prospective Blinded N
Iida 17 2013 Japan 2003-2011 cohort study n/a yes ns yes (endoscopist) 105
Iyer 55 2013 India 2009-2011 cross-sectional observational study n/a no yes no 87
Yi 40 2013 China 2006-2011 cross-sectional observational study n/a no ns ns 226
Antonelli 58 2012 Italy 2007-2010 cohort study n/a no no no 87
Roblin 56 2012 France 2009 observational study n/a no yes yes (pathologist) 60
Aarnio 59 2012 Finland 1995-2009  cohort study n/a no no yes (pathologist) 16
Sipponen 12 2011 Finland ns cross-sectional observational study n/a no yes yes (pathologist) 79
Roblin 57 2011 France 2009 observational study 10 no yes yes (pathologist) 42
Kim 53 2012 Korea 2007-2008 cohort study n/a yes yes no 72
Criscuoli 51 2011 Italy 1997-2007 observational cohort 40 no yes ns 85
Leveque 50 2010 France 2005-2009 cohort study n/a no no ns 53
Suzuki 18 2010 Japan 1999-2007 case-control study n/a no no yes 76
Nakase 15 2010 Japan ns cohort study n/a no ns ns 10
Kim 26 2010 USA 2000-2006 cohort study 23-29 yes no ns 142
Barahona 30 2010 Mexico / Guatamala 1988-2009 cohort study n/a no no no 41
Knösel 13 2009 Germany ns historic case control n/a no no ns 56
Maher 37 2009 Saoudi Arabia 2005-2007 cohort study n/a no yes ns 72
Banerjee 22 2009 India 2005 cross-sectional observational study n/a no yes ns 49
d’Ovidio 39 2008 Italy 2003-2004 observational cohort 24 no yes ns 15
Domenech 54 2008 Spain 2000-2003 observational cohort n/a no yes yes 94
Yoshino 42 2007 Japan 2003-2006 cohort study n/a no no no 30
Minami 45 2007 Japan 1999-2005 cohort study 1 no yes no 23
Matsuoka 62 2007 Japan ns cohort study 2 no yes no 69
Dimitroulia 27 2006 Greece 2000-2003 cross-sectional study n/a yes yes no 85
Kojima 33 2006 Japan 1963-2003 cohort study n/a no no no 126
Alain 52 2005 France 1998-2000 cohort study n/a no yes no 91
de Saussure 47 2004 France 1998-2000 cohort study n/a no yes no 64
Kishore 46 2004 India ns cohort study n/a yes yes no 63
Kambham 28 2004 USA 1992-2002 case control study n/a no no no 80
Takahashi 34 2004 Japan 1993-2002 cohort study n/a no no no 173
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Appendix 2a Prevalence by region, author’s definition of CMV-infection.
Appendix 2b Prevalence by region, author’s definition of CMV-intestinal disease.
Appendix 3a Prevalence by subpopulation, author’s definition of CMV-infection.
Appendix 3b Prevalence by subpopulation, author’s definition of CMV-intestinal disease.
Appendix 1 Characteristics of included studies ; ns: not specified, n/a not applicable
Author Year Country Study period Study type Follow	up	(months) Multi-center Prospective Blinded N
Iida 17 2013 Japan 2003-2011 cohort study n/a yes ns yes (endoscopist) 105
Iyer 55 2013 India 2009-2011 cross-sectional observational study n/a no yes no 87
Yi 40 2013 China 2006-2011 cross-sectional observational study n/a no ns ns 226
Antonelli 58 2012 Italy 2007-2010 cohort study n/a no no no 87
Roblin 56 2012 France 2009 observational study n/a no yes yes (pathologist) 60
Aarnio 59 2012 Finland 1995-2009  cohort study n/a no no yes (pathologist) 16
Sipponen 12 2011 Finland ns cross-sectional observational study n/a no yes yes (pathologist) 79
Roblin 57 2011 France 2009 observational study 10 no yes yes (pathologist) 42
Kim 53 2012 Korea 2007-2008 cohort study n/a yes yes no 72
Criscuoli 51 2011 Italy 1997-2007 observational cohort 40 no yes ns 85
Leveque 50 2010 France 2005-2009 cohort study n/a no no ns 53
Suzuki 18 2010 Japan 1999-2007 case-control study n/a no no yes 76
Nakase 15 2010 Japan ns cohort study n/a no ns ns 10
Kim 26 2010 USA 2000-2006 cohort study 23-29 yes no ns 142
Barahona 30 2010 Mexico / Guatamala 1988-2009 cohort study n/a no no no 41
Knösel 13 2009 Germany ns historic case control n/a no no ns 56
Maher 37 2009 Saoudi Arabia 2005-2007 cohort study n/a no yes ns 72
Banerjee 22 2009 India 2005 cross-sectional observational study n/a no yes ns 49
d’Ovidio 39 2008 Italy 2003-2004 observational cohort 24 no yes ns 15
Domenech 54 2008 Spain 2000-2003 observational cohort n/a no yes yes 94
Yoshino 42 2007 Japan 2003-2006 cohort study n/a no no no 30
Minami 45 2007 Japan 1999-2005 cohort study 1 no yes no 23
Matsuoka 62 2007 Japan ns cohort study 2 no yes no 69
Dimitroulia 27 2006 Greece 2000-2003 cross-sectional study n/a yes yes no 85
Kojima 33 2006 Japan 1963-2003 cohort study n/a no no no 126
Alain 52 2005 France 1998-2000 cohort study n/a no yes no 91
de Saussure 47 2004 France 1998-2000 cohort study n/a no yes no 64
Kishore 46 2004 India ns cohort study n/a yes yes no 63
Kambham 28 2004 USA 1992-2002 case control study n/a no no no 80
Takahashi 34 2004 Japan 1993-2002 cohort study n/a no no no 173
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Appendix 1 Continued
Author Year Country Study period Study type Follow	up	(months) Multi-center Prospective Blinded N
Wada 19 2003 Japan 2000-2002 cohort study n/a no yes no 47
Rahbar 78 2003 Sweden ns cohort study n/a ns ns no 23
Cottone 31 2001 Italy 1997-1999 cohort study <1 no yes no 19
Cooper 49 1977 USA ns cohort study n/a no no no 46
Eyre-Brook 35 1986 United Kingdom 1980-1984 cohort study n/a no no no 26
Wakefield 14 1992 United Kingdom ns case control study n/a ns yes no 50
Maconi 36 2005 Italy 1997-2003 observational n/a no no yes (pathologist) 55
Lavagna 41 2006 Italy 1994-2001 case control study n/a no no no 24
Hirata 16 2007 Japan 17yrs, ns observational n/a no no no 27
Lavagna 61 2007 italy ns observational cohort study 4 no yes no 60
Van Kruiningen 
23
2007 USA, France, 
Belgium
2yrs, ns observational 24 yes no no 70
Kuwabara 29 2007 Japan 1987-2002 observational n/a no no no 22
Herfarth 24 2010 USA 2007-2008 observational 6 no yes yes (pathologist) 19
Matsumoto 43 2014 Japan 2000-2011 observational n/a no no no 222
Kim 38 2012 Korea 2007-2008 observational n/a yes yes no 65
Criscuoli 20 2004 Italy 2000-2003 observational n/a no no no 42
Do Carmo 48 2014 Brasil 2011-2012 observational n/a no no yes 400
Kim 60 2014 Korea 2007-2008 observational cohort 43 yes no no 31
Inokuchi 21 2014 Japan 2004-2011 case control study n/a no no no 118
Kim 44 2014 Korea 2001-2012 case control study n/a no no yes (endoscopist) 229
Mokhtari 25 2012 Iran 2010-2011 case control study n/a no no no 22
Al-Zafiri 32 2012 Canada 2000-2009 observational cohort study (case 
control with historic controls)
n/a no no no 612
Appendix 2a Prevalence by region, author’s definition of CMV-infection
Region Studies	(n) Median	(%) Range	(%)
East Asia (Japan, China, Korea) 16-19, 21, 29, 33, 34, 38, 40, 42-45, 53 15 32 0-78
Central Asia (India, Iran, Saudi Arabia) 22, 25, 37, 46 4 14 8-16
Northern Europe (Sweden, Finland, United Kingdom, 
Germany, France, Belgium)a 23, 35, 47, 50, 52, 78
6 13 1-96
Southern Europe (Italy, Greece, Spain) 20, 27, 31, 36, 51, 61 6 20 4-36
North America (USA, Canada, Mexico)a 23, 24, 26, 28, 30, 32, 49 7 13 1-32
South America (Brazil) 48 1 5 -
a 1 study was included twice because of intercontinental study-population
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Appendix 1 Continued
Author Year Country Study period Study type Follow	up	(months) Multi-center Prospective Blinded N
Wada 19 2003 Japan 2000-2002 cohort study n/a no yes no 47
Rahbar 78 2003 Sweden ns cohort study n/a ns ns no 23
Cottone 31 2001 Italy 1997-1999 cohort study <1 no yes no 19
Cooper 49 1977 USA ns cohort study n/a no no no 46
Eyre-Brook 35 1986 United Kingdom 1980-1984 cohort study n/a no no no 26
Wakefield 14 1992 United Kingdom ns case control study n/a ns yes no 50
Maconi 36 2005 Italy 1997-2003 observational n/a no no yes (pathologist) 55
Lavagna 41 2006 Italy 1994-2001 case control study n/a no no no 24
Hirata 16 2007 Japan 17yrs, ns observational n/a no no no 27
Lavagna 61 2007 italy ns observational cohort study 4 no yes no 60
Van Kruiningen 
23
2007 USA, France, 
Belgium
2yrs, ns observational 24 yes no no 70
Kuwabara 29 2007 Japan 1987-2002 observational n/a no no no 22
Herfarth 24 2010 USA 2007-2008 observational 6 no yes yes (pathologist) 19
Matsumoto 43 2014 Japan 2000-2011 observational n/a no no no 222
Kim 38 2012 Korea 2007-2008 observational n/a yes yes no 65
Criscuoli 20 2004 Italy 2000-2003 observational n/a no no no 42
Do Carmo 48 2014 Brasil 2011-2012 observational n/a no no yes 400
Kim 60 2014 Korea 2007-2008 observational cohort 43 yes no no 31
Inokuchi 21 2014 Japan 2004-2011 case control study n/a no no no 118
Kim 44 2014 Korea 2001-2012 case control study n/a no no yes (endoscopist) 229
Mokhtari 25 2012 Iran 2010-2011 case control study n/a no no no 22
Al-Zafiri 32 2012 Canada 2000-2009 observational cohort study (case 
control with historic controls)
n/a no no no 612
Appendix 2a Prevalence by region, author’s definition of CMV-infection
Region Studies	(n) Median	(%) Range	(%)
East Asia (Japan, China, Korea) 16-19, 21, 29, 33, 34, 38, 40, 42-45, 53 15 32 0-78
Central Asia (India, Iran, Saudi Arabia) 22, 25, 37, 46 4 14 8-16
Northern Europe (Sweden, Finland, United Kingdom, 
Germany, France, Belgium)a 23, 35, 47, 50, 52, 78
6 13 1-96
Southern Europe (Italy, Greece, Spain) 20, 27, 31, 36, 51, 61 6 20 4-36
North America (USA, Canada, Mexico)a 23, 24, 26, 28, 30, 32, 49 7 13 1-32
South America (Brazil) 48 1 5 -
a 1 study was included twice because of intercontinental study-population
Appendix 2b Prevalence by region, author’s definition of CMV-intestinal disease
Region Studies	(n) Median	(%) Range	(%)
East Asia (Japan, China, Korea) 38, 53 2 17 5-29
Central Asia (India, Iran, Saudi Arabia) 55 1 2 -
Northern Europe (Sweden, Finland, United Kingdom, 
Germany, France, Belgium) 52, 56, 57, 59
4 16 0-38
Southern Europe (Italy, Greece, Spain) 20, 51, 54, 58 4 12 6-33
North America (USA, Canada, Mexico) - - -
South America (Brazil) - -
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Appendix 3a Prevalence by subpopulation, author’s definition of CMV-infection
Subpopulation Studies(n) Median	(%) Range	(%)
IBD 20, 26, 27, 32, 34, 37, 40, 46-48, 50, 52 12 12 5-84
UC 17-19, 21, 22, 25, 26, 28, 34, 37, 40, 43, 44, 47, 48, 51 16 14 6-85
CD 26, 34, 37, 40, 47, 48 6 2,5 0-78
Steroid refractory IBD 15-17, 24, 28, 31, 37, 42, 45, 53 10 32,5 0-78
Surgical resection specimens 23, 29, 30, 33, 35, 36, 41, 49, 78 9 13 1-96
Controls 28, 40 2 30 0-60
Colectomy specimen in steroid refractory disease 30, 33, 36 3 27 8-28
Steroid responsive IBD 28 1 3 -
Appendix 3b Prevalence by subpopulation, author’s definition of CMV-intestinal disease
Subpopulation Studies(n) Median	(%) Range	(%)
IBD 20, 56, 58 3 17 6-30
UC38, 51, 53-56 6 19,5 2-43
CD 56 1 11 -
Steroid refractory IBD 20, 53, 54, 58 4 32,5 11-67
Surgical resection specimens 59 1 0 -
Controls 54 1 0 -
Steroid responsive IBD 53 1 33 -
Colectomy specimen in steroid refractory disease - - -


PART III
Challenges	in	daily	IBD	care	–	
Theory versus real-life data

CHAPTER # 
Treatment Targets in Inflammatory Bowel Disease: 
Current Status in Daily Practice
CHAPTER 6 
Tessa	E.	H.	Römkens
Pim Kranenburg 
Arjan van Tilburg
Carolien	Bronkhorst	
Iris	D.	Nagtegaal
Joost	P.	H.	Drenth
Frank Hoentjen
J Crohns Colitis. 2018 Mar 28; 12(4): 425-431
Assessment of Histological Remission 
in	Ulcerative	Colitis:	
Discrepancies Between Daily Practice 
and Expert Opinion
ABSTRACT
Background and Aims
Histological remission (HR) is a potential treatment target in ulcerative colitis (UC). Limited 
‘real world’ data are available on the reliability of histological scoring when assessing minimal 
histological inflammation. The aim of this study was to investigate the reliability of UC 
histological scores in colonic biopsies showing mucosal healing (MH) and limited histological 
inflammation, and to compare the ‘daily practice’ histological assessment with expert reviews 
by gastrointestinal (GI) pathologists.
Methods
We performed a retrospective single-centre study. Colonic biopsies from UC patients with 
MH (Mayo score ≤ 1) were included. All biopsies assessed in daily practice were reassessed 
by three blinded GI pathologists using three histological scores (Geboes score (GS), Riley 
score(RS), Harpaz (Gupta) Index (HGI) and a global visual scale (GVS). We evaluated inter- and 
intra-observer variation between GI pathologists and correlations between scores including 
the initial histological assessment using Cronbach’s alpha and Spearman rho analysis.
Results
In total, 270 biopsies from 39 UC patients were included. The inter-observer concordance 
for all histological indexes was substantial to almost perfect (GS 0.84; HGI 0.61; GVS 0.74, 
RS 0.91). Correlation between the RS and GS was almost perfect (R = 0.86), but we found 
no correlation between the primary histological assessment and reassessment by expert GI 
pathologists.
Conclusions
Current UC histological scores reliably assess limited histological inflammation in UC 
patients. The discrepancy between the initial histological assessment and the reassessment 
by dedicated GI pathologists suggests a gap between daily practice and academic expertise. 
This issue may limit the implementation of HR as a treatment target for UC in daily practice.
     
Key words: Histological remission; ulcerative colitis; pathology; central reading.
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INTRODUCTION
Treatment goals for inflammatory bowel disease (IBD) have changed from assessing primarily 
symptom-based treatment to evaluating treatment targets that combine both patient-reported 
outcome (PRO) remission and endoscopic remission (mucosal healing (MH)).1 The advent of 
biologicals with positive effects on mucosal inflammation contributed significantly to this shift.2-6 
MH is a well accepted treatment target in clinical IBD trials7-10 and is associated with relevant 
clinical outcomes.6, 11-13 Some clinical trials have introduced even more stringent treatment 
targets in IBD such as ‘histological remission (HR)’. HR might be a better predictor for a more 
favorable disease course, in particular in ulcerative colitis (UC).14-18 However, at present there 
is no unified definition of HR, 15, 19, 20 which seems pivotal for the design and comparability of 
clinical trials, but also for the use of HR as treatment target in daily practice. Several scoring 
indexes are available to measure histological activity in UC. Frequently used scores include the 
Geboes score (GS), Riley score (RS) and to a lesser extent the easy to use Harpaz (Gupta) Index 
(HGI). Only limited data on reproducibility of these scores were available until recently.21-23 Two 
studies evaluating the reproducibility and reliability of these histological activity indexes showed 
a strong correlation between scores and good intra-observer reproducibility with moderate to 
good inter-observer agreement.24, 25 The greater portion of patients in both studies however, 
had (mildly) active disease. Indeed, the histological item that showed the strongest intra- 
and inter-observer agreement was ‘erosion/ulceration’, a feature that correlates with active 
disease. In addition, the assessing pathologists were all expert GI-pathologists. This leads us to 
two questions. First, does this high observer agreement still hold when re-evaluating colonic 
biopsies with MH that were initially assessed by a general pathologist as ‘HR’. Secondly, do these 
histological indexes, so far mainly used in clinical trials, correlate with the histological assessment 
in daily practice by a general pathologist? In order to assess these questions, we designed a study 
with the objective to compare the reproducibility and reliability of three histological scoring 
indexes (GS, RS, HGI) and one global visual score (GVS) through intra- and inter-observer 
agreement testing, in colonic biopsies with MH that were primarily assessed as HR in daily 
practice. In addition we investigated the correlation between histological assessment of UC 
biopsies in daily practice and the re-assessment by specialized GI-pathologists.
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MATERIALS AND METHODS
Study design
We designed a retrospective single-centre study in a tertiary referral centre. This trial 
(ISRCTN61139227) was approved by the Ethics Committee of Radboud University Medical 
Centre, Nijmegen, the Netherlands.
Patients
We searched our endoscopy database to identify patients with established UC who met the 
inclusion criteria. Patients were included if they had (i) a colonoscopic examination between 
January 2014 and July 2015; (ii) a well-established diagnosis of UC according to clinical 
and histological criteria (Montreal classification E1–3 were included);26 (iii) endoscopic MH 
throughout the examined colon according to the Mayo endoscopic score ≤1;13,27,28 (after 
inclusion, two groups were distinguished based on the endoscopic Mayo score (0 vs 1)) and 
(iv) obtained and well-documented colonic biopsies from rectum, sigmoid and proximal colon 
(proximal of splenic flexure). Patients were excluded if they had (i) a Mayo endoscopic score >1 
or (ii) a diagnosis of either Crohn’s disease or IBD unclassified. Demographic data of patients 
were anonymously collected from digital patient records.
Assessment of biopsy specimens
Biopsies were paraffin-embedded, sectioned and H&E-stained. The slides were scanned at 200× 
magnification. All biopsies were reassessed by two blinded expert GI pathologists (IN, CB) and 
one GI pathology fellow (AT). Two pathologists are employed in an academic hospital (IN, AT) and 
one in a large non-academic teaching hospital (CB). Prior to the assessment a consensus meeting 
was held and teaching materials with sample images of the different scores were developed. 
Three histological scoring systems (GS, RS and HGI) were used during reassessment, as well as 
a GVS, indicating a ‘first glance’ assessment. The GVS is a visual scale ranging from 0 (no activity) 
to 10 (maximal activity). All three scoring systems are described in detail in Supplementary Data 
Tables S1–S3. The GS21 assesses five features which result in a score ranging from 0 to 5.4, 
with higher scores indicating more inflammation. The original RS evaluates six features which 
are scored on a four point scale (none, mild, moderate or severe), in which equal weight to all 
six measures was given.22 The HGI23 is based on three features resulting in a four-point scale 
(Histological Activity Index 0 to 3) with higher scores indicating greater inflammation. Each 
pathologist scored all biopsies by sections that represent a specific part of the colon (rectum, 
left-sided or proximal of splenic flexure). Each section contained several biopsies, with the worst 
score applied for further analysis. Two blinded pathologists (IN, AT) scored 18 random sections 
twice, with an interval of at least 2 weeks, to evaluate intra-observer reliability. From all biopsies 
obtained during colonoscopy, the report of the ‘general pathologist’ (gp) (the general pathologist 
who initially assessed the biopsies in daily clinical setting) was evaluated and used as a baseline 
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to construct two groups for analysis. Biopsies that were initially evaluated as ‘histological 
remission’ (gpHR) were compared with those showing ‘histological inflammation’ (gpHI), with 
regard to inter-observer agreement and intra-observer reliability for all scores. In addition, 
we assessed the correlation between the primary histological assessment and the different 
histological scores as well as the correlation between endoscopic Mayo score and histological 
scores. Biopsies were divided and compared by location (rectum, left-sided colon, colon proximal 
of splenic flexure) and Montreal classification (E1–3).
Statistical analysis
SPSS version 22.0 and Scilab were used for the statistical analysis. We used descriptive statistics 
to analyze the results using counts and proportions for categorical data and means and standard 
deviations for continuous variables. We evaluated inter- and intra-observer variation of GI 
pathology experts for GS, HGI and GVS total scores in biopsies taken from endoscopically 
healed mucosa with Cronbach’s alpha statistics, and for the 95% confidence interval we used 
bootstrapping and provided the percentage of agreement. We used the interpretation of 
kappa values as suggested by Landis29: 0.00 poor; 0.00–0.20 slight; 0.21–0.40 fair; 0.41–0.60 
moderate; 0.61–0.80 substantial; 0.81–1.00 almost perfect. For the RS we evaluated inter- 
and intra-observer concordance between the six different items of the RS with Cronbach’s 
alpha statistics. Where there was almost perfect inter-observer concordance, we provide the 
percentage of agreement, because Cronbach’s alpha statistics could not reliable be used. The 
relationship between indexes was studied by Spearman’s correlation coefficient. We compared 
the outcome of biopsies that are primarily assessed as ‘normal’ (gpHR) or ‘abnormal’ (gpHI) by 
the general pathologist, and GI pathology experts.
150   |   Chapter 6
RESULTS
General
We assessed 77 sections with 270 H&E-stained biopsies (143 rectum (53%), 20 sigmoid 
(7%), 107 proximal of splenic flexure (40%)) from 43 endoscopies (39 colonoscopies, four 
sigmoidoscopies) in 39 patients. The median number of biopsies was 4.61 in the rectum and 
3.34 in the proximal colon. Sixty-three sections (82%) were initially assessed by the general 
pathologist as histologically healed (gpHR). Demographic variables of the included patients and 
details on endoscopy are summarized in Table 1.
Endoscopic Mayo score – histological activity scores
In 82% (32/39) of the colonoscopies we found an endoscopy score of Mayo 0 in the entire colon, 
with 100% of patients (39/39) showing Mayo 0 in the colon proximal of the splenic flexure. 
In 33/43 endoscopies we found a Mayo score of 0 in the rectosigmoid (76.7%). Eighty-seven 
per cent (67/77) of all evaluated sections were biopsy sections taken from areas in the colon 
classified as endoscopy score Mayo 0, with 13% (10/77) scored as Mayo 1.
Endoscopy and histology scores – general pathologist vs expert GI-pathologists
The general pathologist assessed 84.8% of the rectosigmoid biopsies, endoscopically scored 
as Mayo 0, as gpHR; in the proximal colon biopsies this was 94.1% (Table 2). For endoscopy 
score Mayo 1, the general pathologist assessed 20% (2/10) of the biopsies in the rectum and 
sigmoid as gpHR. The results of the re-evaluation of the Mayo 0 and 1 biopsies by expert GI-
pathologists using three histological scores (GS, HGI, RS) are depicted in Table 2. To calculate 
these percentages for all three GI-pathologists, we used the sum of all biopsies. The used cut-
offs of the GS (<0.1, <3.1) were used in concordance with the literature.15
Inter-observer agreement expert GI-pathologists
For all evaluated histological scores, inter-observer concordance was higher in sections assessed 
as Mayo score 1 vs sections assessed as Mayo score 0 (Table 3 and Table S4).
Harpaz (Gupta) index (HGI)
Overall inter-observer concordance in the HGI was substantial (0.62). In primary assessment 
both as gpHR (0.68) and as gpHI (0.63) this was substantial. When the evaluated sections were 
divided according to Mayo score, the inter-observer concordance for HGI was moderate for 
Mayo score 0 (0.55) and substantial for Mayo score 1 (0.64) (Table 3).
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Geboes score (GS)
Overall inter-observer concordance for the GS with and without subscores was almost perfect 
(0.84 and 0.83). When the primary histological assessment consisted of gpHR the inter-observer 
concordance was substantial (0.65 and 0.63), and for gpHI there was a higher concordance (0.91 
and 0.91). When the evaluated sections were distinguished according to the endoscopic Mayo 
score, the inter-observer concordance for GS with subscoring was substantial for Mayo score 0 
(0.7) and almost perfect for Mayo score 1 (0.93), and for GS without subscoring the result was 
similar (0.68 and 0.92) (Table 3).
Riley score (RS)
Inter-observer concordance was determined for each separate item of the RS. The inter observer 
concordance for all six items was substantial to almost perfect (Table S4). Where the evaluated 
sections were distinguished according to the initial assessment, inter-observer concordance 
was moderate to substantial for all six items in gpHR; in gpHI this was almost perfect for five out 
of six items, with ‘crypt architectural irregularities’ as the only outlier with a moderate result. 
When the evaluated items were divided according to Mayo score, inter-observer concordance 
for all items of the RS was fair to substantial in the case of Mayo score 0 (range 0.35–0.69) and 
almost perfect in five out of six items (range 0.90–0.95) in the case of Mayo score 1, with again 
‘crypt architectural irregularities’ as an outlier with a substantial result (Table S4).
Global visual score (GVS)
Overall inter-observer concordance in the GVS was substantial (0.74). In those sections 
primarily assessed as gpHR this was moderate (0.52), whereas in biopsies scored as gpHI this 
was substantial (0.78). When the evaluated sections were divided according to Mayo score, 
the inter-observer concordance for GVS was moderate in the case of Mayo score 0 (0.52) and 
almost perfect in the case of Mayo score 1 (0.92) (Table 3).
Intra-observer reproducibility histological activity scores
Intra-observer reproducibility of reader 1 (IN) and reader 2 (AT) in all scores is given in Table 4. 
Eighteen randomly selected sections (18/77; 23.4%) with 40 biopsies were blindly reassessed 
a second time by these two expert GI-pathologists. Overall, reader 1 showed the highest intra-
observer reproducibility for the HGI with a kappa of 1 and with 100% agreement. For reader 2, 
the highest intra-observer reproducibility (0.86) was for GS without subscoring. With regard to 
the RS, reader 1 showed 100% agreement for ‘acute inflammatory cell infiltrate, crypt abscesses, 
mucin depletion and surface epithelial integrity’. Reader 2 showed similar results for ‘crypt 
abscesses and surface epithelial integrity’.
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Correlations between primary assessment (gp), endoscopic Mayo score and histological 
activity scores 
Correlation between GS and GVS was substantial (R = 0.73), as was that between the RS and 
the GVS (R = 0.75). Correlation between HGI and GVS was moderate (R = 0.41). Correlation 
between the RS and the GS was almost perfect (R = 0.86). Between the RS and the HGI, 
correlation was moderate (R = 0.44), as was that between HGI and GS (R = 0.56). Correlation 
between the primary assessment and the Mayo score was moderate (R = 0.52). There was no 
correlation between the primary assessment and the GVS (R = −0.04), the HGI (R = 0.03), the 
GS (R = 0.00) and the RS (R = −0.01) as scored by the expert GI-pathologists. There was no 
correlation between the Mayo score and the GVS (R = −0.07), HGI (R = −0.03), GS (R = −0.11) 
and RS (R = −0.09) as scored by the expert GI-pathologists.
Histological remission in Ulcerative Colitis   |   153
6
DISCUSSION
This study documents poor concordance between ‘daily practice’ histological assessment 
of HR in UC biopsies by a general pathologist and expert reviews by GI-pathologists. This 
finding is important as our study mirrors daily practice where clinicians are struggling with 
the question whether to alter UC medication and the presence of HR may tip the balance 
in favor of a specific treatment strategy. 
We found strong correlations among expert GI-pathologists between the most frequently 
used histological activity scores for UC (RS and GS) and we observed a substantial inter-
observer concordance for three histological scores (GS, HGI, RS), when re-evaluating UC 
biopsies assessed as HR by a general pathologist. 
Our study confirmed the reported excellent diagnostic properties of the most widely used 
UC histological disease activity indexes 24,25 specifically for UC colonic biopsies with MH and 
limited histological inflammation. The significant discrepancy we found between histological 
assessment of UC biopsies in daily practice and expert GI-pathologists is probably explained 
by bias and the need for expertise. The GI-pathologists from our research panel were blinded 
for both clinical and endoscopic data, whereas the initial assessor (in clinical practice) had 
full access to clinical and endoscopy results. It is conceivable that the clinical information 
available to the general pathologist influenced the conclusions of the histological evaluation. 
Secondly, routine histological assessment of IBD mucosal biopsies obtained from a colon 
with MH is complex and probably requires expertise that goes beyond routine clinical 
review. Indeed, some IBD studies have shown considerable inter-observer variability 
between pathologists.30, 31 Histological inter-observer disagreement is by no means rare, 
nor is it limited to UC. In cancer treatment where results from pathology examinations are 
crucial, central pathology reading of biopsies taken in the context of trials is ubiquitous 32 
and has made its way into daily oncology care.33–35 This concept appears to have traction in 
IBD trials,36 but is not yet in daily practice. 
We applaud the development of novel UC histological activity indexes 37–39 because we need 
accurate assessment of histological activity in both IBD trials and clinical practice. There 
are two other histological indexes for UC that merit discussion. Both the Nancy Index and 
the Robarts Histopathology Index (RHI) have shown good reproducibility, reliability and 
responsiveness, and underwent the most extensive validation of all existing histological 
activity indexes for UC.37,38,40 The validation process for both indexes has been performed 
by expert pathologists, and both mainly use key items that are also present in existing 
scores such as GS, RS, HGI, Gramlich and GVS. These key items had high intra- and inter-
observer agreement and were subsequently included in the Nancy Index and RHI. Given the 
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overlap of the included histological items (such as ulceration and acute inflammatory cell 
infiltrate), inclusion of either the Nancy Index or the RHI in our study would not change our 
key message. The real matter at stake, based on current study results, is the gap between the 
initial and expert histological assessment. Efforts to overcome this gap should be directed 
at dedicated learning pathways and/or central reading facilities. The Nancy Index might 
gain a future central role in these learning pathways because it is simple and easy to use. 
We found higher inter-observer concordance between expert GI-pathologists in the 
biopsies that were assessed by a general pathologist as histological inflamed compared to 
HR for all three histological activity scores. Similar results were found after categorization 
into endoscopic Mayo score 0 and 1, in favor of the Mayo 1 group. Both findings suggest 
that is it more complicated, even for specialized GI-pathologists, to reach an agreement 
in cases of minor histological inflammation. This assumption concurs with a study from 
the 1990s that investigated the reliability of the interpretation of IBD colonic biopsies by 
specialized GI-pathologists. True normal biopsies were frequently assessed as ‘possible’ or 
‘likely’ ‘non-specific inflammation’ without agreement on this item.30
In our study we found no correlation between the endoscopic Mayo score and any 
histological scores. In the case of Mayo 0 at endoscopy, we found histological activity in 
20% (GS > 3.1) to 80% of cases (GS > 0.1) depending on the definition of HR used. In line 
with these results, a previous study described histological inflammation (GS ≥ 3.1) in 40% 
of cases with MH at endoscopy.41 Unfortunately there is no unified definition of HR and the 
cut-off level of histological activity that is clinically relevant is still of debate.15 
Our study has several strengths and clinical implications. To mimic daily practice with regard 
to HR decision-making, we only used biopsies reported as endoscopic MH, and we involved 
expert GI-pathologists from both academic and non-academic hospitals. For these histology 
analyses, we used blinded readers, which reduces the potential bias of taking the clinical 
condition of the patient into consideration. Most importantly, the described discrepancy 
between histological assessment of UC biopsies in daily practice and reassessment by 
dedicated GI-pathologists may have important implications in daily practice. Medical 
decision-making may increasingly depend on histological remission, and therefore it is 
important to realize and act upon this finding. 
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There are some limitations of this study. First, the retrospective design of the study harbors 
the risk of bias. Secondly, the consensus meeting between GI-pathologists, before initiation 
of the study, may have caused bias by achieving a better inter-observer agreement. Third, 
we did not use central reading 42 for the endoscopic Mayo score, but used the Mayo score 
as reported by the endoscopist. In addition, the Mayo score has a variable inter-observer 
concordance,42–44 although this is likely to have little impact on the scope of this article.
In summary, the use of existing histological activity indexes evaluating UC colonic biopsies 
that were initially assessed as HR resulted in substantial inter-observer concordance. Of 
alarm is the observation that there was no correlation between the primary assessment 
of UC biopsies by the general pathologist and the reassessment by blinded expert GI-
pathologists. This may have important implications for the selection process of a unified 
histological disease activity score in UC, and for the implementation of HR as a UC treatment 
target in daily practice.
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TABLES
Table 1 Demographic variables and details on endoscopy 
Patients	characteristics	(N=39)
Age (yrs) (Mean ± SD) 53.4 ± 16.09
Duration UC (yrs) (Mean ± SD) 23.0 ± 12.9
Male gender (N, %) 23 (59%)
Montreal classification (N, %) E1 6 (15.4%)
E2 12 (30.8%)
E3 21 (53.8%)
Medication (N, %) Mesalamine 28 (71.8 %)
Thiopurines 13 (33.3%)
Corticosteroids 2 (5.1%)
Anti-TNF* 3 (7.7%)
Topical therapy 7 (17.9%)
Endoscopy	(N=43)
Sigmoidoscopy (N, %) 4 (9.3)
Colonoscopy (N, %) 39 (90.7)
Mayo score 1 rectum 9 (20.1)
Mayo score 1 rectosigmoid 10 (23.3%)
Mayo score 1 proximal of splenic flexure# 0 (0%)
*1 patient used combination thiopurine/infliximab; #N= 39 colonoscopies 
Table 2 Histological reassessment of the Mayo 0 and 1 biopsies by expert GI-pathologists -
% HR according to general pathologist (gpHR) versus expert GI-pathologists 
Mayo score General pathologist Expert	GI-pathologists
gpHR* HGI<1# GS<0.1# GS<3.1# RS 0#
Mayo 0 overall 89.6% (60/67) 90.0% (181/201) 29.4% (59/201) 91.0% (183/201) 25.4% (51/201)
Mayo 0 rectosigmoid 84.8% (28/33) 88.9% (88/99) 25.3% (25/99) 88.9% (88/99) 21.2% (21/99)
Mayo 1 rectosigmoid 20% (2/10) 70.0% (21/30) 16.7% (5/30) 63.3% (19/30) 20.0% (6/30)
Mayo 0 proximal colon 94.1% (32/34) 91.2% (93/102) 33.3% (34/102) 93.1% (95/102) 29.4% (30/102)
HGI= Harpaz Gupta Index; GS= Geboes score; RS=Riley score; *GpHR= Biopsies initially evaluated 
as ‘histological remission’ by general pathologist; #common cut-offs for histological remission
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Table 3 inter-observer concordance GI-pathologists for each histological scoring index 
Index Cronbach α	(95%	CI) 	agreement	(%)
Global Visual Scale (GVS) Overall 0.74 (0.46-0.86) 8.0%
GpHR* 0.52 (0.34-0.62) 9.8%
GpHI** 0.78 (0.12-0.93) 0.0%
Mayo 0# 0.51 (0.37-0.64) 9.2%
Mayo 1## 0.92 (0.39-0.96) 0.0%
Harpaz Gupta Index (HGI) Overall 0.61 (0.43-0.78) 76.6%
GpHR* 0.51 (0.21-0.66) 82.5%
GpHI** 0.63 (0.31-0.88) 50.0%
Mayo # 0.55 (0.33-0.70) 80.6%
Mayo 1## 0.64 (0.21-0.914 50.0%
Geboes Score (GS) with subscoring Overall 0.84 (0.68-0.91) 11.7%
GpHR* 0.65 (0.35-0.79) 14.3%
GpHI** 0.91 (0.75-0.97) 0.0%
Mayo 0# 0.70 (0.50-0.81) 13.4%
Mayo 1## 0.93 (0.76-0.98) 0.0%
Geboes Score (GS) without subscoring Overall 0.83 (0.67-0.90) 35.1%
GpHR* 0.63 (0.34-0.78) 36.5%
GpHI** 0.91 (0.76-0.97) 28.6%
Mayo 0# 0.68 (0.46-0.80) 34.3%
Mayo 1## 0.92 (0.74-0.99) 40.0%
Riley Score (RS) Overall 0.91 (0.75-0.96) 14.3%
GpHR* 0.73 (0.46-0.86) 15.9%
GpHI** 0.95 (0.75-0.98) 7.1%
Mayo 0# 0.79 (0.58-0.88) 14.9%
Mayo 1## 0.96 (0.74-0.98) 10.0%
(*Biopsies initially evaluated as ‘histological remission’ by general pathologist;**Biopsies initially evaluated 
as ‘histological inflammation’ by general pathologist, #Biopsies taken from colon segments assessed as 
endoscopic Mayo score 0, ##Biopsies taken from colon segments assessed as endoscopic score Mayo 1)
162   |   Chapter 6
Table 4 intra-observer reproducibility for each histological scoring index and separate items of the 
Riley Score 
Reader	1	(IN)	 Reader	2	(AT)	 Reader	1	(IN)	 Reader	2	(AT)	
Index Cronbach α	(95%	CI) Cronbach α	(95%	CI) Agreement	(%) Agreement	(%)
GVS 0.34 (-0.78-0.75) 0.85 (0.61-0.95) 55.6% 50%
HGI 0.00 (0.00-1.00) 0.61 (-0.05-0.90) 94.4% 88.9%
GS with subscoring 0.73 (0.27-0.90) 0.86 (0.63-0.95) 72.2% 55.6%
GS without subscoring 0.61 (-0.05-0.85) 0.86 (0.64-0.95) 88.9% 66.7%
RS 0.79 (0.44-0.92) 0.82(0.51-0.93) 61.1% 44.4%
RS item Cronbach α	(95%	CI) Cronbach α	(95%	CI) Agreement	(%) Agreement	(%)
Acute inflammatory cell infiltrate 0.00 (0.00-1.00) 0.93 (0.82-0.98) 88.9% 94.4%
Crypt abcesses 0.00 (0.00-1.00) 1.00 (0.00-1.00) 94.4% 100%
Mucin depletion 0.00 (0.00-1.00) -0.18 (-0.44-1) 77.8% 83.3%
Surface epithelial integrity 1.00 (0.00-1.00) 0.00 (0.00-1.00) 100% 94.4%
Chronic inflammatory cell infiltrate 0.79 (0.44-0.92) 0.78 (0.41-0.92) 94.4% 72.2%
Crypt architectural irregularities 0.93 (0.80-0.97) 0.79 (0.44-0.92) 72.2% 72.2%
GVS= Global Visual Scale; HGI= Harpaz Gupta Index; GS= Geboes score; RS=Riley score
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Table 4 intra-observer reproducibility for each histological scoring index and separate items of the 
Riley Score 
Reader	1	(IN)	 Reader	2	(AT)	 Reader	1	(IN)	 Reader	2	(AT)	
Index Cronbach α	(95%	CI) Cronbach α	(95%	CI) Agreement	(%) Agreement	(%)
GVS 0.34 (-0.78-0.75) 0.85 (0.61-0.95) 55.6% 50%
HGI 0.00 (0.00-1.00) 0.61 (-0.05-0.90) 94.4% 88.9%
GS with subscoring 0.73 (0.27-0.90) 0.86 (0.63-0.95) 72.2% 55.6%
GS without subscoring 0.61 (-0.05-0.85) 0.86 (0.64-0.95) 88.9% 66.7%
RS 0.79 (0.44-0.92) 0.82(0.51-0.93) 61.1% 44.4%
RS item Cronbach α	(95%	CI) Cronbach α	(95%	CI) Agreement	(%) Agreement	(%)
Acute inflammatory cell infiltrate 0.00 (0.00-1.00) 0.93 (0.82-0.98) 88.9% 94.4%
Crypt abcesses 0.00 (0.00-1.00) 1.00 (0.00-1.00) 94.4% 100%
Mucin depletion 0.00 (0.00-1.00) -0.18 (-0.44-1) 77.8% 83.3%
Surface epithelial integrity 1.00 (0.00-1.00) 0.00 (0.00-1.00) 100% 94.4%
Chronic inflammatory cell infiltrate 0.79 (0.44-0.92) 0.78 (0.41-0.92) 94.4% 72.2%
Crypt architectural irregularities 0.93 (0.80-0.97) 0.79 (0.44-0.92) 72.2% 72.2%
GVS= Global Visual Scale; HGI= Harpaz Gupta Index; GS= Geboes score; RS=Riley score
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SUPPLEMENTARY FILES
Table 1 Gupta Index
Grade 0 Inactive or absent No epithelial infiltration by neutrophils
Grade 1 Mild Neutrophil infiltration of <50% of sampled crypts and cross-sections
Grade 2 Moderate Neutrophil infiltration of > 50% of sampled crypts and cross-sections
Grade 3 Severe Erosion, or ulceration
Table 2 Riley Score
The acute inflammatory cell infiltrate
A. None
B. Mild
C. Moderate
D. Severe
Crypt abscesses 
A. None
B. Mild
C. Moderate
D. Severe
Mucin depletion
A. None
B. Mild
C. Moderate
D. Severe
Surface epithelial integrity
A. None
B. Mild
C. Moderate
D. Severe
Chronic inflammatory cell infiltrate
A. None
B. Mild
C. Moderate
D. Severe
Crypt architectural irregularities
A. None
B. Mild
C. Moderate
D. Severe
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Table 3 Geboes Index
Grade 0: Structural (architectural changes)
0.0 No abnormality
0.1 Mild abnormality
0.2 Mild or moderate diffuse or multifocal abnormalities
0.3 Severe diffuse or multifocal abnormalities
Grade 1: Chronic inflammatory infiltrate
1.0 No increase
1.1 Mild but unequivocal increase
1.2 Moderate Increase
1.3 Marked increase
Grade 2: Lamina propria neutrophils and eosinophils
2A: Eosinophils 2B: Neutrophils
2A.0 No increase 2B.0 No increase
2A.1 Mild but unequivocal increase 2B.1 Mild but unequivocal increase
2A.2 Moderate increase 2B.2 Moderate increase
2A.3 Marked increase 2B.3 Marked increase
Grade 3: Neutrophils in epithelium
3.0 None
3.1 <5% Crypts involved
3.2 <50% Crypts involved
3.3 >50% Crypts involved
Grade 4: Crypt destruction
4.0 None
4.1 Probable – Local excess of neutrophils in part of crypt
4.2 Probable – marked attenuation
4.3 Unequivocal crypt destruction
Grade 5: Erosion or ulceration
5.0 No erosion, ulceration or granulation tissue
5.1 Recovering epithelium + adjacent inflammation
5.2 Probable erosion focally stripped
5.3 Unequivocal erosion
5.4 Ulcer or granulation tissue
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Table 4 inter-observer concordance each item Riley score
Riley	Score	(RS)	Item Cronbach 	(95%	CI) Agreement	(%)
Acute inflammatory cell infiltrate Overall 0.78 (0.51-0.88) 58.4%
GpHR* 0.41 (0.05-0.63) 60.3%
GpHI** 0.90 (0.71-0.96 50.0%
Mayo 0 0.56 (0.27-0.73) 61.2%
Mayo 1 0.91 (0.59-0.96) 40.0%
Crypt abcesses Overall 0.91 (0.88-0.94) 96.1%
GpHR* 0.00 (0.00-1.00) 98.4%
GpHI** 0.93 (0.83-0.98) 85.7%
Mayo 0 0.00 (0.00-1.00) 98.5%
Mayo 1 0.92 (0.78-0.98) 80.0%
Mucin depletion Overall 0.79 (0.57-0.89) 70.1%
GpHR* 0.58 (0.26-0.77) 73.0%
GpHI** 0.90 (0.70-0.97) 57.1%
Mayo 0 0.67 (0.44-0.81) 74.6%
Mayo 1 0.90 (0.52-0.96) 40.0%
Surface epithelial integrity Overall 0.77 (0.16-0.91) 71.4%
GpHR* 0.08 (-0.20-0.37) 76.2%
GpHI** 0.87 (0.28-0.96) 50.0%
Mayo 0 0.27 (-0.17-0.49) 73.1%
Mayo 1 0.93 (0.51-0.99) 60.0%
Chronic inflammatory cell infiltrate Overall 0.83 (0.67-0.90) 41.6%
GpHR* 0.65 (0.35-0.82) 42.9%
GpHI** 0.92 (0.83-0.96) 35.7%
Mayo 0 0.69 (0.42-0.82) 40.3%
Mayo 1 0.95 (0.86-0.98) 50.0%
Crypt architectural irregularities Overall 0.69 (0.55-0.80) 24.7%
GpHR* 0.63 (0.45-0.76) 28.6%
GpHI** 0.52 (-0.17-0.83) 7.1%
Mayo 0 0.65 (0.48-0.78) 25.4%
Mayo 1 0.78 (0.35-0.94) 20.0%
*GpHR= Biopsies initially evaluated as ‘histological remission’ by general pathologist; **GpHI= Biopsies 
initially evaluated as ‘histological inflammation’ by general pathologist; Mayo= endoscopic Mayo score
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PATIENT CASE
Mr v D is a 25-year-old male who was diagnosed with mild-moderate ulcerative colitis (pancolitis) in 2010. 
He was treated with topical therapy, glucocorticosteroids and mesalazine as induction and maintenance 
therapy. Since 2010, the disease activity is waxing and waning. This comes with the relapsing and remitting 
nature of the disease, but also may be attributed to the behavior of Mr v D himself. He often forgets 
appointments at the IBD outpatient clinic and does not respond to phone calls with his IBD treatment team, 
but even more often he forgets to take his maintenance medication. Sometimes, we do not see him for a 
year, only to return with severe symptoms indicative of a relapse of his ulcerative colitis. At those moments 
he is always very motivated to use his medication with quiescent disease as a result. Between his relapses 
he is preferably a normal young man, who likes to play sports, go out with his friends, and busy working. 
He wants to be like everyone else, he does not want to be sick and prefers having a normal life. Having said 
that, adherence remains a major problem. There have been many conversations with the IBD nurse, the 
psychologist and with his gastroenterologist. They have used ‘motivational interviewing’ techniques to gain 
insight into his intrinsic motivation about whether or not to take his medication. All kind of tools are tried 
to improve his adherence as a mobile app, medicine boxes and reminders in his diary. To this day, however, 
adherence remains his biggest problem. 
ABSTRACT
Objective
5-Aminosalicylicacid (5-ASA) is the cornerstone of ulcerative colitis treatment, with 
(assessment of) nonadherence as a challenge. Multi-matrix release (MMX)-mesalazine 
has the advantage of once-daily (OD) dosing. Primarily we assessed urinary (NAc-) 5-ASA 
excretion, as measured by High-Performance Liquid Chromatography (HPLC), in order 
to monitor nonadherence, in healthy volunteers taking MMX-mesalazine. Secondly, we 
established urinary (NAc-)5-ASA cut-off levels for (partial) nonadherence. 
Method
We studied 25 healthy adult volunteers who used MMX-mesalazine 2400 mg OD (days 1-4), 
followed by 1200 mg twice daily (BID) (days 8-11), separated by a drug-free interval of 3 days. 
Daily morning urine spot samples were collected. The cut-off level for adherence was set at 
the lowest steady state (NAc-)5-ASA urinary concentration level. 
Results
Stability of urinary 5-ASA and NAc-5-ASA, stored at room temperature during 24 hours was 
96.4 ± 8.3% and 96.4 ± 4.1%. Recovery of urinary 5-ASA and NAc-5-ASA was 114.3 ± 10.4% 
and 107.5 ± 6.4%. The limit of detection and quantification were 1.1 ug/ml and 3.5 ug/ml 
for NAc-5-ASA and 0.4 ug/ml and 1.3 ug/ml for 5-ASA. The maximal 5-ASA within-run and 
between-run relative SD were 10.4% and 12.5%. The cut-off level for nonadherence was 
determined at 9.67 (OD) and at 15.39 (BID) mg/mmol (NAc-) 5-ASA per mmol creatinine. 
Conclusion
HPLC is a feasible, sensitive and reproducible method to measure urinary (NAc-) 5-ASA 
excretion in volunteers taking MMX-mesalazine. This study establishes urinary (NAc-) 5-ASA 
cut-off levels for MMX-mesalazine nonadherence that may be useful in clinical practice and 
future trials.
Keywords: Inflammatory bowel disease; IBD; Adherence; Compliance; MMX-mesalazine; 
High-performance liquid chromatography (HPLC).
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INTRODUCTION
Adherence is an important element for a successful treatment of patients with ulcerative 
colitis (UC). 5-Aminosalicylic acid (5-ASA) is a central component in UC treatment, but the 
reported prevalence of drug nonadherence is high and varies from 40 to 91%.1,5-6 One of the 
reasons for this large variation is lack of direct and objective methods to screen for and monitor 
nonadherence in UC patients. Nonadherence puts patients at an increased risk for relapse1-6, 
and steep incline in costs.7 Already in 2006, a Cochrane review concluded that future trials 
with 5-ASA should focus on enhancement of patient’s adherence,8 but assessing adherence 
has proven complex. Electronic monitoring using microelectronic chips that log date and time 
of medication bottle opening, is expensive and does not measure true intake of medication, but 
only opening of a bottle. On the other hand self-reporting measures are less reliable.9-12 A more 
direct and objective way to measure adherence is to assess drug levels in biological fluids such as 
urine or plasma, and has been reliably measured by High- Performance Liquid Chromatography 
(HPLC).13-17 A potential caveat of drug level monitoring at a clinical visit is the so called ‘white 
coat compliance’, which means that adherence tends to improve preceding a clinical visit.11,18,19 
Urinalysis is preferred here because of more stable drug metabolites that reflect medication use 
over a prolonged period of time. In 2003, Shale reported that 58% of patients with undetectable 
urinary drug levels admitted to be nonadherent. 5 Subsequent 5-ASA adherence studies using 
urinalysis applied different formulations, brands, and dosage frequencies. The novel once daily, 
high dosage (1.2 gr/tablet) MMX-mesalazine formulation has not yet been studied.20-22 We now 
report a study to describe feasibility, sensitivity, and reproducibility of High-Performance Liquid 
Chromatography (HPLC) to measure urinary (NAc-) 5-ASA excretion in healthy volunteers 
taking MMX-mesalazine. This allows us to determine cut-off levels for adherence, which can be 
used in future trials as well as in clinical practice.
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METHODS
Population 
This pilot study enrolled 25 healthy volunteers, who were studied for a total of 14 days. 
Volunteers were recruited via internet or billboard advertisements. Inclusion criteria were 
age between 18 and 80 years and use of adequate contraceptives during the study period. 
Pregnancy, significant co-morbidities or the use of co-medication (especially NSAIDs and drugs 
that possibly effect renal function) were exclusion criteria. After obtaining written informed 
consent, all volunteers were invited for baseline and screening visits by a research nurse. At 
baseline we obtained a brief medical history and a physical examination including urine spot 
and blood samples. Each volunteer received a trial number for identification purposes during 
the study. All study-related data were documented in a paper case report form (CRF) that was 
subsequently processed in a computerized database.
Study design 
The schematic outline of the study is described in Figure 1. Volunteers used 2400 mg MMX-
mesalazine once daily (OD) (2 tablets of 1200 mg), on study days 1 to 4, and 1200 mg twice daily 
(BID), on study days 8 to 11. After day 4 and day 11, there was a drug-free wash-out interval of 3 
days. OD medication was taken at breakfast (between 7 and 10 AM). BID medication was taken at 
breakfast (between 7 and 10 AM) and dinner (between 17 and 20 PM). The morning medication 
was taken under the watchful eye of the research nurse; the evening medication was either taken 
under nurse supervision, or assisted by webcam or smart-phone. At baseline and at study day 14 
a blood sample was collected to analyze creatinine, hemoglobin, leucocytes, platelets, amylase, 
bilirubine, gamma-GT, and ASAT. The safety profile of MMX-mesalazine is similar to delayed-
release mesalazine; it is recommended to check renal function at regular intervals.23-25 Volunteers 
recorded adverse events through a purpose designed diary. All volunteers donated daily morning 
urine spot samples, which were frozen at -20°C, prior to HPLC analysis (samples collected before 
taking the morning dose of 5-ASA). In a previous study steady state urinary 5-ASA concentrations 
were reached after 48 hours.5 Therefore mean individual urinary (NAc-) 5-ASA-excretion was 
determined on the individual steady state urinary values from day 3 to day 5 and day 10 to 12. The 
cut-off-level for adherence was defined as the lowest (NAc-) 5-ASA urinary concentration level 
found in the subjects, taking 2400 mg (OD or BID) MMX-mesalazine. All volunteers received a 
financial compensation (150 Euro) for their efforts. This trial (ISRCTN15765858) was approved 
by the Ethics Committee of Radboud university medical center, Nijmegen in the Netherlands.
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5-ASA medication 
MMX-mesalazine with MMX Multi Matrix System technology (Mezavant®; Shire 
Pharmaceuticals) is an oral, high-strength 1200 mg/ tablet, OD formulation of 5-ASA, that 
incorporates a gastro resistant, pH-dependent film coating combined with an MMX Multi Matrix 
System polymer core. The coating is thought to delay the release of 5-ASA during transit through 
the upper gastrointestinal tract, while hydrophilic and lipophilic excipients within the MMX 
tablet core are designed to prolong release of 5-ASA throughout the colon. 
High-performance Liquid chromatography (HPLC) 
Spot urine samples for further biochemical testing were frozen at -20°C by the volunteers, 
transferred at room temperature and stored at -20°C in the laboratory until further analysis. 
No difference in (NAc- )5-ASA concentration was detected after 7 freeze-thawing cycles of 
urine samples (once freeze thawing: 54.0 mg/mmol creatinine; 7 times freeze thawing 54.1 
mg/mmol creatinine). Samples were prepared by solvent extraction and by dilution technique. 
Routinely, at the start and end of each sequence calibration samples were used. These samples 
were prepared by adding 4 standard (NAc-) 5-ASA solutions to 0.05 M phosphate buffer (pH 
7.4). This was repeated after 42 samples. The reproducibility of our analyses was determined by 
repeating the test on the same urine sample every 30 samples. Urinary 5-aminosalicylic acid (5-
ASA) and N-acetyl-5-ASA (NAc-5-ASA) were measured by HPLC. The total 5-ASA concentration 
(5-ASA + NAc-5-ASA) is expressed as a ratio relative to the urinary creatinine excretion, to 
correct for variations in urinary concentration. 5 Urinary creatinine was measured using the 
Architect C16000 on basis of the Jaffe reaction,26 both obtained from Abbott Diagnostics (Lake 
Forest, Illinois, USA). Stock solutions of 5-aminosalicylic acid (Cayman Chemical Company, Ann 
Arbor, Michigan, USA), N-acetyl-5-aminosalicylic acid (Santa Cruz Biotechnology Inc, Santa 
Cruz, California, USA) and 4-aminosalicylic acid (Sigma-Aldrich, St. Louis, Missouri, USA) are 
obtained by dissolving each compound in water, with a concentration of 100 μg/ml, 100 μg/ml 
and 6000 μg/ml, respectively. These stock solutions are stored at -80°C and are used to calibrate 
and standardize the assay. 5-ASA and NAc- 5-ASA are quantified by HPLC exactly as described 
by Hussain,13 using a Jasco HPLC system (JASCO, Tokyo, Japan) equipped with a PU-2089 plus 
pump, an AS-2055 plus auto sampler and a FP-2020 plus fluorescence detector (excitation 
315 nm, emission 430 nm). Chromatographic separation of the eluent was attained using a 
supelcosil ABZ column (150 x 4.6 mm I.D., 5 um silica particles) protected by a Supelco guard 
column (20 x 4.6 mm I.D., 5 um silica particles) both purchased from Sigma. The mobile phase 
consisted of 0.1 M acetic acid, acetonitrile and triethylamine (1600:114:6, v/v/v) at pH 4.3. The 
flow-rate was 1.5 ml/min. Sample preparation was performed following instruction of Hussain,13 
with the exception of filtering the urine after centrifuging. The urine was diluted tenfold in 0.05 
M phosphate buffer (pH 7.4). To a 0.1 ml aliquot, 0.3 ml of 0.05 M phosphate buffer, 0.1 ml of 
internal standard (4-ASA), 20 ul propionic anhydride and 0.5 ml of methanol was added. The 
accuracy was assessed by spiking NAc-5-ASA and 5-ASA in blank matrices. The spiked samples 
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were prepared in at least triplicate at three different concentrations. The precision is based on 
the degree of repeatability of an analytical method under normal operation and is expressed 
as the percent relative standard deviation (RSD). To calculate the RSD 12 samples with known 
concentrations of NAc-5-ASA and 5-ASA were measured. 
The limit of detection (LOD) and limit of quantification (LOQ) were determined by using the 
linear regression method. LOD is defined as the lowest concentration of (NAc-) 5-ASA in urine 
that can be detected. The LOD is expressed as a concentration at 3:1, LOD=3.3(SD/S), where S 
is the slope of the calibration curves. The limit of quantification (LOQ) is defined as the lowest 
concentration of (NAc-) 5-ASA in urine that can be determined with acceptable precision and 
accuracy. The LOQ is expressed as LOQ=10 (SD/S). Ten samples were measured to calculate 
the LOD and LOQ.
Statistics 
The sample size of this small intervention study was determined at 25, to the proposal of Julious 
with regard to pilot studies.27 We used descriptive statistics for the characteristics of the tested 
cohort. All results were expressed as mean and SD or median and range values, unless otherwise 
indicated. Total urinary 5-ASA concentration (5-ASA and NAc-5-ASA) was expressed as a ratio 
to the urinary creatinine concentration, in mg 5-ASA/mmol creatinine. To determine the cut-off 
level of adherence as measured by total urinary 5-ASA excretion, we use the individual steady-
state urinary 5-ASA-levels, for both dosing frequencies. These individual results are depicted in 
a scatter plot of urinary total 5-ASA to creatinine ratios. Each point in this plot represents one 
of the 25 individuals who took part in this study. To describe the reproducibility, variability and 
the range of urinary 5-ASA-excretion, the median (NAc-) 5-ASA/creatinine values of the total 
patient group are plotted in a column bar graph.
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RESULTS
Demographics 
In a 4-month period 30 healthy volunteers were screened to participate in this pilot study. Four 
volunteers were excluded because of relevant comorbidity and comedication. One volunteer 
started with the pilot study, but had to quit on day 6, because of arthritis of the shoulder that 
necessitated NSAID treatment, which was an exclusion criterion. In total twenty-five volunteers 
were included and completed the whole study period of 14 days. Demographic variables of this 
study group and adverse events are presented in Table 1. Mean age of the volunteers was 38.1 
years (SD 8.5); fifty two percent of the volunteers were male. Adherence was 100% assessed 
by nurse controlled medication intake. 
HPLC 
Stability, accuracy, sensitivity and specificity 
Stability of 5-ASA and NAc-5-ASA in urine, stored at room temperature during 24 hours was 
96.4 ± 8.3% and 96.3 ± 4.1%, respectively. Stability data of urinary (NAc-) 5-ASA concentration 
at room temperature up to 192 hours are depicted in a Supplementary file (Figure 5a and 5b). 
No effect of 7 freeze-thawing cycles was detected on the concentrations of 5-ASA and NAc-5-
ASA. The retention time for respectively NAc-5-ASA, 5 ASA and 4-ASA is 6, 11 and 16 min. The 
accuracy or recovery of urinary 5-ASA and NAc-5-ASA was respectively 114.3 ± 10.4% and 
107.5 ± 6.4%. The linearity of the method was determined through analysis of five calibration 
curves containing non-zero concentrations. 
The limit of detection (LOD) was 1.16 ug/ml for NAc-5-ASA and 0.43 ug/ml for 5-ASA. The 
limit of quantification (LOQ) was respectively 3.51 ug/ml (NAc-5-ASA) and 1.29 ug/ml (5-ASA). 
The highest measured within-run relative standard deviation (R.S.D.) was respectively 4.1% 
for NAc-5-ASA, and 10.4% for 5-ASA. The highest measured between-run R.S.D was 9.4% for 
NAc-5-ASA and 12.5% for 5-ASA.
Cut-off level 5-ASA 
In Figure 3 the median (NAc-)5-ASA levels expressed as a ratio to the urinary creatinine 
concentration in the total patient group (N=25) are depicted. Steady state levels were 
respectively reached at day 4 and day 11, and lasted until day 5 and day 12. Figure 4 shows 
mean individual steady state levels measured at day 4 to 5, and at day 11 to 12. Cut-off level for 
adherence was defined as the lowest individual steady state (NAc-)5-ASA urinary concentration 
level found in the studied subjects. In the once daily medication schedule the cut-off level for 
adherence was 9.67 mg (NAc-)5-ASA per mmol creatinine, and in the twice daily group this cut-
off was determined at 15.39 mg (NAc-) 5-ASA per mmol creatinine. Figure 1 shows individual 
data of the total patient group on day 6 (48 hours after last medication taken) and day 7 (72 hours 
178   |   Chapter 7
after last medication taken). This figure provides insight into (partial) adherence of patients in 
daily practice, as the measured (NAc-)5-ASA urinary concentration level at day 6 is comparable 
to the value measured in a patient not taking his/her medication for two consecutive days. The 
lowest individual (NAc-)5-ASA urinary concentration level measured on day 6 is 0.03 mg (NAc-) 
5-ASA per mmol creatinine (median 15.1; range 0.03-66.24), and on day 7 this is 0.02 mg (NAc-) 
5-ASA per mmol creatinine (median 2.2; range 40.61).
Adverse events 
During the pilot study no serious adverse events occurred. Adverse events probably related to 
the study medication occurred in 48% of the total group, and 12% complained of gastrointestinal 
symptoms (3/25). Routine laboratory measurements, particularly creatinine, remained 
unchanged during the complete study period (Table 2).
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DISCUSSION
This study documents the pharmacokinetics of a novel mesalazine formulation (MMX). We 
found that the use of HPLC for 5-ASA urinalysis in volunteers using MMX-mesalazine is feasible, 
reproducible, stable and sensitive, and is accompanied by a low inter-and intra-assay variation. 
This is in line with previously published studies, with other 5-ASA formulations, which showed 
that HPLC is a reliable tool to recover 5-ASA metabolites from urine samples.13-17 
There has been a paucity of pharmacokinetic data on MMX-mesalazine. A literature search 
revealed published data derived from a single phase II clinical trial, the manufacturer-
prescribing information, and an abstract published in 2007.27-30 These sources document a 
high pharmacokinetic variability among volunteers, comparable to our data in Figure 3 and 4. 
They achieved steady state after 2 days, in contrast to our study (steady state achieved after 
3 days in both dosing frequencies). We determined objective 5-ASA urinary cut-off values for 
(partial) nonadherence in our study that may be used in clinical practice or for the purpose of 
determination of adherence in clinical trials. Medication adherence occurs when the patient 
takes his/her medication according to the prescribed dosage, time, and frequency. Logically, 
if patients take no medication at all, they are absolute nonadherent, which corresponds to 
undetectable 5-ASA urinary levels. In practice, however, most patients occasionally forget to 
take their medication,17,31 which defines them as partially nonadherent. As such, it is important 
to provide objective 5-ASA urinary cut-off values to define partial nonadherence. 
A strong element of our study is the use of one single 5-ASA formulation, and the directly 
observed intake of MMX-mesalazine, which is efficacious in attaining complete adherence. 
A comprehensive review on this topic concluded that urinary 5-ASA excretion is comparable 
for many oral 5-ASA formulations, but that 5-ASA preparations with a foregut release 
profile demonstrate greater variability in urinary excretions. More recently released 5-ASA 
formulations, as MMX-mesalazine, were not included in this review.21 Recent literature 
mentions a distinct variability in 5-ASA metabolism and distribution following oral dosing, 
and discovered an association between higher doses of oral mesalazine with higher serum 
concentrations and urinary excretion,32 a finding that was described before.5 We defined cut-
off values for nonadherence for two different dosage schedules, which we consider an asset. 
We found a higher cut-off level in the twice daily group (15.39 mg/mmol (NAc-) 5-ASA per mmol 
creatinine) compared to the once daily group (9.67 mg/mmol (NAc-) 5-ASA per mmol creatinine). 
Significance levels could not be determined because of the small sample size. Even though dosing 
frequency does not affect steady-state pharmacokinetics of delayed-release mesalazine, earlier 
studies found peak levels of 5-ASA serum concentrations in the early morning following divided 
daily dosing.32-34 The indiscriminately use of different formulations, and dosage schedules may 
provide inaccurate values in defining a cut-off value in urinary 5-ASA excretion. 
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This study comes with some limitations. First of all, it is a small intervention study that carries 
the design of a pilot study. Secondly, we studied healthy volunteers instead of UC patients. 
A substantial part of the UC patients have comorbidity or comedication that may affect the 
pharmacokinetic properties of 5-ASA.30,35 In patients with active UC, pharmacokinetics might 
be influenced by diarrhea, changed intestinal transit time, and luminal PH. The contribution of 
these elements and the ultimate effect on 5-ASA pharmacokinetics is incompletely understood 
and the literature reports conflicting results.21,36-40 Interestingly, the pharmacokinetics of healthy 
volunteers and patients with quiescent UC are comparable,40,41 and similar tissue concentrations 
of 5-ASA and NAc-5-ASA have been detected in both groups.13 Therefore, in this specific 
subgroup of UC, data might be extrapolated. We did not perform formal plasma, C
max 
analysis 
or AUC, which are accepted methods in pharmacokinetic studies. We specifically wanted to 
describe feasibility and reproducibility of HPLC in case of MMX-mesalazine users, and chose 
spot urinalysis because of the applicability of this method in daily practice. Of course, white 
coat compliance might affect results of spot urinalysis in the outpatient clinic. But, as described 
before,5,42 and again shown in our study, it took more than three days without medication at all, 
to find near undetectable 5-ASA urine levels. For these reasons, we think this effect is negligible. 
Another matter of concern can be the costs of HPLC, which of course must be seen in the light 
of the costs of nonadherence. 
In summary, HPLC spot 5-ASA urinalysis is fast, reproducible and sensitive. The cut-off values for 
nonadherence in once or twice daily dosing are slightly different. Relevant for clinical practice is 
that we describe objective cut-off values for (partial) nonadherence, which is the most common 
way of nonadherence. A spot 5-ASA urine sample below the described cut-off values should 
trigger the treating physician to consider and discuss possible nonadherence.
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TABLES
Table 1 Demographic variables and adverse events
Variable N	(%)
Volunteers (N) 25 (100)
Male (N, %) 13 (52)
Medical history 
- None
- Minor irrelevant surgery (appendectomy/tonsillectomy, knee surgery)
- IBS
- Various
7 (28)
12 (48)
1 (4)
5 (20)
Severe adverse events 0 (0)
Adverse events (AE) 
- Renal
- Gastrointestinal
- Miscellaneous
17 (68)
0 (0)
3 (12)
14 (56)
AEs related to study medication 0 (0)
AEs not related to study medication 5 (20)
AES probably related to study medication 12 (48)
Variable Mean	(SD)
Age (yrs) 38.1 (8.5)
BMI 25.6 (6)
Table 2 Laboratory results visit day 1 and 14
Variable Visit day 1
Mean	(SD)
Visit day 14 
Mean	(SD)
p-value
Creatinine (Umol /l) 74.6 (6.4) 75.4 (9.1) NS
Amylase (U/l) 64.6 (19.3) 67.4 (27.4) NS
Hemoglobin (mmol/l) 8.9 (0.6) 9.0 (0.7) NS
Thrombocytes (*10 9/l) 244 (50.7) 260 (61.1) NS
Leucocytes (*10 9/l) 6.7 (1.8) 6.7 (2.0) NS
Bilirubine (Umol/l) 10.6 (4.0) 10.6 (4.4) NS
Gamma-GT (Umol/l) 27.6 (15.0) 28.5 (16.4) NS
ASAT (U/l) 24.4 (4.7) 27.1 (8.6) NS
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Figure 1 Schematic outline of the study
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Urinalysis of MMX-mesalazine as a tool to 
monitor	5-ASA	adherence	in	daily	IBD	practice
ABSTRACT
Adherence is pivotal but challenging in ulcerative colitis (UC) treatment. Many methods 
to assess adherence are subjective or have limitations. (Nac-)5-aminosalicylic acid (5-
ASA) urinalysis by High-performance liquid chromatography (HPLC) seems feasible and 
reproducible in healthy volunteers. We performed a prospective study in adult quiescent 
UC patients to evaluate the feasibility of spot (Nac-)5-ASA urinalysis by HPLC to assess 
adherence in daily inflammatory bowel disease (IBD) care. Twenty-nine patients (51.7% 
male, mean age 52 ± 11 years) were included (median FU 9 months) and weekly spot urine 
samples were collected. We found large variation in spot (Nac-)5-ASA urinary excretion that 
was unrelated to brand, dosing schedule or dosage of 5-ASA. In conclusion, spot (Nac-) 5-ASA 
urinalysis is not applicable to assess 5-ASA adherence in daily IBD care.
Keywords: adherence, compliance, HPLC, inflammatory bowel disease, MMX-mesalazine.
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INTRODUCTION
Adherence to drug therapy is indispensible for successful inflammatory bowel disease (IBD) 
treatment, because nonadherence bears a higher risk of relapse 1–4 and higher costs.5, 6 The 
reported prevalence of nonadherence to drugs is around 40–91% in UC patients on 5-ASA.7–11 
Self-report measures for adherence have well-known limitations 12 and overestimate actual 
use,13 with electronic monitoring systems being more reliable but costly.14, 15 Another ‘more 
objective’ method to measure adherence is to assess serum or urinary drug levels. Potential 
pitfalls of spot serum drug analysis are poor correlation with daily steady-state concentrations,16 
and ‘white coat compliance’.13, 16, 17 Urinalysis with more stable drug metabolites is therefore 
preferable. High-performance liquid chromatography (HPLC) can be used to measure urinary 
5-ASA and N-acetyl-5-ASA (Nac-5-ASA) metabolites.18–24 In 2015, we performed urinalysis in 
healthy volunteers using MMX-mesalazine (Mezavant®). HPLC spot (Nac-)5-ASA urinalysis 
proved to be fast, reproducible and sensitive.25 The question arose whether these results could 
be extrapolated to UC patients on 5-ASA, in view of the presence of diarrhea, comorbidity and 
use of comedication in UC patients. To this end, we conducted a study in UC patients to assess 
feasibility, reliability and usefulness of HPLC 5-ASA urinalysis for 5-ASA adherence in daily IBD 
practice.
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METHODS
We conducted a randomized prospective study (trial number NTR4648) in UC patients 
using 5-ASA, modeled after a pilot study in healthy volunteers.25 The study was approved by 
the Ethics Committee of Radboud University Medical Center, Nijmegen, the Netherlands. 
Informed consent was obtained. We included adult UC patients (Montreal E1–E3),26 who were 
in clinical remission (Simple Clinical Colitis Activity Index (SCCAI) <5) 27 and treated with 5-ASA 
monotherapy or combination with topical therapy. Patients were randomized at baseline to 
either 2400 mg MMX-mesalazine (Mezavant®) once-daily (OD) or 1200 mg twice daily (BID). 
At randomization and during follow-up, we collected clinical characteristics, blood and fecal 
samples, and weekly spot urinary (Nac-)5-ASA samples. Urine samples were frozen at -20°C 
by the UC patients, and stored at -20°C in the laboratory until further analysis with HPLC as 
described in detail previously.25 To mimic daily practice, patients visited the outpatient clinic 
twice a year, urine and feces samples were collected at home, and quarterly interviews were 
conducted by telephone or digitally.
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RESULTS
We included 29 patients with a median follow-up of 9 months. Missing values were not imputed. 
Demographic data, SCCAI, Morisky adherence scale (MMAS-8) 28, 29 and laboratory results are 
described in Table 1. In line with the SCCAI, laboratory results did not change during 6 months 
of follow-up, but fecal calprotectin fluctuated. Self-reported adherence was high according to 
MMAS-8. 
At screening, patients used different brands and dosages of 5-ASA medication. Twenty patients 
provided a spot urine sample at screening to measure (Nac-)5-ASA urinary excretion, which 
showed a large variation independent of dosage or brand. Results are depicted in Figure 1, 
where each point reflects an individual patient.
UC patients on 2400 mg MMX-mesalazine collected and froze urine samples every week to 
perform (Nac-)5-ASA urinalysis with HPLC. Results of all analyses were comparable for both 
dosing frequencies. The results varied greatly, both between and within individuals (Figure 2A). 
Results are displayed as median, inter-quartile range, minimum and maximum. As reference 
material, a visual comparison of steady state results of (Nac-)5-ASA urinary excretion in 
volunteers using 2400 mg MMX-mesalazine (median of both dosing frequencies: OD2400 mg 
and BID 1200 mg) is displayed in Figure 2B).25
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DISCUSSION
We found large variation in spot (Nac-)5-ASA urinary excretion at any time point, both between 
and within individual UC patients. The variation was independent of the use of different brands, 
dosages or dosage schemes of 5-ASA. Although 24–96 h urinary 5-ASA excretion was found 
comparable for most oral 5-ASA formulations, this cannot be extrapolated to spot urinary 
excretion values because other factors such as disease activity, dosing schedules, and timing 
of urinalysis may impact results.30, 31 It is challenging to establish cut-off values for (partial) 
adherence based on spot urinalysis when using different formulations of 5-ASA. Naturally, 
undetectable drug levels matching complete nonadherence speak for themselves and may be 
used in daily practice. However, the question arises whether this relatively laborious method 
would be cost-effective in the entire IBD population in daily practice as partial (non)adherence 
is the main issue at stake, whereas complete nonadherence is ‘only’ seen in about 12% of UC 
patients using 5-ASA.11, 24
To overcome the issues of different dosing and brands, we switched all UC patients to one 
5-ASA-formulation and dosage. Still, we found a wide variability in median (Nac-)5-ASA 
urinary excretion both between different patients, but also within individuals (Figure 2A).
We found larger variability and ranges in (Nac-)5-ASA urinary excretion in UC patients 
compared to volunteers (Figure 2). We did not use statistics because of small sample sizes, 
and different coverage time in both groups. Direct observation of medication intake, and 
a strict timetable of urine collection in the healthy volunteers might have played a role in 
this observation. However, the contribution of UC disease activity appears to be a relevant 
factor. UC is a relapsing-remitting disease 32 and, in concordance with this, our patients had 
fluctuating disease activity as reflected by varying fecal calprotectin levels. We noticed that 
clinical activity score (SCCAI) remained stable during 6 months of follow-up, which accords 
with literature date.33 Inverse correlation with UC activity and mucosal colonic concentrations 
of 5-ASA have been described, probably reflecting lower absorption ability due to active 
mucosal activity and ulcers.34, 35 Differences in colonic transit time or intestinal pH according 
to UC activity and extent may also lead to altered absorption of 5-ASA.30 IBD patients use 
more comedication with possible interactions36 and have additional comorbidities 37–39 that 
might affect pharmacokinetics.
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All patients reported high adherence levels according to MMAS, but this might reflect 
overestimation.13, 40 We did not compare the (Nac-)5-ASA urinalysis with methods superior to 
MMAS such as pharmacy data, tablet counts or MEMS.40 While MEMS is expensive, pharmacy 
data and pill count would have been good alternatives during the study period. However, we 
wanted to find an easy and feasible adherence tool that can be implemented in ‘real-world’ 
IBD practice. Our trial mirrored real-world practice with a similar pattern of hospital visits 
(routinely twice a year) and chronic prescriptions for these quiescent UC patients to minimize 
the ‘positive study effect’ on adherence.41
In conclusion, spot (Nac-)5-ASA urinalysis is not suitable for assessing 5-ASA adherence in daily 
IBD practice due to large inter- and intra-patient variability, not even when using one single 
brand and dosage. In view of our findings, it is not possible to set cut-off values for (partial) 
adherence in UC patients. Alternative strategies are needed to reliably monitor medication 
adherence.
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What is already known about this subject
•  It is challenging to objectively measure adherence.
•  HPLC can be used to perform (Nac-)-5-ASA urinalysis.
•  24–96 h urinary (Nac-)5-ASA excretion is comparable for most oral 5-ASA formulations.
What this study adds
•  Results from (Nac-)5-ASA excretion measured in 24–96 h urine cannot be extrapolated to 
results measured in spot urine.
•  There is a wide variation in urinary (Nac-)5-ASA excretion in UC patients regardless of 
disease activity, 5-ASA brand or dosing schedules.
•  Spot (Nac-)5-ASA urinalysis is not suitable for assessing (partial) 5-ASA adherence in daily 
IBD practice. 
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TABLES
Table 1 Demographics and laboratory results
Demographics N=29a 
Male (N, %) 15 (51.72%)
Age (years) 52 ± 11 (20-67)
Duration disease (months) 168 ± 114 (9-468)
Duration FU (months) 9.7 ± 4.1 (1.6-18)
Baselinea 3 months 6 monthsa
Laboratory results N=29 N=17 N=19
Fecal calprotectin (μg g-1) (median) 117 (5-1800) 46 (5-483) 74 (5-1578)
Hemoglobin (mmol l-1) 9.1 ± 0.9 (7.1-11) - 9.2 ± 0.8 (8-10.4)
CRP (mg l-1)(median) 3 (3-20) - 3 (2-26)
Albumin (g l-1) 39.2 ± 2.8 (33-44) - 38.2 ± 2.2 (34-42)
Creatinine (mg mmol l-1) 75.3 ± 14.6 (53-113) - 76.9 ± 14.0 (53-107)
N=29 N=22 N=18
SCCAI (median) 2 (0-5) 2 (0-4) 2 (0-9)
MMAS-8 (median) 10 (1-11) 10 (4-11) 11 (5-11)
aData mentioned as mean ± SD (range), unless specified otherwise
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Figure 1 Individual spot (Nac-)5-ASA urinary excretion (5-ASA/mg mmol l-1creatinine) using different 
brands and dosages 5-ASA at screening
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Figure 2a Individual (Nac-)5-ASA urinary excretion (5-ASA/mg mmol l-1 creatinine) in 29 UC patients 
using 2400 mg MMX-mesalazine. 
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Figure 2b Individual steady state results of (Nac-)5-ASA urinary excretion (5-ASA/mg mmol l-1 creatinine) 
in 25 healthy volunteers using 2400 mg MMX-mesalazine
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ABSTRACT
Background & Aims
Anti-TNF therapy is the mainstay of treatment for moderate to severe inflammatory Bowel 
Disease (IBD). Some patients lose response with time and therapeutic drug monitoring (TDM) 
could assist to increase the efficacy of anti-TNF therapy, but may contribute to higher health 
care costs. We performed a real-life prospective cohort study to assess whether proactive 
TDM in IBD patients on Remicade® (Infliximab (IFX)) is cost-effective compared to empiric 
IFX intensification combined with reactive TDM (conventional strategy).
Methods
All IBD patients using IFX in a Dutch teaching hospital were included. To assess costs and 
effects for the proactive TDM strategy, prospective cohort data from these patients were 
used. For the conventional treatment strategy, costs and effects were calculated with a model, 
based on baseline variables (fecal calprotectin (FCP), clinical activity score) and literature 
parameters. Primary outcome was cost-effectiveness during six months of follow up using 
total health care costs and number of patients with a clinical flare.
Results
At baseline, 72/95 patients (75,8%) were in clinical remission. Median IFX TLs was 4,1 (2,2-
6,1) µg/ml and median FCP level 110 µg/g (41-465). Mean health care costs/ patient were 
€11.055,43 in the proactive TDM group and €9.437,07 by using the conventional strategy. In 
the proactive TDM group 28,42% had a flare during 6 months, with an expected flare in the 
conventional group of 35,79%, leading to an ICER of €218,70 per prevented flare. The ICUR 
was calculated as €881.688,69 per QALY gained, with a mean utility of 0.843 in the proactive 
TDM group and 0.830 by using the conventional strategy.
Conclusion
Proactive TDM of Remicade® (IFX) in our real-life IBD cohort results in less disease flares, 
but is not cost-effective during six months of follow up.
Key words: Inflammatory bowel disease; Therapeutic Drug Monitoring, cost effectiveness, 
anti-TNF therapy, Infliximab.
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INTRODUCTION
Inflammatory Bowel Disease (IBD) is a chronic, progressive and disabling inflammatory disease 
of the gastrointestinal tract. Both Ulcerative Colitis (UC ) and Crohn’s Disease (CD) are part of 
the phenotypical spectrum of IBD1, 2 and tumor necrosis factor alpha blockers (anti-TNF) are 
the mainstay of treatment for moderate to severe IBD.3 A large proportion of IBD patients lose 
response with time and require dose intensification.4-8 Empiric dose intensification for anti-
TNF therapy failures is common practice and achieves remission in 39–56% of patients.9-11 
Therapeutic drug monitoring (TDM) of anti-TNF therapy as Remicade® (infliximab (IFX)) 
involves measurement of drug levels and antidrug antibodies (ATI). During maintenance 
therapy approximately 20% of patients have low (<1 μg/ml) trough levels (TLs) of IFX which 
is associated with active disease and often accompanied with high ATI levels.12, 13 IFX TLs > 
7 μg/ml do not carry clinical advantage compared to levels below the 7 μg/ml threshold.13-15 
Recommended therapeutic cut-offs for IFX TLs range between 3 to 8 μg/ml16-19 depending on 
disease phenotypes or treatment endpoints. TDM can be performed as a routine proactive 
strategy in patients who are on maintenance therapy and in remission, or alternatively as a 
reactive testing method in active disease. A recent AGA guideline advices reactive TDM of 
anti-TNF therapy in active IBD, but stops from making recommendations on the use of routine 
proactive TDM.20 This contrasts a recent consensus statement that suggested that anti-TNF 
therapy TDM must be considered in case of treatment failure, but also as a proactive strategy 
following successful induction, when a drug holiday is considered or during clinical remission 
when TDM results have the potential to change management.19 While effective, the advent of 
anti-TNF therapy has introduced a new pattern of healthcare spending in IBD with a shift of 
healthcare costs from hospitalization and surgery towards medication costs.21 TDM might assist 
to increase the efficacy of anti-TNF therapy, but may also contribute to higher health care costs. 
Some reports on anti-TNF therapy suggest that TDM results in cost reduction in IBD patients 
with secondary failure on IFX,10, 22 but others showed less favorable results in achieving IFX TLs 
levels of 3-7 μg/ml.23 
We performed a real-world study on the effects of proactive TDM in IBD patients on IFX. Until 
June 2016, empiric IFX dose intensification after treatment failure was common practice in 
IBD patients in our teaching hospital, as was reactive TDM in case of persistent failure. Since 
June 2016, we introduced proactive IFX TDM as standard of care. We assumed that our cohort 
would be comparable with a previously published cohort of a Dutch teaching hospital.24 We 
hypothesized that introducing proactive TDM would reduce health care costs expenses, with 
limited impact on clinical efficacy. This real-life prospective cohort study was designed to assess 
whether real-life proactive TDM in IBD patients on IFX is cost-effective compared to empiric 
IFX intensification combined with reactive TDM, after six months of follow-up. 
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METHODS 
Study design
This single-center, prospective, observational cohort study was carried out in a teaching 
hospital (the Jeroen Bosch hospital) in the Netherlands. The study was approved by the 
local Medical Ethics Review Committee. The study compares a proactive TDM treatment 
strategy to a conventional (combined clinical and reactive TDM) treatment strategy. To 
assess costs and effects for the proactive TDM strategy, prospective cohort data from IBD 
patients using IFX in the JBZ was used. For the conventional treatment strategy, costs and 
effects were calculated with a model, based on baseline variables (clinical activity score and 
FCP) and literature parameters. 
Study end points 
Primary outcome was cost-effectiveness during six months of follow up using total health 
care costs and number of patients with a clinical flare. A clinical flare is defined as clinical 
need to change medication, or Simple Clinical Colitis Activity Index (SCCAI) > 5 for UC and 
the Harvey-Bradshaw Index (HBI) > 5 for CD.25-27 Secondary outcomes were ATI, adverse 
events or severe adverse events, numbers of biochemical flare (FCP > 250)28 and quality 
of life (measured with EQ-5D-3L) during six months follow-up.
Treatment regimes
 Proactive TDM based treatment
All IBD patients treated with Remicade® (IFX) were treated according to a proactive TDM-
based treatment algorithm (Appendix 1), from June 2016 onwards. Informed consent was 
obtained from all eligible patients between June 2016 and March 2017 to collect their 
personal en medical data and to complete short clinical activity (SCCAI/HBI) and EQ-
5D questionnaires at each infusion visit. Inclusion criteria comprised of a confirmed IBD 
diagnosis, age ≥18 years, treatment with IFX (beyond induction phase) and ability to give 
informed consent. 
Patients were treated with 5 mg/kg body weight IFX every 8 weeks and IFX dose adjustments 
were performed according to the algorithm (Appendix 1) based on IFX TLs, ATI, FCP and 
clinical presentation. IFX TLs and antibodies were assessed prior to the infusion on the IFX 
infusion day, with a maximum of one day before. We divided the measured TLs into four 
categories: <1, 1-3, 3-7 and >7 μg/ml. TLs 3-7 μg/ml were considered to be in the therapeutic 
range.23, 29 IFX TLs were measured by a previously validated and described enzyme-linked 
immunosorbent assay from Sanquin Biologics Laboratory, Amsterdam, the Netherlands 
(Sanquin).30 ATI levels were measured by a previously validated radio-immunoassay from 
Sanquin, which measures the free fraction of serum ATI in antibody units per milliliter.31 
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Positive ATI (>12 AE/ml) were only valid with IFX TLs < 3 μg/ml, due to drug interference 
with antibody detection. FCP levels were collected on the infusion day or maximum two 
weeks before or after infusion. As cut-off value to define biochemical remission we used 
FCP levels of 250 μg/g.28
Conventional treatment strategy (symptom based with empiric dose adjustments and reactive TDM)
Patients were treated with 5 mg/kg body weight IFX every 8 weeks and IFX dose adjustments were 
performed based on clinical disease activity, with reactive TDM in case of persistent treatment 
failure after dose intensification. In case of clinical disease activity the IFX interval was decreased 
from eight to six weeks first. When this did not result in relief of symptoms, TLs and FCP were 
measured. Based on these parameters combined with clinical symptoms, the dosage or interval 
was adjusted (10mg/kg or interval 1x/4 wks) or the treatment was switched to another drug. 
Prospective data collection
FCP, IFX levels, clinical disease activity and quality of life scores were collected prospectively 
at each IFX infusion visit. Clinical disease activity was assessed with the SCCAI for UC and the 
HBI for CD.25, 26 The cut-off point for clinical remission was HBI <5 or SCCAI <5. Quality of life 
was measured with the EQ-5D-3L.32 Utilities were calculated using the Dutch tariff.33 
A ‘ proactive TDM study team’ followed the flow of patients through the algorithm. This team 
consisted of one independent investigator (ABG), one gastroenterologist (TR) and one IBD 
nurse. This team routinely checked all IFX levels and collected FCP levels. They advised the 
treating clinicians on IFX dosage and infusion intervals based on the treatment algorithm 
(Appendix 1) by e-mail. Standardized theoretic advice was given such as ‘increase or decrease 
intervals and/or dosage, repeat TLs levels within 4 months, or to consider to stop or switch the 
treatment’. Prior to start of the study all treating practitioners were informed during a clinical 
lesson about the proactive TDM based treatment algorithm and the treatment algorithm was 
made available to them. Prior to start of the study, all physicians committed to the protocol and 
agreed to comply with its recommendations, unless there were compelling clinical reasons not 
to do so. From June 2016 onwards treating physicians of IBD patients on IFX regularly received 
advice from ‘the proactive TDM study team’ that arose from the algorithm. The final decision 
with respect to dosing and interval was left to the discretion of the treating physician, who was 
best able to take all relevant additional matters as disease phenotype, adverse drug events, 
relevant co-morbidities) into account.
Modeling
Since we did not collect standard FCP or clinical disease activity and quality of life questionnaires 
during the period before the proactive TDM period, the effectiveness of conventional treatment 
strategy, was assessed using a model. We established a decision model, using baseline variables of all 
212   |   Chapter 8
IFX treated IBD patients at start from the proactive TDM based care period. For patients in clinical 
remission at baseline, the assumption was made that their treatment would remain unchanged for 
the next six months. The chance of developing a flare during six months of follow up were modeled 
based on their baseline FCP levels. Probabilities used in the model are shown in Table 1.
For patients who were not in clinical remission at baseline, IFX treatment schedule was adjusted 
as previously described. The chance to develop a flare during 6 month of follow up in patients who 
were not in remission at baseline were modeled based on probabilities found in literature (Table 1). 
Analysis 
Demographic variables (age, gender, diagnosis, Montreal classification, 34 abdominal surgery, 
co-medication and duration of IFX treatment) at start of the study are presented as means and 
SD when normally distributed and median and IQR otherwise. Nominal variables are presented 
with N and percentage.
Cost analysis 
The first part of the cost analysis consisted of the prospective collection of the quantity of 
healthcare consumption over the six months follow-up. The following variables were used: pre-
medication, co-medication, dosage and interval of IFX, radiology exams, number of outpatient 
visits, telephonic consultations with the gastroenterologist or with the IBD-nurse, number 
of endoscopies, number of consulted IBD-related specialists (rheumatologist, dietician) and 
number of hospitalizations. The second part of the cost analysis consisted of the determination 
of the unit costs for these healthcare consumptions. Reference prices were used for hospital-
related care 35, and costs for medication were derived from ‘Zorginstituut Nederland’.36 Since the 
dosage of pre- and co-medication was unknown, this was based on a Dutch pharmacotherapeutic 
database 36 and dosages used in the COIN study.21 Productivity costs or costs related to other 
sectors than health care were not taken into account in the analysis.
For the conventional care, baseline data for pre-medication and co-medication were used. 
Costs for IFX was calculated based on dosage and interval. For the other costs, no exact data 
were available, and therefore these costs were extrapolated. Chances on making health care 
costs when having a flare or not during six months follow-up were comparable for conventional 
care and proactive TDM based care, with two exceptions. First, for the conventional care, it 
was assumed that patients visit their gastroenterologist (or IBD nurse) twice a year, as this is 
common practice in our hospital in stable disease. Second, there were more telephonic consults 
with the IBD nurse than usual in the proactive TDM based care, because patients wanted to be 
informed about the FCP and IFX TLs results. The assumption was made that in the conventional 
care the number of telephonic consults was half of the number of telephonic consultations in 
the proactive TDM based care.
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Qualy’s – Utility
The Incremental Cost Utility Ratio (ICUR) was calculated by dividing the difference in costs 
through the difference in Quality Adjusted Life Years (QALY). The ICUR represents the costs 
per gained QALY. Mean utility over 6 months per patient was calculated separately for patients 
with a flare and patients without a flare. By multiplying this with the percentage of patients 
with and without a flare, the mean utility for both strategies was calculated. Follow-up was six 
months, which means that maximal 0,5 QALY could be reached. To calculate the QALY’s in six 
months, mean utility was divided by 2.
Calculation of the ICER
The incremental cost-effectiveness ratio (ICER) was calculated by dividing the difference in 
costs per patient with the difference in percentage in flares. The ICER represents the costs per 
prevented flare in the proactive TDM care. 
Scenario analysis
Costs were calculated with the costs price for Remicade®. Meanwhile, cheaper biosimilars 
became available 37 with different price tags in every hospital. 
To investigate the effect of cost reduction upon treatment with IFX biosimilars, a scenario 
analysis was performed with 10-80% cost reduction as a plausible range of extremes. Since our 
cohort study was performed in daily clinical practice, nonadherence to the treatment algorithm 
is likely. To assess the effect this nonadherence on the ICER, costs were also calculated with 
full adherence to the treatment algorithm. To investigate specific patient groups, the ICER was 
separately calculated for those patients in clinical remission.
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RESULTS
Demographics
A total of 117 patients were included in this study. Due to incomplete data, 12 patients were 
excluded. The demographics of the 95 remaining patients are depicted in Table 2. At baseline, 
72 patients (75,8%) were in clinical remission. Baseline median SCCAI score was 4 (range 2-5) 
and median HBI score 3 (range 1-8). Median IFX TLs was 4,1 (range 2,2-6,1) μg/ml and median 
FCP level was 110 (range 41-465). At the first TLs measurement since start of the proactive 
TDM regime, 45 patients (47,4%) had TLs between 3 and 7 μg/ml. Of these 45 patients, 21 
(46,7%) had FCP level <100 μg/g. (Figure 1). These baseline characteristics were used in our 
model, missing FCP data were imputed.
Outcome and costs
During 6 months follow-up using the proactive TDM regime, 14 of the 72 patients (19,4%) that 
were in clinical remission at baseline had a clinical flare. For the conventional strategy it was 
calculated that 27 (37,5%) would have had a clinical flare. Of the 23 patients that had active 
disease at baseline, 13 (56,5%) had a clinical flare. For the conventional strategy it was calculated 
that 8 (34,8%) would have had a clinical flare. Costs per patient are higher for the proactive TDM 
strategy, except for patients that were not in clinical remission at baseline and also had a flare 
during 6 months of follow-up (Figure 2).
Calculation of the ICER and ICUR
By using the proactive TDM strategy, mean health care costs per patient were €11.055,43 and 
in the conventional group €9.437,07. In the proactive TDM group 28,42% of the patients had 
a flare during 6 months of follow-up, with an expected flare in 35,79% of the patients in the 
conventional strategy group during 6 months follow up. By dividing the differences in costs 
through the differences in effect, the ICER is €218,70 per prevented flare (Table 3). Mean utility 
was 0,7994 for patients with a flare during 6 months follow-up and 0,8472 for patients with no 
flare. Mean utility in the proactive TDM based strategy was calculated to be 0,834 and mean 
utility in the conventional treatment strategy 0,830. By dividing the difference in costs per 
patient and the difference in QALY’s, the ICUR is calculated as €881.688,69 per QALY gained 
(Table 4).We performed a sensitivity analysis to provide insight into the uncertainty associated 
with our decision model. The result of the sensitivity analysis is depicted in supplementary 
Figure 4. 
Secondary outcomes
One patient had positive ATI (350 AE/ml) with an IFX TLs of 0,03 μg/ml. One patient had positive 
ATI (42), but an IFX TL of 4,90, making this ATI measurement unvalid and unusable. One AE was 
reported, being a pulmonary allergic reaction to Remicade®. No SAE’s were reported.
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Scenario analysis
Biosimilars
Figure 3a shows the effect of cost reduction of biosimilars instead of Remicade® on the ICER. 
With cost reduction > 80%, the ICER is higher than the commonly used Willingness To Pay 
(WTP) threshold of €80.000 per QALY.
Protocol deviation
This study was performed in daily clinical practice. Not all advices resulting from the algorithm 
were followed by the treating physicians. Dosage or interval adjustments, repeated FCP or 
through level measurements were not always performed according to the treatment algorithm. 
During follow up 244 FCP and 265 TLs tests were performed, whereas according to the given 
advice only 143 tests should have been performed. This results in extra costs of €92,26 per 
patient. Twenty-seven percent (3/11) of the advices to lower the IFX dosage in case of TLs >7 
μg/ml and remission, was followed. Eighty-three percent (20/24) of the advices to increase 
dosage or interval of IFX in case of disease activity and TLs ≤ 3 μg/ml was followed. If all advices 
about dosage or interval adjustments had been followed, this would have resulted in savings of 
€744,43 per patient. In total, if protocol adherence would have been 100%, costs per patient in 
the proactive TDM strategy decrease from €11.055,43 to €10.310,99. This results in a decrease 
of the ICUR from €881.688,69 to €476.119,40 per gained QALY.
Figure 3b shows the combined effect of cost reduction of the use of biosimilars and of full 
protocol adherence on the ICER. 
Subgroup analysis
To find out the effect of only using the proactive TDM strategy for patients in clinical remission 
at baseline, the ICER for that group was calculated. For this group, the ICER was €453.454,55.
Of the patients in clinical remission at baseline with FCP levels < 100 μg/g and TLs levels 
between 3 -7 μg/ml or 1-3 μg/ml, only 1 patient (4,8%) had a flare. The costs of proactive TDM 
in these patients was €185,81 per patient.
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DISCUSSION
Proactive TDM of Remicade® (IFX) in our real-life IBD cohort results in less disease flares, but 
is not cost-effective during six months of follow up. The use of biosimilars of IFX with significant 
cost-reduction may tip the balance in favor of proactive TDM but to date a willingness to pay 
(WTP) of € 80000/QALY is far from being met. In day-to-day practice there appears to be a 
threshold for both gastroenterologists and patients to lower or discontinue IFX dosing. This 
behavior affects the cost-effectiveness analysis, as in general treatment advices that indicated 
regime intensification (coming from our TDM algorithm) were followed. 
Currently reactive TDM for anti-TNF therapy is recommended by the AGA guidelines and 
Australian IBD consensus group where TDM is described as an important component of 
personalized therapy in IBD.19, 20 The concept of reactive TDM is also incorporated in daily care 
as 90% of the questioned US gastroenterologists use it, with almost 40% using it proactively.42 
Available evidence indicate that a reactive TDM strategy for anti-TNF therapy in IBD compared 
with empirical management leads to major cost savings, without negative impact on efficacy.10, 
22, 43-45
Routinely proactive TDM is under debate. Proactive TDM is recommended in specific 
circumstances such as early drug optimization after induction therapy, in clinical remission when 
TDM results would change management for example in IFX de-escalating strategies or when 
considering a drug holiday. 9, 19, 46, 47 Available data on proactive TDM and costs are scarce and 
show that the observed cost-reduction of proactive TDM is mainly caused by dose de-escalation 
or discontinuation of IFX.23 
In our real-life IBD cohort on IFX, we show that proactive TDM is not cost-effective, and that 
each prevented flare comes with 218 euro additional costs. The costs of additional testing 
turned out to be negligible, which is in concordance with earlier literature.44 
The scenario analysis reveals two major findings. First, drug costs of Remicade® (IFX) are of 
great influence on the ICER. With the advent of biosimilars, the cost price for IFX will decrease, 
which will have a (major) positive effect on the ICER, resulting in a cost-effective strategy. 
Second, the advices from the TDM algorithm to intensify the IFX dosage appeared to be followed 
much more strictly by the treating gastroenterologists than the advices to de-escalate (83 
versus 27%) or discontinue IFX. A prior retrospective study concerning reactive TDM showed 
overall poor adherence to evidence-based TDM decision by clinicians.48 
Therapeutic drug monitoring of Infliximab in Inflammatory Bowel Disease   |   217
8
Interestingly, the hesitation to de-escalate or discontinue IFX therapy is at odds with results 
from our recent nationwide Dutch survey among IBD treating gastroenterologists. Here, 
the majority claimed that they were willing to stop immunosuppressive medication after 
more than one year of deep remission with a preference of stopping anti-TNF therapy over 
thiopurines.49 There is no international consensus on this topic, and downstream treatment 
guidelines are not available. According to the Dutch IBD guideline the decision to stop anti-
TNF therapy should be taken on an individual basis, with complete remission (clinical, biological 
and endoscopic) as a minimum condition.50 One might consider a drug holiday and discontinue 
IFX in patients with undetectable IFX TLs, longer duration of steroid-free remission, mucosal 
healing and normal inflammatory biomarkers.51-54 Available literature on proactive TDM shows 
promising results. proactive TDM led to de-escalated IFX therapy in 13-27% of patients without 
a negative impact on remission rates.23, 55 After withdrawal of IFX during 7 years of follow up in 
the STORI cohort only 30% of patients had a major complication or failure of IFX restart.56 In 
addition, recent data from the field of rheumatology indicate that under specific circumstances 
(sustained remission, no corticosteroids) dose reduction or even discontinuation is possible 
without significant clinical consequences.57-59 Our study emphasizes the need for objective 
patient risk stratification, in order to steer the decision-making process on down-titrating IFX 
dosage. Currently in the Netherlands a de-escalation trial for Adalimumab in CD is running. The 
information that will come from this study may have wide implications for daily IBD practice 
(LADI trial; NCT03172377)and will aid to select those patients who will benefit from de-
escalating biological therapy without loss-of response. 
The therapeutic range for IFX TLs varies greatly (2-10 μg/ml) 16-18, 60 as it depends on the 
treatment end point and disease phenotype. At baseline 25% of our cohort had intended TLs of 
IFX (3-7 μg/ml) and FCP levels <100 μg/g, suggesting deep remission.61 Only half of the patients 
in clinical remission were in deep remission with FCP levels < 100 μg/g and even 22% of the 
patients in clinical remission had a biochemical flare with FCP > 250 μg/g. This discrepancy 
between clinical symptoms and mucosal healing (MH) is known,62 and provides space for therapy 
optimization to ensure MH with better long term outcomes.63 
This study has several strengths and clinical implications. The major strength of this cohort study 
is the fact that it was carried out in daily IBD practice. We saw that advice for dose de-escalation 
was less likely to be followed by attending physicians and it is imperative to explore the reasons 
for this behavioral resistance. Second, we compared proactive TDM not only with a conventional 
strategy based on symptoms, but with a combined conventional strategy including the above 
supplemented with FCP and reactive TDM. This ‘conventional strategy’ does more justice to the 
current IBD treatment strategy. Another strong point is the primary outcome as used for the 
cost-effectiveness analysis. As IBD is a remitting relapsing disease the percentage of patients 
with a flare during six months follow-up is more reliable than the percentage of patients with a 
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flare at one time point. Next, our study uses prospective data, which reduces the chance of bias. 
This study comes with limitations. The major limitation of our study is inherent to the design of 
the study. We used modeling techniques and performed an observational study. Bias constitute 
a major threat to the validity of nonrandomized observational studies in general, although as 
earlier mentioned, we used a prospective study design, and enrolled all IBD patients on IFX 
without selection. Still, an RCT would have been a better study design, but this was no realistic 
option because proactive TDM already had become the standard of care for all IBD patients on 
IFX in our hospital. Modeling simplifies the real world and the reliability of the results coming 
from modeling trials depends on assumptions based on literature data. The alternative of using 
retrospective data of our prospective cohort as a control group would have led to more biased 
and incomplete data. The analysis was performed for all IBD patients together. Preferably UC 
and CD patients were analyzed separately, because FCP is a stronger predictive marker in UC 
than in CD.64, 65 However the primary outcome of our study would not have changed by analyzing 
them separately as only 22% of our cohort were UC patients. Finally we only took health-care 
related costs into account and we did not use the societal perspective whereas IBD is known 
to result in productivity loss.21 
In conclusion, proactive TDM for Remicade® (IFX) in IBD patients may prevent IBD flares, but 
comes with higher costs. When considering quality adjusted life years, proactive TDM is not 
cost-effective. The most important influences on the ICER are high cost-prices of biological 
drugs, and hesitance to de-escalate or discontinue IFX by clinicians. Prospective real-world 
clinical IBD trials on de-escalating anti-TNF therapy are indispensable for daily practice to be 
able to perform an adequate patient risk stratification and to realize high quality individualized 
IBD care with maximum clinical effects of anti-TNF therapy at the lowest possible cost. 
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TABLES
Table 1 Probabilities for a flare after six months
Variable Probability Source 
Flare FCP <100 0 Mooiweer 38 * 
Flare FCP 100-250 0,524 Ferreiro 39 
Flare FCP >250 0,783 Ferreiro 39 
Flare after increase of dosage 0,355 Kopylov 40* 
Flare after decrease of interval 0,3 Kopylov 40* 
Flare after switch to Adalimumab 0,62 Gisbert 41* 
*Positive Predictive Value calculated based on sensitivity and specificity
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Table 2 Demographic variables
Variable median (IQR) N (%) (total N= 95)
Females 57 (60)
Age (years) 42,00 (30-53)
Ulcerative Colitis 21 (22,1)
Montreal classification Disease extent E1 3 (14,3) 
E2 14 (66,7) 
E3 4 (19,0) 
Severity of disease S1 18 (85,7) 
S2 2 (9,5)
S3 1 (4,8) 
S4 0 
Crohn’s disease 72 (75,8)
Montreal classification Age at diagnosis A1 0 (0) <16
A2 38 (52,8) 17-40
A3 34 (47,2) >40
Disease localization L1 30 (41,7) 
L2 28 (38,9) 
L3 14 (19,4) 
L4 5 (6,9) 
P+ 20 (27,8) 
Disease behavior B1 52 (72,2)
B2	18 (25,0)
B3 2 (2,8)
IBD-U 2 (2,1)
Length IFX therapy (months) 43,00 (21-71)
Abdominal surgery 19 (20,0)
Ileocecal resection 16 (84,2)
Hemicolectomy (r)  1 (5,3)
Sigmoid resection  1 (5,3)
Small bowel  2 (10,5)
Other operations  8 (42,1)
Co medication 48 (50,5)
Mesalazine 16 (33,3)
Budesonide enema  1 (2,2)
Steroids  0
Azathioprine 15 (31,3)
Mercaptopurine 12 (25,0)
Methotrexaat  3 (6,3)
Tioguanine  6 (12,5)
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Table 3 calculation of the ICER (costs per prevented flare) 
Costs per 
patient
∆costs % flares ∆flares ICER
TDM Based Strategy €11.055 - 28,4 % - -
Symptom
Based Strategy
€9437 €1.618 35,8 % 7,4 % €219
Table 4 calculation of the ICUR (costs/gained QALY)
Costs per 
patient
∆costs Mean 
utility
QALY ‘s in 
6 months
∆QALY’s ICUR
Symptom
Based Strategy
€11.055 - 0,834 0,417 -
TDM
Based Strategy
€9437 €1.618 0,830 0,415 0,0018 €881.689
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FIGURES
95  
Patients 
5 TL <1 
Calprotectin <100: 0 
Calprotectin 100-250: 1 
Calprotectin >250: 4 
Missing: 0 
29  
TL 1-3 
Calprotectin <100: 13 
Calprotectin 100-250: 4 
Calprotectin >250: 7 
Missing: 5 
45  
TL 3-7 
Calprotectin <100: 21 
Calprotectin 100-250: 7 
Calprotectin >250: 11 
Missing: 6 
16  
TL >7 
Calprotectin <100: 5 
Calprotectin 100-250: 3 
Calprotectin >250: 6 
Missing: 2 
Figure 1 Baseline disease activity characteristics and IFX through levels
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€ 14.503,14
€ 9.800,70
€ 13.428,21
€ 10.421,43
€ 9.439,86
€ 8.357,84
€ 12.604,44
€ 11.042,44
Baseline 
95 patients 
72 (75,8%) 
clinical 
remission 
 14 (19,4%)  clinical flare 
58 (80,6%) no 
clinical flare 
23 (24,2%) no 
clinical 
remission 
13 (56,5%) clinical flare 
10 (43,5%) no 
clinical flare 
Outcome after six months  Costs per patient Proactive TDM  treatment  
strategy  
Outcome after six months Costs per patient Conventional treatment  
strategy  
52,8% calprotectin >100 
78,3% calprotectin >100 
Baseline 
95 patients 
72 (75,8%) 
clinical 
remission 
27 (37,5%) clinical flare 
45 (62,5%) no 
clinical flare 
23 (24,2%) 
no clinical 
remission 
8 (34,8%) clinical flare 
15 (62,5%) no 
clinical flare 
52,8% calprotectin >100 
78,3% calprotectin >100 
Figure 2 Outcome after 6 months of follow up
Therapeutic drug monitoring of Infliximab in Inflammatory Bowel Disease   |   229
8
    






  


 

    






  


 



Figure 3a the effect of cost reduction of using biosimilars (instead of Remicade®)
    






  


 

    






  


 



Figure 3b the combined effect of cost reduction of using biosimilars and of full protocol adherence
 
230   |   Chapter 8
SUPPLEMENTARY FIGURES
Appendix 1Treatment algorithm
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Figure 4 Sensitivity analysis of the decision model

PART IV
Concluding remarks

CHAPTER # 
Treatment Targets in Inflammatory Bowel Disease: 
Current Status in Daily Practice
CHAPTER 9a 
General discussion
DISCUSSION
The discussion of this thesis is divided in two parts. The first part (Chapter 9a) is a general 
discussion and the second part (Chapter 9b) consists of an extensive reflection on the studies 
described in chapter 7. 
In Chapter 9a we aim to systematically discuss the answers to the research questions we 
have raised in the introduction of this thesis. In addition we used these outcomes to suggest 
future research directions and provide tools for clinical implementation.
Chapter 9b consists of an extensive reflection on the design, modeling and execution of an 
RCT as described in chapter 7, specifically leading to ‘lessons learned’ from the study course 
and outcomes as well as recommendations for future research.
Overall we conclude that although the general aim of this thesis was ‘to further improve 
daily real-life IBD care’ and ‘IBD patients were the reasons to start this thesis’, the most 
important lesson learned from this thesis, is to center clinical research around IBD patients 
rather than the reverse. The patient should be more involved in the design of a trial and play 
an important role in the execution. This patient involvement may prevent researchers to 
make assumptions that do not match the patient’s world of experience. In addition we need to 
measure clinically relevant outcomes in IBD trials and in clinical practice. Earlier the US Food 
and Drugs Administration (FDA)1 advocated routine use of PROMs as co-primary endpoints 
in future clinical trials. To date there is an increased awareness for patient-reported outcomes 
as a treatment target in clinical trials and also in daily practice. Recently an IBD Working 
Group of clinical and outcome specialists, patients and their associations from 12 countries 
developed a standard set of patient-centered outcomes for IBD that need to be evaluated 
in real-world practice.2 Despite these positive turns PROMs are not routinely used in daily 
IBD practice yet and in our opinion patient involvement in the set-up and execution of trials 
is still undervalued and should be emphasized more. 
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GENERAL DISCUSSION
PART I Treatment targets in IBD
Which treatment targets and definitions are used in Dutch real world IBD practices and what 
factors in daily IBD care may influence clinical decision-making? 
Three-quarters of all respondents of our nation-wide survey among Dutch gastroenterologists 
use MH as key treatment goal, with almost half of them using deep remission (defined as 
clinical, biochemical and endoscopic remission). To reach deep remission the majority is 
willing to intensify IBD treatment. Mayo score ≤ 1 in UC and ‘macroscopic normal mucosa’ 
in CD are mostly used to define MH in IBD. 
Implications
To date MH is a central theme in clinical trials, but it was unknown whether this concept has 
been adopted in clinical practice. Our data suggest that the concept of MH for UC and CD 
is embraced by many Dutch IBD practices, despite the fact that guidelines are ambiguous 
3, 4 and a Swiss survey found opposite results. 5 Although our data suggest that it has, a 
recent retrospective study showed that UC patients in ‘real-world’ practices did not achieve 
the theoretically proposed ‘treat-to-target’ endpoints (composite clinical and endoscopic 
remission). The difference they found between theory and daily practice was significantly 
associated with therapeutic factors and the treating hospital, whereas disease-related or 
patient related factors played no role in this.6 
With this thought in mind, the question remains to what extent the theoretical answers of 
our respondents are actually applied in daily clinical IBD care. More prospective real-life 
data are necessary to evaluate this.
A single definition for MH in IBD is lacking. More than half of the participants use the Mayo 
score (0 or ≤ 1) to define MH in UC, which is in line with the recommendation of the IOIBD 
consensus group in 2015,7 whereas recently UCEIS 0 was proposed as definition.8 Our 
finding may have important implications as we show that in daily practice the most pragmatic 
and ‘easy to use’ UC activity scoring systems are used. More accurate and validated systems 
are available 9, 10 but these seem complex and rather time consuming,11 likely explaining 
its infrequent use in daily practice. With the recent recommendations for MH in mind 
(UCEIS 0), it seems essential to simplify the existing validated scoring systems to enable 
implementation and widely use in daily practice.
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Reflection and future directions
This nation-wide survey has limitations. The low response rate and voluntary participation in 
this survey make the results more sensitive to bias. In contrast the purposive sampling, national 
design of the survey, and the inclusion of physicians from both general and academic hospitals, 
allow for extrapolation of results. Secondly, what it really is all about, is that we do not know 
to what extent the theoretical answers of our respondents are actually applied in daily clinical 
practice. Elaborating on this we need prospective ‘real-life’ data to gain insight into the ‘daily 
routine’ in an IBD practice in 2018. These data will enable us to specifically evaluate if and how 
the ‘treat-to-target’ concept is implemented in clinical IBD practice and display the obstacles 
and drawbacks we may encounter .
What is the prevalence of fatigue in IBD outpatients and can we define determinants of fatigue 
in IBD outpatients? 
Overall, we found that two-thirds of all IBD outpatients reported significant fatigue by using 
the PFS, without difference between CD and UC. Even 40% of IBD patients in clinical remission 
reported fatigue. We did not find one possible determinant of fatigue, except for a non-significant 
trend towards activity of disease. Similar prevalence numbers were found in other IBD studies 
12, 13 with the highest prevalence of fatigue in active disease. Active IBD is the most accepted 
cause of fatigue with treatment aimed at induction of remission available. In quiescent disease 
however, improving but also accepting fatigue is a difficult problem to discuss in the consulting 
room both for patient and doctor. Because fatigue is multi-factorial with unclear pathogenic 
mechanisms and lack of unified definitions or classifications there is no unequivocal treatment.14, 
15 In addition to anti-inflammatory therapy, emotional, psychological and behavioral factors may 
play a role as well, but also patients’ and health care practitioners’ negative fatigue perceptions 
are key factors to be addressed.13, 16-19
Implications
We found, in our observational cohort study in 2011, that fatigue is a highly prevalent, debilitating 
and multi-factorial symptom that negatively affects the quality of life of IBD patients. To date this 
finding has basically remained unchanged illustrated by the recent listing of fatigue as an unmet need 
in IBD.20 However, something did change in the area of fatigue. The emerging (clinical) research on 
fatigue in IBD 13, 15-18, 20-31 created an increased awareness for this important but often overlooked 
symptom. Because of this, more attention has been directed at fatigue in IBD both in daily practice 
as well as in clinical trials, with specific attention to the enormous impact fatigue has on everyday 
life of an IBD patient. As a result, practical manuals and guidelines have been developed for use in 
daily IBD practice.27 It is important for IBD health care providers to acknowledge the daily burden 
of fatigue in IBD patients, as this may encourage patients to talk about it as a legitimate problem. We 
therefore propose to set up dedicated training programs for IBD specialists and nurses to assist their 
IBD patients in recognizing and dealing with fatigue in their daily lives. 
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Reflection
Limitations of our study are as follows. We cannot draw conclusions about causality of 
determinants of fatigue in IBD as we only investigated associations. Next, we used the HBI as 
a scale to evaluate clinical disease activity in our total IBD cohort, although it is only validated 
for CD patients. The SCCAI would be the preferred disease activity measure for UC patients. 
We used the Piper fatigue scale (PFS) to evaluate fatigue in our IBD cohort. Although the PFS 
is a widely used validated instrument to measure fatigue in chronic diseases, it is not disease 
(IBD) specific. To date a variety of (partially) validated IBD fatigue scales has been developed 
and tested likely to measure IBD fatigue adequately. 31, 32
Nonetheless, the use of a different fatigue scale would likely not have changed the key message 
of our paper being the high prevalence and enormous impact of fatigue even in quiescent IBD.
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PART II The outcome of IBD trials - 
the impact of using different 
definitions and cut-offs in IBD 
Which definitions for MH in UC are used in literature and how do heterogeneous definitions for 
MH impact reported prevalence of MH?
In our meta analysis we identified 19 different definitions and cut-offs for MH. Overall, by using 
the MH definition of the original articles, 43.7% of all UC patients treated with 5-ASA achieved 
MH. As might be expected, studies with less stringent definitions reported higher MH rates. 
Implications and reflection
Our data confirm the need for one single definition for MH. It is impossible to accurately 
compare and interpret data from heterogeneous UC studies that use different definitions and 
cut-offs to describe a primary outcome measure as MH. Less stringent definitions inevitably 
lead to better results. It would have been preferable to convert the definition for MH from each 
individual trial that we included in our systematic review as this would have reduced inter-study 
heterogeneity and would have improved the accuracy of the overall MH rate. However, this would 
likely not have changed our key message. This message is clear: we need a unified and widely 
used definition of MH in UC patients that is easy to implement and correlates with clinically 
relevant outcomes. Recently an international IBD consensus group on this topic recommended 
UCEIS 0 as definition for endoscopic remission (MH), but this recommendation has to undergo 
prospective testing in clinical UC trials.8 Daily practice data seem also indispensable to enable 
worldwide use. 
What is the efficacy of 5-ASA on MH in UC? 
We conclude that 5-ASA formulations can achieve MH in nearly half of all patients with mild-to-
moderate UC, regardless of the 5-ASA formulation. This is highly effective as it is comparable 
to the use of azathioprine (53%)33 and biologicals (32%-62%) in UC patients, depending on the 
used definition of MH and duration of follow up 34-37 However no head-to-head comparisons 
have been made in the cited articles. In addition, it is likely that the UC patients in the 5-asa 
efficacy studies had milder disease activity and patients using immunosuppressive agents have 
more extensive or severe disease activity, making it more difficult to achieve MH. Therefore 
caution is warranted in interpreting and comparing these data.
Implications
Because 5-ASA is effective in achieving MH in mild-moderate UC, it remains to be the first-line 
therapy, both for topical 5-ASA treatment in cases of proctitis or proctosigmoiditis, as for oral 
5-ASA in case of left-sided or pancolitis, with a clear dose-response relation in the oral group 
(higher MH rates by using ≥3g/day). This treatment recommendation based upon our findings, 
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has clear implications for daily IBD care as nowadays there is much debating by politicians, 
hospital directors and health care providers about controlling healthcare-related costs and 
value-based healthcare. Since 5-ASA formulations are relatively inexpensive but very effective, 
they can contribute to the philosophy of cost-effective care. 
Reflection and future directions
To draw conclusions by pooling data of several partly heterogenic studies, as we did in our 
meta analysis, can be misleading. Statistical heterogeneity between the included studies was 
low, but still heterogeneity must be taken into account when interpreting the results. As in 
all meta-analyses this manuscript harbors the risk of publication bias or missing data in the 
included studies. Possible confounding aspects are for example the permitted co-medication, 
co-morbidity, duration of treatment, and difference in defining the extent of disease. Despite 
the mentioned limitations, it is clear that 5-ASA medication is very effective for the treatment of 
mild to moderately active UC. In daily practice it is important to prescribe the 5-ASA medication 
in an adequately high dose to achieve optimal effect. Prospective studies performed in daily 
IBD practice would allow more insight into the prescribing behavior and dosing schedule of 
clinicians in daily IBD care.
Which definitions for CMV colitis and CMV infection are used in IBD literature and what is the 
effect of different definitions for CMV infection and colitis on the reported prevalence of these 
entities? 
In our systematic review we identified nearly 30 different definitions for CMV infection and 
intestinal disease. Prevalence numbers highly depended on the used definition of the original 
articles, the studied population and study region. The highest prevalence for CMV infection was 
found when using positive serum PCR as a definition, whereas for CMV intestinal disease this 
applies to the use of tissue PCR >10 copies/mg tissue.
Implications
The role of cytomegalovirus (CMV) during exacerbations of UC is yet a matter of debate. The 
use of different definitions for CMV infection, reactivation and CMV intestinal disease in IBD 
patients has great impact on the reported prevalence rates (ranging from 1-84%). This leads to 
heterogeneous and incomparable study results complicating clinical decision-making in daily 
practice, including decisions on anti-viral therapy, escalating immunosuppressive therapy for 
IBD flares, or de-escalating immunosuppressive agents or corticosteroids. To date prospective 
data are scarce. Most retrospective series contain small numbers of severely ill patients that 
belong to heterogeneous subgroups with different co-morbidity, using different co-medication 
and variable dosages of steroids. Therefore to define the role of CMV in UC, we need large 
prospective randomized trials, preferably with data from daily practice. This is easier said 
than done. It will be a very difficult task to succeed because it concerns a relatively small 
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heterogeneous patient group, the diagnostic possibilities for CMV differ globally and still there 
are no clear definitions for CMV colitis and CMV infection. Therefore we propose, in line with 
the transplant medicine,38 to organize a global consensus meeting on CMV in IBD to formulate 
one unified definition for clinically relevant CMV (intestinal) disease in IBD. With this definition 
as a starting point, prospective randomized multicenter studies using ‘real-life’ data will allow 
us to compare different treatment methods in matched patient groups.
Reflection and future direction
Our study comes with some limitations. Most are undeniably related to the lack of large 
randomized prospective trials. None of the included studies were randomized, most of them 
had a retrospective design and most did not use blinding of endoscopists or pathologists. 
The heterogeneous design of the included studies and wide variations in used definitions for 
both CMV infection and intestinal disease made it impossible to perform a meta-analysis. As 
mentioned before a global consensus meeting seems essential and randomized controlled 
multicenter trials are badly needed to determine the prevalence of significant CMV in UC and 
to define which subgroup of UC patients will benefit from early antiviral treatment or change 
in immunosuppressive medication.
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PART III Challenges in daily IBD care – 
Theory versus real-life data
What is the inter-observer agreement of UC histological scores in colonic biopsies with MH that 
show limited histological inflammation? 
We found strong correlations among expert GI-pathologists between the two most frequently 
used histological activity scores for UC (RS and GS), when re-evaluating UC biopsies assessed 
as histological remission (HR) by a general pathologist. Therefore we concluded that current UC 
histological scores reliably assess limited histological inflammation in UC patients.
Implications
Our study confirms the previously reported excellent diagnostic properties of the widely used 
UC histological disease activity indexes.39, 40 We specifically studied UC colonic biopsies with 
MH and limited histological inflammation. Important is that we only used expert-GI pathologists 
to assess the biopsies, but still found higher inter-observer agreement in those biopsies that 
showed the most inflammation. This is in line with a recent study comparing three histological 
indexes (GS, NI and RHI)41 and may suggest that is it more complicated, even for specialized 
GI-pathologists, to reach an agreement in case of minor or (near) absence of histological 
inflammation.
Reflection and Future directions
The retrospective design of our study comes with risk of bias. We tried to overcome this by 
blinding our GI-pathology experts. However, the prior held consensus meeting between GI-
pathologists, may also have caused bias by achieving a better inter-observer agreement. 
Future research concerning HR needs to answer two questions. First we need one single 
definition for HR, which to date is lacking.42, 43 Second we need to know which cut-off for each 
histological score or specific histological feature is clinically relevant as a prognostic tool for 
future disease course in patients with quiescent UC. Although this is actually what really 
matters, it differs greatly in the available studies.44, 45
Does ‘daily practice’ histological assessment of UC colonic biopsies by a general pathologist 
correlate with expert reviews by gastrointestinal (GI)-pathologists?
We found a large discrepancy between the initial histological assessment by a general pathologist 
and the re-assessment by dedicated GI-pathologists. 
Implications
Our finding has large implications for everyday IBD care as it suggests a gap between daily 
practice histological assessment and academic expertise. In present time, medical decision-
making depends on MH and may increasingly depend on histological remission. In daily practice 
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IBD clinicians may be struggling with the question whether or not to discontinue UC medication 
in quiescent UC and the presence of HR may tip the balance in favor of this. It is important to 
realize that routine histological assessment of IBD mucosal biopsies obtained from a colon with 
MH is complex and probably requires expertise that goes beyond routine clinical review. This 
may also have implications for the selection process of an easy to use unified histological disease 
activity score in UC. Currently ‘easy-to-use’ IBD histology scores are introduced in an attempt 
to simplify the evaluation of histological healing in daily care.46, 47
Reflection and future directions
The retrospective design of the study harbors the risk of bias. Secondly, the consensus meeting 
between GI-pathologists, before initiation of the study, may have influenced the inter-observer 
agreement positively. Inevitably, using the Mayo score as reported by the endoscopist and not 
central reading of endoscopy videos may lead to biased results. 
We believe that future research and IBD guidelines concerning MH need to focus and act upon 
the described discrepancy between academic expertise and daily histological assessment of UC 
biopsies. We need to introduce and implement dedicated learning pathways into daily IBD care, 
implement ‘easy-to-use’ IBD histology scores, and provide the opportunity for central pathology 
reading in case of expected important clinical decision-making. These steps are crucial in order 
to implement histological remission as a therapeutic target that holds clinical relevance.
Is HPLC a feasible and reproducible method to detect urinary (NAc-) 5-ASA excretion as a measure 
of adherence in healthy volunteers taking MMX-mesalazine? 
We performed a pilot study with 25 healthy volunteers and concluded that HPLC is a feasible, 
sensitive and reproducible method to measure urinary (NAc-) 5-ASA excretion in volunteers 
taking MMX-mesalazine, showing a low inter- and intra-assay variation. However we found a 
large variation in (Nac-)5-ASA urinary excretion between individuals. An extensive reflection 
on this pilot study with recommendations for future research is described in the second part of 
the discussion of this thesis under the heading ‘lessons learned’.
Can we determine cut-off levels for adherence to 5-ASA, by measuring urinary (NAc-) 5-ASA 
excretion in volunteers taking MMX-mesalazine? 
We did determine cut-off levels of partial adherence in our pilot study concerning healthy 
volunteers. However these levels turned out not te be useful in UC patients, as these numbers 
are influenced by co-morbidity, co-medication, diarrhea, changed intestinal transit time and 
luminal PH, that all may affect the pharmacokinetic properties of 5-ASA. At best, undetectable 
urinary drug metabolites can be used to assess complete non adherence. An extensive reflection 
on this topic is described in the second part of the discussion of this thesis under the heading 
‘lessons learned’.
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Is spot (Nac-)5-ASA urinalysis by HPLC feasible to assess adherence in IBD patients in daily IBD care? 
We showed in a small intervention study including 29 UC patients that results from (Nac-) 
5-ASA excretion measured in 24-96 h urine cannot be extrapolated to spot urine and that there 
is a wide variation in urinary (Nac-)5-ASA excretion in UC patients regardless of disease activity, 
5-ASA brand, or dosing schedule. We concluded that spot (Nac-)5-ASA urinalysis is not suitable 
for assessing (partial) 5-ASA adherence in daily IBD practice.	An extensive reflection on this 
intervention study with recommendations for future research is described in the second part 
of the discussion of this thesis under the heading ‘lessons learned’.
Does proactive TDM-based IFX treatment in real-life IBD practice result in better clinical response 
compared to conventional treatment? 
Is proactive TDM-based IFX treatment cost-effective in real-life IBD practice compared to 
conventional treatment after six months of follow-up? 
We performed a real-life prospective cohort study to assess whether proactive TDM in IBD 
patients on Remicade® (IFX) is cost-effective after six months of follow-up and secondly leads 
to better clinical response. We concluded that proactive TDM of Remicade® (IFX) in this IBD 
cohort results in less disease flares, but is not cost-effective during six months of follow up.
Implications
We did not achieve our primary outcome measure cost-effectiveness in the proactive TDM 
group. However, as documented earlier 48 we found less clinical flares in the proactive TDM 
treatment group compared with the conventional therapy (combined clinical and reactive TDM 
strategy) group. Current guidelines advise positively on the use of reactive TDM, but show some 
restraint in the standard deployment of proactive TDM.49, 50 The main reasons for this hesitation 
are the lack of unified definitions for proactive or reactive TDM, the possible harm to the patient, 
for example due to different interpretation of cut-off levels and finally the matter of costs and 
cost-effectiveness.51 We showed that the findings that influenced the ICER the most, are the 
high drug costs of Remicade® (IFX) and the hesitation of patients and physicians to de-escalate 
or discontinue IFX therapy. With the implementation of biosimilars, the cost price for IFX greatly 
decreases, which will have a major positive effect on the ICER and eventually may lead to this 
strategy becoming cost-effective. In terms of stopping criteria or phasing out IFX therapy 
there are no international guidelines available which complicates clinical decision-making. The 
Dutch IBD guideline says that for each patient, the decision to stop anti-TNF therapy should be 
taken on an individual basis, with minimum conditions that must be met before a responsible 
consideration can be made to stop anti-TNF therapy. When it comes to costs, the key question 
remains at what society is willing to pay to prevent one relapse of disease.
246   |   Chapter 9 a
Reflections and future directions
The observational design of our study harbors the risk of bias and the reliability of modeling 
techniques depends on assumptions based on literature data. An RCT however was no option 
because proactive TDM had already become the standard of care for all IBD patients on IFX 
in our hospital. The follow-up of our study was six months. IBD is a chronic, recurrent and 
relapsing disease in which every relapse has impact on costs and therefore a longer follow up 
would have done more justice to reality. Future IBD research concerning IBD and costs needs 
to focus on two aspects. First we applaud the increasing opportunities in the development 
of cheaper biosimilars that will eventually lead to a major cost reduction. Next, echoing the 
rheumatologists, we need de-escalation and stop trials and guidelines concerning anti-TNF 
therapy. Currently in the Netherlands a de-escalation trial for Adalimumab in CD started (( 
LADI trial) NCT03172377) and soon a trial on stop criteria for anti-TNF therapy in CD will start 
((CEASE trial)Project Idea GGG number: 80-84800-98-91039). These trials are essential to 
work the way in daily practice and to overcome the threshold for gastroenterologists to apply 
de-escalating biological therapy in selected patients. This will result in a huge cost saving with 
limited negative effects on the clinical outcome.
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RCT FROM THEORY TO DAILY IBD PRACTICE -  
LESSONS LEARNED
The randomized controlled trial (RCT) is considered the gold standard for testing a therapeutic 
intervention. However, the conduct and implementation of an RCT in a complex health-care 
system such as a regular IBD practice comes with numerous obstacles and startup problems. 
These obstacles can be attributed to several factors as modeling, randomization, recruitment 
of both patients and health care workers, blinding, sampling and monitoring.52, 53
We have experienced this firsthand in the execution of our RCT entitled: ‘Improving adherence 
in ulcerative colitis patients on 5-ASA.’ A project that started as a prospective RCT ultimately 
resulted in a pilot study and a follow-up study that led to a compact publication (chapter 7) 
containing prospective observational data from a small cohort of IBD patients. 
In this section, I want to reflect on this RCT and would like to take you briefly through the process 
of design, the course, implementation and eventually failure of our RCT which led to premature 
discontinuation of this trial. Instead of describing a point-to-point and systematic evaluation of 
the design and implementation process of the study, I will describe in a narrative way the pitfalls 
and lessons learned. 
In 2012 the concept and design of the study was conceived. In 2014 we eventually started this 
adherence study based on existing literature on poor adherence to 5-ASA in UC patients,54-58 and 
based on our own real-life observations. In daily practice many UC patients struggle to swallow 
their tablets every day, despite the fact that they are very well aware of the positive influence 
of 5-ASA on their illness. Yet, both UC patients and IBD caregivers have difficulty to talk openly 
about the complex matter of (non) adherence. 
The aim of our RCT was to assess the influence of once daily versus twice daily use of 5-ASA 
medication on adherence and to assess the influence of the use of an application (app) on 
adherence in UC patients on 5-ASA. Our hypothesis was that that both once daily dosing and 
assisted treatment using an app would improve adherence. The study design was a randomized, 
controlled prospective multi-centre trial including patients with quiescent UC using 5-ASA. 
Patients would be randomly assigned to either once daily Mezavant® (2400 mg) or twice daily 
Mezavant® (2dd1200 mg), and to either the standard treatment regime or assisted treatment 
regime with interactive apps on their mobile phone or iPad (Figure 1), with a total follow up 
of 18 months. Primary outcome was adherence, measured by presence of 5-ASA metabolites 
in urine at six months. Secondary outcomes were adherence measured by presence of 5-ASA 
metabolites in urine at 12 and 18 months, quality of life, clinical and endoscopic remission, costs 
and safety. 
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Figure 1 Interactive app ‘IBD Check’
Patient involvement
The first and most important lesson learned was that in hindsight we should have designed our 
RCT in close collaboration with our UC patients or at least should have consulted them about 
their needs and concerns to serve them properly. It appears that we have designed a study 
for UC patients, but not by UC patients or in collaboration with UC patients. We made many 
assumptions, mostly based on literature instead of on direct communication with patients. 
Human factors – patients
Having said that, the next lesson also deals with patients or actually even more with people 
in general. Nothing in clinical research appears to be as complex as humans. This applies to 
both patients and caregivers, which was evident in the implementation and execution of our 
trial. On the patient side of the story, it appeared that we had underestimated the fact that 
patients are very keen to keep their specific (brand of) 5-asa medication. This is a well-known 
phenomenon described for different drugs.59, 60 Patients are reluctant to change their brand, 
even if this reduces the pill burden. For this reason many patients did not want to participate in 
our trial where they had to switch to a different 5-ASA brand. 
In addition, our population of quiescent UC patients using 5-ASA turned out to be less versatile 
with mobile phone applications than expected and did not always know how to properly handle 
an app or tablet, or they simply did not have one. This led to fewer inclusions than expected and 
handling of the app caused disquiet in the assisted treatment arm. This unrest arose both at 
start-up in the trial, if patients did not get the app working (despite the presence of a helpdesk), 
but also during continuation of the trial when patients often did take their medication, but forgot 
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to log this on the app and were therefore incorrectly reported as non adherent. Unfortunately 
the app appeared not feasible for this specific goal in this specific patient group. Indeed part of 
the intervention group left the app towards the end of the trial. 
Trial participation was further limited due to the load of trial visits and handling. Most patients 
don’t want to be ‘patients’ and want to live their lives as healthy and normal as possible. Specifically 
this subgroup of quiescent UC patients who ‘only’ use 5-ASA, and no immunosuppressive 
medication are used to a ‘fairly normal life’ with as little burden of their illness and as few hospital 
visits as possible. Collecting the urine weekly, the telephone consultations every three months 
and completing questionnaires every three months turned out to be too much trouble for them 
and almost one third of the patients enrolled stopped for logistical reasons.
Human factors – care providers
The same issues applied to some of the involved care providers and research nurses. Some 
gastroenterologists proved to be loyal to the brand of 5-ASA prescribed by them. The physicians 
concerns towards switch of medication and possible drawbacks is known from literature.61 This 
simple fact may have prevented them from encouraging patients to be enrolled in the RCT. Next, 
we overestimated the abilities of physicians to be well trained in social media and modern ICT 
resources. Despite an extensive trainee period about the use of the database and app, some 
were simply unable to properly use these platforms, let alone instruct patients on this topic. 
Individual dysfunction and miscalculations of the trial staff have also led to a less favorable 
outcome in this relatively small project carried by a single department. 
All of the above led to fewer inclusions, a lot of unrest and more dropouts than expected. What 
we have learned from this course is that human factors are crucial and should be taken into 
account when designing and conducting a trial. Both the patient and the caregivers themselves 
can make or break your trial.
Modeling of complex health care interventions
The third very important lesson learned seems obvious, but still we underestimated it because 
we were too eager to start with our study. Health care interventions are often complex in 
themselves and are always applied in complex settings.62,63 Therefore careful modeling of 
complex interventions is an essential step in the design of trials that concern innovations in 
health care. A well thought-out design and defining the best primary outcome by extensive 
modeling of a study is the key to success. 
Although we mostly based our hypothesis on published studies, we were forced to make some 
assumptions. Of course we did model our study design and execution, but in retrospect we 
should have put even more efforts in modeling our intervention prior to start of the study and 
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rethink all assumptions that underlie the hypothesis. For this we could have used for example 
the revised MRC framework that concerns complex interventions in complex health care 
settings.64-66 The modeling process of our study design and execution took many months, with 
frequent consultation between different disciplines such as clinicians, pharmacists, laboratory 
staff and trial employees. As mentioned we should have consulted UC patients or the patient 
association in this process. 
Primary outcome measure
The primary outcome measure was clear and would be adherence, but the question was which 
method would provide a reliable, reproducible and easy to use in daily practice tool to measure 
this. It soon became clear that patient reported data bear risk of bias. We considered electronic 
monitoring with Medication Event Monitoring Systems (MEMs) the most reliable choice, but MEMs 
appeared too expensive in study context, let alone in daily practice which would make it difficult 
to implement. After extensive consideration we came to (Nac) 5-asa urinalysis by HPLC. Initially, 
we planned to carry out the intervention study without a prior pilot study by using cut-offs from 
literature. However, because data were scarce and heterogeneous since different 5-asa preparations 
were used interchangeably, the local ethics committee advised to conduct a pilot study. 
This pilot study was performed in healthy volunteers instead of UC patients because of logistical 
and ethical arguments. However a substantial part of the UC patients do have co-morbidity or co-
medication that may affect the pharmacokinetic properties of 5-ASA. In patients with active UC, 
pharmacokinetics might be influenced by diarrhea, changed intestinal transit time, and luminal 
pH. The contribution of these elements and the ultimate effect on 5-ASA pharmacokinetics is 
incompletely understood and the literature reports conflicting results. We knew these arguments, 
and discussed them extensively, but data were equivocal and there were also arguments to assume 
that the pharmacokinetics of stable UC patients corresponded to those of healthy volunteers.67, 
68 Therefore we assumed that in this specific subgroup of UC, data from healthy volunteers might 
be extrapolated to UC patients in a reliable manner. In retrospect, this assumption deserved 
reconsideration and confirmation. At least we should have had reasonable doubts about this 
assumption prior to use in our RCT. 
The next issue is the required number of patients in a pilot study which is also debatable. The sample 
size of our pilot study was determined at 25, which is normal practice prior to clinical intervention 
research.69 In this pilot study we documented a high pharmacokinetic variability among volunteers. 
Yet, we assumed we could determine useful cut-off values for partial non adherence from this data. 
In retrospect, at best we can conclude that in case of low (Nac-) 5-ASA urine levels one should be 
aware of possible non adherence and this finding might help in a discussion with your patient. Fully 
reliable cut-off values could not be determined in view of the high intra-individual variation. We might 
have used undetectable drug levels, matching complete non adherence. 
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The concerns that arose from our pilot study were confirmed by the results of our intervention 
study. In our intervention study in UC patients we also found large variation in spot (Nac-)5-
ASA urinary excretion at any time point, both between different UC patients but also in every 
individual patient, independent of the use of different brands, dosages or dosage schemes of 
5-ASA. We found larger variability and ranges in (Nac-)5-ASA urinary excretion in UC patients 
compared to the results of the pilot study in volunteers. Direct observation of medication intake, 
and a strict time table of urine collection in the healthy volunteers might have played a role in 
this observation. However, the contribution of UC disease activity appears to be a relevant 
factor. We therefore concluded during our intervention study that spot (Nac-)5-ASA urinalysis 
is not suitable for assessing 5-ASA adherence in daily IBD practice. Our lesson learned is that 
our primary outcome measure being adherence measured by (Nac) 5-asa urine levels turned 
out not to be the best choice, as careful interpretation of the results of our pilot-study may 
have revealed. 
Monitoring and interim analysis
The last lesson learned does not need explanation and is that close monitoring and interim 
adjustment of a study is a prerequisite for success. 
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SUMMARY
Inflammatory Bowel Disease (IBD) is a chronic, progressive and disabling inflammatory 
disease of the gastrointestinal tract, with unknown etiology. IBD encompasses Ulcerative 
Colitis (UC) and Crohn’s Disease (CD). The global IBD incidence and prevalence is rising and 
in the Netherlands it is estimated that there are around 90,000 patients. IBD cannot be cured 
and available drugs are able to suppress symptoms and inflammation, but do not significantly 
alter the disease course. This thesis comes from real-life IBD practice and is divided into three 
parts. The first part concerns research focusing on IBD treatment targets. The second part 
investigates the effect of used definitions (strict or broad) on outcomes in IBD trials and the 
third part focuses on the translation of evidence gained through clinical studies to real-life IBD 
practice. 
Chapter 1 includes a general introduction and outline of this thesis. 
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PART I Treatment targets in IBD 
In  Chapter 2 we describe a nation-wide structured survey on IBD management in daily practice. 
We investigated the current practice and used definitions of IBD treatment targets among 
Dutch gastroenterologists, and aimed to map factors that may have influenced clinical decision-
making. Three-quarters of all respondents use mucosal healing (MH) as key treatment goal, with 
almost half of them using deep remission as treatment target (defined as clinical, biochemical 
and endoscopic remission). To reach deep remission the majority is willing to intensify IBD 
treatment. The most widely used definitions of MH in IBD were Mayo score ≤ 1 in UC and 
‘macroscopic normal mucosa’ in CD. Our data suggest that the concept of MH for both UC and 
CD is embraced by many Dutch IBD health care providers. However, we do not know to what 
extent the answers of our respondents and proposed ‘treat-to-target’ endpoints are actually 
applied in daily clinical practice. Elaborating this theme we need prospective ‘real-life’ data to 
gain insight into the ‘daily routine’ of an IBD practice in 2018, in order to evaluate the actual 
implementation of the ‘treat-to-target’ concept in daily IBD care. 
Chapter 3 describes a single-centre case–control study that examined prevalence of fatigue in 
consecutive IBD patients, visiting the outpatient clinic of the gastroenterology department of 
the Radboud University medical centre and examined different dimensions of fatigue by using 
the Piper Fatigue scale (PFS). We used Lynch syndrome gene carriers (Lynch) as a control group. 
Overall, we found that two-thirds of all IBD outpatients reported significant fatigue by using 
the PFS, without difference between CD and UC. Even 40% of IBD patients in clinical remission 
reported fatigue. We did not find one possible determinant of fatigue, except for a non-significant 
trend towards disease activity. It is important for IBD health care providers to acknowledge the 
daily burden of fatigue in IBD patients, and therefore we propose to initiate dedicated training 
programs for IBD specialists and nurses to assist their IBD patients in recognizing and dealing 
with fatigue in their daily lives. 
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PART II The outcome of IBD trials - 
the impact of using different 
definitions and cut-offs in IBD
In Chapter 4 we performed a systematic review and meta-analysis to review efficacy of 
5-Aminosalicylic acid (5-ASA) on mucosal healing (MH) in UC and to describe and compare all 
used definitions for MH in UC. We conducted a structured search of PubMed and the Cochrane 
Central Register of Controlled Trials to identify English-language randomized controlled clinical 
trials with 5-ASA in UC providing data about MH. Studies were eligible if they had a randomized 
controlled design, reported on induction of endoscopic MH, studied 5-ASA preparations mono 
therapy and were performed in patients with mild to moderate active UC. Overall, by using the 
MH definition of the original articles, 43.7% of all patients, with mild-to-moderate UC treated 
with 5-ASA achieved MH, regardless of the 5-ASA formulation. Based upon these findings, 5-ASA 
treatment remains to be the first-line therapy in these patients. This applies to local treatment 
in the case of proctitis or proctosigmoiditis as well as for oral treatment in case of left-sided or 
pancolitis, with a clear dose-response relation in the oral group (higher MH rates by using ≥3g/
day). In our meta-analysis we identified 19 different definitions and cut-offs for MH. As might 
be expected, studies with less stringent definitions reported higher MH rates. Therefore our 
key message is clear: we need a unified and widely used definition of MH in UC patients, that is 
easy to implement and correlates with clinically relevant outcomes. 
In Chapter 5 we performed a systematic review that concerns the impact of using different 
definitions and cut-offs for Cytomegalovirus (CMV) intestinal disease (colitis), CMV reactivation 
and CMV infection in IBD literature. We performed a structured search of the medical literature 
using MEDLINE, EMBASE and the Cochrane central register of controlled trials to identify 
English-language (clinical) trials concerning diagnostics and prevalence of CMV in IBD. Studies 
were eligible if they reported on prevalence and/or diagnostic criteria to define CMV infection 
or CMV colitis in IBD. In our systematic review we identified nearly 30 different definitions 
for CMV infection and colitis. Prevalence numbers highly depended on the used definition of 
the original articles, the studied population and study region. The highest prevalence for CMV 
infection was found when using positive serum PCR as a definition, whereas for CMV colitis 
this applies to the use of tissue PCR >10 copies/mg tissue. To date, prospective data are scarce 
and most retrospective series contain small numbers of severely ill patients that come from 
heterogeneous subgroups. Therefore to define the role of CMV in UC, we need one unified 
global definition for clinically relevant CMV (intestinal) disease in IBD. With this definition as a 
starting point, prospective randomized multicenter studies using ‘real-life’ data will allow us to 
compare different treatment methods in matched patient groups. 
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PART III CHALLENGES IN DAILY IBD CARE – 
THEORY VERSUS REAL-LIFE DATA
In chapter 6 we describe a retrospective single-centre cohort study concerning intra-observer 
agreement of histological scoring systems in colonic biopsies from UC patients with MH (Mayo 
≤ 1) and limited histological inflammation. We investigated the reliability and correlation of 
UC histological scores and compared the ‘daily practice’ histological assessment of a general 
pathologist with expert reviews by gastrointestinal (GI)-pathologists.	 We found a large 
discrepancy between the initial histological assessment by a general pathologist and the re-
assessment by dedicated GI-pathologists. This finding has large implications for everyday IBD 
care as it suggests a gap between daily practice histological assessment and academic expertise. 
We believe that future research and IBD guidelines concerning MH need to focus and act upon 
this discrepancy and for example introduce and implement dedicated learning pathways into 
daily IBD care. The implementation of ‘easy-to-use’ IBD histology scores and the opportunity 
for central pathology reading in case of expected important clinical decision-making may well 
make the difference. In order to implement histological remission as a therapeutic target that 
holds clinical relevance, these steps are crucial. In addition we found strong correlations among 
expert GI-pathologists between the two most frequently used histological activity scores for 
UC (RS and GS), when re-evaluating UC biopsies assessed as HR by a general pathologist. We 
concluded that current UC histological scores reliably assess limited histological inflammation 
in UC patients. 
In Chapter 7 we describe two intervention studies with MMX-mesalazine and the use of 
High- Performance Liquid Chromatography (HPLC) to evaluate adherence by measuring 
urinary N-acetyl-5-ASA (Nac-5-ASA) excretion. First a prospective pilot study in 25 healthy 
volunteers taking MMX-mesalazine was performed to investigate feasibility of HPLC to detect 
urinary (NAc-) 5-ASA excretion and try to determine cut-off levels for adherence of 5-ASA. 
We concluded that HPLC is a feasible, sensitive and reproducible method to measure urinary 
(NAc-) 5-ASA excretion in volunteers taking MMX-mesalazine, showing a low inter- and intra-
assay variation, but with a large variation in (Nac-)5-ASA urinary excretion between individuals. 
We did determine cut-off levels for partial adherence in our pilot study concerning healthy 
volunteers, but these levels turned out not te be useful in UC patients with co-morbidity, co-
medication and diarrhea, that all may affect the pharmacokinetic properties of 5-ASA. Only 
undetectable urinary drug metabolites can be used to assess complete non adherence. 
The second small intervention study is a randomized prospective multi-centre study concerning 
UC patients taking MMX-mesalazine in daily practice. We investigated the feasibility of spot 
(Nac-)5-ASA urinalysis by HPLC to assess adherence in IBD patients. We showed that results 
from (Nac-) 5-ASA excretion measured in 24-96 h urine cannot be extrapolated to spot urine 
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and that there is a wide variation in urinary (Nac-)5-ASA excretion in UC patients regardless 
of disease activity, 5-ASA brand, or dosing schedule. We concluded that spot (Nac-)5-ASA 
urinalysis is not suitable for assessing (partial) 5-ASA adherence in daily IBD practice.	
Chapter 8 describes a prospective single-centre cohort study to evaluate whether proactive 
Therapeutic Drug Monitoring (TDM) in IBD patients treated with Remicade® (Infliximab (IFX)) 
was cost-effective and secondly resulted in a better clinical response after six months of follow-
up compared to conventional treatment. We concluded that proactive TDM of Remicade® 
(IFX) in this IBD cohort results in less disease flares, but is not cost-effective during six months 
of follow up. We showed that the high drug costs of Remicade® and the hesitation of patients 
and physicians to de-escalate or discontinue IFX therapy mostly influenced the ICER. With the 
implementation of biosimilars, the cost price for IFX greatly decreases, which will have a major 
positive effect on the ICER and eventually this strategy may reach the level of cost effectiveness. 
In terms of stopping criteria or phasing out IFX therapy there are no international guidelines 
available which complicates clinical decision-making. According to the Dutch IBD guideline, 
the decision to stop anti-TNF therapy should be taken on an individual basis, with minimum 
conditions that must be met. Currently promising prospective de-escalation or stop trials 
concerning anti-TNF therapy are started in the Netherlands, which may give us more guidance in 
difficult clinical decision-making. However, when it comes to costs, the key question will remain 
at what society is willing to pay to prevent one relapse of disease.
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NEDERLANDSE SAMENVATTING
Inflammatoire darmaandoeningen (Inflammatory Bowel Diseases (IBD)) zijn chronische, 
progressieve en invaliderende ontstekingsziekten van het maag-darmkanaal, met onbekende 
etiologie. IBD omvat colitis ulcerosa (UC) en de ziekte van Crohn (CD). De algemene incidentie 
en prevalentie van IBD neemt wereldwijd toe, met naar schatting ongeveer 90.000 IBD 
patiënten in Nederland. IBD kan niet worden genezen en de huidige beschikbare medicijnen zijn 
wel in staat om symptomen en ontstekingen te onderdrukken, maar ze kunnen het ziekteverloop 
niet significant veranderen. 
Dit proefschrift is ontstaan vanuit de dagelijkse IBD praktijk en bestaat uit drie delen. 
I]  Het eerste deel betreft onderzoek gericht op de behandeldoelen in IBD. 
II]  Het tweede deel onderzoekt het effect van gebruikte definities (wel of niet strikt) op 
uitkomsten in klinische IBD studies.
III]  Het derde deel richt zich op de vertaalslag van gegevens die uit klinische studies verkregen 
zijn naar de IBD praktijk van alledag. 
Hoofdstuk 1 bevat een algemene inleiding en overzichtsschets van dit proefschrift.
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DEEL I Behandeldoelen in IBD
In hoofdstuk 2 beschrijven we een landelijk onderzoek met vragenlijsten onder maag-, darm-, 
en lever (MDL)-artsen naar IBD-behandeling in de dagelijkse praktijk. We onderzochten de 
huidige praktijk en bestudeerden de definities die Nederlandse MDL-artsen gebruiken ten 
aanzien van IBD behandeldoelen. Daarnaast probeerden we factoren in kaart te brengen 
die van invloed bleken op klinische besluitvorming. Driekwart van alle deelnemers gebruikte 
mucosale genezing (mucosal healing (MH)) als belangrijkste behandeldoel, waarbij bijna de helft 
van hen diepe remissie als behandeldoel gebruikte (gedefinieerd als klinische, biochemische 
en endoscopische remissie). Om diepe remissie te bereiken, bleek de meerderheid bereid 
om de IBD-behandeling te intensiveren. De meest gebruikte definities van MH in IBD waren 
Mayo score ≤ 1 in UC en ‘macroscopisch normale mucosa’ in CD. Onze gegevens suggereren 
dat het concept van MH voor zowel UC als CD wordt omarmd door veel Nederlandse MDL-
artsen die IBD patiënten behandelen. We kunnen uit deze resultaten echter niet afleiden in 
welke mate de theoretische antwoorden van onze respondenten over de voorgestelde ‘treat-
to-target’-eindpunten daadwerkelijk worden toegepast in de dagelijkse klinische praktijk. Om 
de daadwerkelijke implementatie hiervan in de dagelijkse IBD-zorg te evalueren hebben we 
prospectieve gegevens uit de ‘dagelijkse IBD-praktijk anno 2019’ nodig. 
Hoofdstuk 3 beschrijft een case-control studie die de prevalentie van vermoeidheid onderzocht 
bij IBD-patiënten, die een regulier bezoek brachten aan de polikliniek MDL van het Radboud 
UMC. De verschillende dimensies van vermoeidheid werden onderzocht met behulp van de 
Piper Fatigue-schaal (PFS) . We gebruikten gezonde Lynch syndroom-gendragers (Lynch) 
als controlegroep. We vonden dat tweederde van alle geïncludeerde IBD-patiënten (zonder 
verschil tussen CD en UC ) een aanzienlijke vermoeidheid rapporteerden. Zelfs 40% van de IBD-
patiënten in klinische remissie rapporteerden invaliderende vermoeidheid. Er was een trend 
zichtbaar die liet zien dat er meer vermoeidheid is bij actieve ziekte, doch dit was niet significant. 
Er werden geen andere oorzaken van vermoeidheid gevonden. Gezien de hoge prevalentie 
van invaliderende vermoeidheid is het belangrijk voor IBD-patiënten dat hun zorgverleners 
de dagelijkse last van hun vermoeidheid herkennen en erkennen. Om dit te bewerkstelligen 
stellen we voor om speciale trainingsprogramma’s voor IBD-specialisten en -verpleegkundigen 
te initiëren. 
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DEEL II De uitkomsten van IBD-trials -  
impact van het gebruik van 
verschillende definities bij IBD
In Hoofdstuk 4 hebben we een systematische review en meta-analyse uitgevoerd om de 
werkzaamheid van 5-Aminosalicylzuur (5-ASA) op MH in UC te beoordelen en om alle 
gebruikte definities (strikt of niet) voor MH in UC te beschrijven en te vergelijken. We hebben 
een gestructureerd onderzoek uitgevoerd in PubMed en het Cochrane Central Register of 
Controlled Trials om Engelstalige, gerandomiseerde, gecontroleerde klinische onderzoeken 
met 5-ASA in UC te identificeren, die gegevens bevatten over MH. Studies kwamen in 
aanmerking als ze een gerandomiseerd gecontroleerd ontwerp hadden, rapporteerden 
over inductie van endoscopisch MH, monotherapie met 5-ASA-preparaten bestudeerden 
en werden uitgevoerd bij patiënten met milde tot matig actieve UC. Over het algemeen 
bereikte 43,7% van alle patiënten met milde tot matige UC die waren behandeld met 5-ASA 
MH. Dit was bij gebruik van de MH-definitie van de originele artikelen, ongeacht het merk 
en de formule van het 5-ASA-preparaat. Op basis van deze bevindingen, concluderen wij 
dat behandeling met 5-ASA de eerstelijns behandeling bij deze patiëntengroep blijft. Dit 
geldt voor lokale behandeling in het geval van proctitis of proctosigmoiditis, alsook voor 
orale behandeling in geval van linkszijdige of pancolitis, met een duidelijke dosis-respons 
relatie in de orale groep (hogere MH-waarden bij gebruik van ≥3 g / dag). In onze meta-
analyse identificeerden we 19 verschillende definities en grenswaarden voor MH. Zoals 
te verwachten, rapporteerden onderzoeken met minder strenge definities hogere MH-
percentages. Daarom is onze kernboodschap duidelijk: we hebben een uniforme definitie 
van MH nodig bij UC-patiënten, die gemakkelijk te implementeren is en correleert met 
klinisch relevante uitkomsten.
In Hoofdstuk 5 hebben we een systematische review uitgevoerd met betrekking tot de 
impact van het gebruik van verschillende definities en grenswaarden voor Cytomegalovirus 
(CMV) colitis, CMV-reactivatie en CMV-infectie in de bestaande IBD-literatuur. We hebben 
een gestructureerde zoekactie in de medische literatuur uitgevoerd met behulp van 
MEDLINE, EMBASE en het centrale Cochrane-register van gecontroleerde onderzoeken 
om Engelstalige (klinische) onderzoeken te identificeren met betrekking tot diagnostiek en 
prevalentie van CMV bij IBD. Studies kwamen in aanmerking als ze rapporteerden over de 
prevalentie en/of diagnostische criteria om CMV-infectie of CMV colitis in IBD te definiëren. 
In onze systematische review identificeerden we bijna 30 verschillende definities voor 
CMV-infectie en CMV-colitis. Prevalentiecijfers waren in hoge mate afhankelijk van de 
gebruikte definitie van de originele artikelen, de bestudeerde populatie en het studiegebied. 
De hoogste prevalentie voor CMV-infectie werd gevonden bij gebruik van positieve serum-
PCR als definitie, terwijl dit bij CMV-colitis geldt voor het gebruik van weefsel-PCR> 10 
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kopieën / mg weefsel. Tot op heden zijn er weinig prospectieve gegevens en de meeste 
retrospectieve series bevatten kleine aantallen ernstig zieke patiënten die afkomstig zijn uit 
heterogene subgroepen. Om de rol van CMV in UC vast te kunnen stellen, hebben we één 
algemene wereldwijde definitie nodig voor klinisch relevante CMV infectie en colitis bij IBD. 
Met deze definitie als uitgangspunt, kunnen prospectieve gerandomiseerde multicenter 
onderzoeken met behulp van gegevens uit de dagelijkse praktijk ons in staat stellen om 
verschillende behandelmethoden in gematchte patiëntengroepen te vergelijken.
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A
DEEL III Uitdagingen in dagelijkse IBD-zorg – 
Theoretische data versus 
de dagelijkse praktijk 
In hoofdstuk 6 beschrijven we een retrospectieve cohort studie over inter- en intra-observer 
variatie van histologische scoringssystemen in colonbiopten van UC-patiënten met MH 
(Mayo ≤ 1) en beperkte histologische ontsteking. We onderzochten de betrouwbaarheid en 
correlatie van UC histologische scores en vergeleken de histologische beoordeling uit de 
‘dagelijkse praktijk’ van een algemene patholoog met specialistische herbeoordelingen door 
pathologen met aandachtsgebied gastroenterologie (GE). We vonden een sterke correlatie 
tussen de beoordelingen van deskundige GE-pathologen van de twee meest gebruikte scores 
voor histologische activiteit voor UC (Riley Score en Geboes Score), bij het opnieuw evalueren 
van colon biopten van UC patiënten die door een algemene patholoog als histologisch in 
remissie werden beoordeeld. We concludeerden hieruit dat de huidige UC histologische scores 
betrouwbaar beperkte histologische ontsteking bij UC-patiënten kunnen beoordelen.
We vonden echter een grote discrepantie tussen de initiële histologische beoordeling door een 
algemene patholoog en de herbeoordeling door toegewijde GE-pathologen. Deze bevinding 
suggereert een kloof tussen de dagelijkse praktijk en academische expertise, die grote gevolgen 
kan hebben voor de dagelijkse IBD-praktijk. Wij zijn dan ook van mening dat toekomstig 
onderzoek en IBD-richtlijnen met betrekking tot MH rekening moeten houden met deze 
discrepantie en bijvoorbeeld specifieke leertrajecten moeten introduceren en implementeren 
voor algemene pathologen in de dagelijkse IBD-zorg. De implementatie van nieuwe histologische 
IBD scores die eenvoudig zijn in gebruik, maar ook de mogelijkheid tot centrale herbeoordeling 
(central reading)van histologische biopten door getrainde GE-pathologen, in het geval van 
verwachte belangrijke klinische besluitvorming, zou wel eens een belangrijk verschil kunnen 
maken. Om histologische remissie als een therapeutisch klinisch relevant behandeldoel te 
kunnen implementeren, zijn deze stappen cruciaal. 
In Hoofdstuk 7 beschrijven we twee interventiestudies met MMX-mesalazine en het gebruik 
van High-Performance Liquid Chromatography (HPLC) om de therapietrouw te evalueren door 
middel van het meten van urine-excretie van (N-acetyl-)5-ASA ((Nac-)5-ASA). Eerst werd een 
prospectieve pilot-studie uitgevoerd bij 25 gezonde vrijwilligers die MMX-mesalazine namen 
om de haalbaarheid van HPLC te onderzoeken voor detectie van (NAc-) 5-ASA-excretie in de 
urine en om grenswaarden voor de therapietrouw voor 5-ASA te bepalen. We concludeerden 
dat HPLC een haalbare, gevoelige en reproduceerbare methode is om (NAc-) 5-ASA-excretie in 
de urine te meten bij vrijwilligers die MMX-mesalazine gebruiken, met een lage inter- en intra-
assay variatie, maar met een grote variatie in (Nac- ) 5-ASA-urine-uitscheiding tussen individuele 
vrijwilligers. We hebben in onze pilot-studie in gezonde vrijwilligers wel afkapwaarden bepaald 
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voor gedeeltelijke therapietrouw, maar deze waarden bleken niet bruikbaar te zijn bij UC-
patiënten. Dit heeft waarschijnlijk te maken met hun co-morbiditeiten, comedicatie en diarree, 
die mogelijk allemaal van invloed zijn op de farmacokinetische eigenschappen van 5-ASA. 
Alleen niet-detecteerbare geneesmiddel -metabolieten in de urine kunnen worden gebruikt 
om volledige therapieontrouw te beoordelen.
De tweede kleine interventie studie is een gerandomiseerde prospectieve studie met betrekking 
tot UC-patiënten die MMX-mesalazine gebruiken in de dagelijkse praktijk. We onderzochten 
de haalbaarheid van (Nac-) 5-ASA urineonderzoek met behulp van HPLC in een portie urine 
om de therapietrouw bij IBD-patiënten te beoordelen. We toonden aan dat het resultaat van 
(Nac-) 5-ASA-excretie gemeten in 24-96- uurs urine niet kan worden geëxtrapoleerd naar een 
enkele portie urine, en dat er een grote variatie is in (Nac-) 5-ASA-urine excretie bij UC-patiënten 
ongeacht de ziekteactiviteit , het merk 5-ASA of het doseringsschema. Onze eindconclusie 
is dat (Nac-) 5-ASA urineonderzoek in een portie niet geschikt is voor het beoordelen van 
(gedeeltelijke) 5-ASA therapietrouw in de dagelijkse IBD-praktijk.
Hoofdstuk 8 beschrijft een prospectieve cohort studie om te evalueren of pro-actief ‘Therapeutic 
Drug Monitoring’ (TDM) bij IBD-patiënten behandeld met Remicade® (Infliximab (IFX)) 
kosteneffectief was, met als tweede vraag of dit klinisch effectief was na zes maanden follow-
up, in vergelijking met conventionele behandeling. We concludeerden dat pro-actief TDM van 
Remicade® (IFX) in dit IBD-cohort minder opvlammingen van de ziekte veroorzaakt, maar niet 
kosteneffectief is gedurende zes maanden follow-up. Hoge medicatiekosten van Remicade® en 
de aarzeling van patiënten en artsen om de IFX-therapie af te bouwen of te stoppen, bleken vooral 
invloed te hebben op de Incremental Cost Effectiveness Ratio (ICER). Met de implementatie van 
biosimilars neemt de kostprijs voor IFX enorm af, wat een groot positief effect op de ICER zal 
hebben en uiteindelijk ertoe zal leiden dat deze strategie kosteneffectief wordt. In termen van 
stopcriteria of afbouwen van IFX-therapie zijn er geen internationale richtlijnen beschikbaar 
wat de klinische besluitvorming ingewikkeld maakt. Volgens de Nederlandse IBD-richtlijn 
moet de beslissing om anti-TNF-therapie te stoppen op individueel niveau worden genomen, 
met minimale voorwaarden waaraan moet worden voldaan. Momenteel worden in Nederland 
veelbelovende, prospectieve afbouw- en stopstudies gestart met betrekking tot anti-TNF-
therapie, wat ons meer onderbouwing zal gaan bieden bij moeilijke klinische besluitvorming. 
Als het echter om kosten gaat, zal de belangrijkste vraag blijven wat de maatschappij bereid is 
te betalen om één opvlamming van de ziekte te voorkomen.
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LIST OF ABBREVIATIONS: 
CBT Cognitive behavioral therapy 
CD Crohn’s Disease
CDEIS Crohn‘s Disease Endoscopic Index of Severity
FCP fecal calprotectin
FDA Food and Drugs Administration 
GI Gastro intestinal
gp  the general pathologist who initially assessed the biopsies in daily clinical setting 
GpHR Biopsies initially evaluated as ‘histological remission’ by general pathologist
GpHI Biopsies initially evaluated as ‘Histological inflammation’ by general pathologist
GS Geboes score 
GVS Global Visual Score
HGI Harpaz (Gupta) Index 
HR histological remission 
IBD Inflammatory Bowel Disease
IBDU IBD unclassified
ICER Incremental Cost Effectiveness Ratio
IFX Infliximab
IOIBD International Organization for the Study of Inflammatory Bowel Diseases
MH Mucosal healing
MMH Microscopic mucosal healing/ histological remission
PRO(M) patient-reported outcome (measures)
QALY Quality Adjusted Life Year
RS Riley score
SES-CD Simple endoscopic score for Crohn’s disease
TDM Therapeutic Drug Monitoring
TLs Trough levels
UC Ulcerative Colitis
UCEIS Ulcerative Colitis Endoscopic Index of Severity
WHO World Health Organization 
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